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Summary 
 
Setting 
This study was conducted in the Tygerberg district, in the Western Cape, South Africa. 
 
Background 
Tuberculosis is a major global health problem. Studies that follow individuals in close contact 
with active TB cases have provided a wealth of insight on TB transmission and on immune 
responses activated by M. tuberculosis infection, however, robust correlates of protection 
against TB are not known. The purpose of this study is to explore immunological profiles 
associated with TST conversion from negative to positive in household contacts of active TB 
cases in a high TB incidence area of the Western Cape. 
Methods 
Interferon gamma Elisa study 
Whole blood of 17 of adult and adolescent TST negative recent contacts of smear positive 
active TB cases was stimulated with a panel of 22 M.tb specific antigens, which, were also 
used to stimulate whole blood of the same number of age and gender matched recruitment 
TST positive contacts and active TB cases. The 7-day culture supernatants were used to 
quantify and to compare IFN- production using the ELISA. 
Luminex Assay study 
Whole blood culture supernatants of 17 subjects that were initially TST negative, converting 
to TST positive by month 6, and that of 9 participants that had not converted 6 months into 
the study were used in the Luminex LINCO 27-plex assay. This was done to determine which 
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of the 27 cytokines may be associated with TST conversion after stimulation with 6 M.tb 
specific antigens at recruitment and 5 at month 6.  
Results 
Markedly different immune responses were observed between TST negative household 
contacts, TST positive household contacts and new active TB cases. IFN-production in 
response to M.tb PPD, Rv3019c, ESAT6/CFP10 fusion protein, TB10.4, Rv1737c, Rv1733c, 
Rv1735c, Rv2029c, Rv2450c, Rv0867c and Rv1009 antigens could discriminate between the 
not infected, M.tb infection and active TB.  
This study showed that at study recruitment M.tb PPD induced high IP-10, IL-8, GM-CSF, 
IL-2, IL-5 and IL-13 levels in fast TST convertors and that when this group had become TST 
positive at month 6, all these cytokines were further enhanced as a result of this antigen.  At 
month 6, ESAT6/CFP10 fusion protein produced significantly higher MCP-1, IP10 and IFN-
concentrations in fast TST convertors only. 
Dos-R antigens produced significantly higher VEGF, IL-12p70 and IL-10 at recruitment in 
slow convertors. At month 6, these antigens resulted in high IL-12p40 and IL-12p70levels in 
both fast and slow TST convertors. At this time point, Dos-R antigens produced high levels 
of MIP-1, IL-1and IL-1ra in fast convertors, whereas they resulted in decreased 
production of G-CSF, IL-10 and VEGF in slow TST convertors. 
Conclusion 
The capability of both Rv2029c and Rv2450c antigens to distinguish between infection and 
disease states and their positive association in the TST positive group only may be important 
in the identification of possible diagnostic or vaccine candidates. In TST negative contacts, 
M.tb PPD, Rv1737c or Rv2029c may be useful predictors of the rate of infection in TST 
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negative household contacts. The multiple cytokine profile studies may offer a valuable 
platform for understanding host-pathogen relations which could lead to the identification of 
potential vaccine or diagnostic candidates.  
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Opsomming 
Instelling 
Hierdie studie is uitgevoer in die Tygerberg-distrik, in die Wes-Kaap, Suid-Afrika. 
Agtergrond 
Tuberkulose is 'n groot globale gesondheid probleem. Studies wat volg individue in noue 
kontak met 'n aktiewe TB-gevalle het op voorwaarde dat' n rykdom van insig oor TB-oordrag 
en op immuun antwoorde geaktiveer word deur M. tuberkulose-infeksie, maar robuuste 
korrelate van beskerming teen TB is nie bekend nie. Die doel van hierdie studie is 
immunologiese profiele verband hou met TST sukses te verken van negatief na positief in die 
huishouding kontakte van aktiewe TB-gevalle in 'n hoë TB voorkoms gebied van die Wes-
Kaap. 
 
Metodes 
Interferon gamma Elisa studie 
Hele bloed van 17 van volwasse en adolessente TST negatiewe onlangse kontakte van die 
smeer positiewe aktiewe TB-gevalle was gestimuleer met 'n paneel van 22 TB spesifieke 
antigene wat ook gebruik word om te stimuleer hele bloed van dieselfde getal van ouderdom 
en geslag gekoppel werwing TST positiewe kontakte en aktiewe TB-gevalle. Die  produksie 
met7-dag kultuur supernatants is gebruik om te kwantifiseer en IFN- behulp van die ELISA 
te vergelyk. 
 
Luminex  studie 
Vol bloed kultuur supernatants van 17 vakke wat aanvanklik TST negatief is, herlei dit na die 
positiewe TST per maand 6 en dat van 9 deelnemers wat nie 6 maande omskep in die studie 
is gebruik in die Luminex LINCO 27-kompleks toets. Dit is gedoen om te bepaal watter van 
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die 27 cytokines kan geassosieer word met TST omskakeling na stimulasie met 6 TB 
spesifieke antigene op werwing en 5 by die maand 6. 
 
Resultate 
Opmerklik verskillende reaksies tussen hierdie drie studiegroepe is waargeneem. Elf antigene 
kan diskrimineer tussen die nie besmet is, M.tb infeksie en aktiewe TB insluitende M.tb PPD, 
Rv3019c, ESAT6/CFP10 fusie-proteïen, TB10.4, Rv1737c, Rv1733c, Rv1735c, Rv2029c, 
Rv2450c, Rv0867c en Rv1009. 
Hierdie studie het getoon dat studie-werwing M.tb PPD veroorsaak hoë IP-10, IL-8, GM-
CSF, IL-2, IL-5 en IL-13-vlakke in 'n vinnige TST omsetters en dat wanneer hierdie groep 
geword het TST positief maand 6, is verder al hierdie cytokines versterk as gevolg van 
hierdie antigeen. By die maand 6, ESAT6/CFP10 fusie-proteïen geproduseer aansienlik hoër 
MCP-1, IP10  en IFN- konsentrasies in 'n vinnige TST converters alleen. Dos-R antigene 
wat aansienlik hoër VEGF, IL-12p70 en IL-10 by werwing in stadige omsetters. By die 
maand 6, hierdie antigene het gelei tot hoë IL-12p40 en IL-12p70levels in beide 'n vinnige en 
stadige TST omsetters. In  en IL-1ra , IL-1  hierdie tyd punt, Dos-R antigene wat hoë 
vlakke van MIP-1  in 'n vinnige converters, terwyl hulle gelei tot verminderde produksie van 
G-CSF, IL-10 en VEGF in slow TST omsetters. 
 
Sluiting 
Die vermoë van beide Rv2029c en Rv2450c antigene om te onderskei tussen infeksie en 
siekte state en hul positiewe assosiasie in die TST positiewe groep slegs van belang kan wees 
in die identifisering van moontlike diagnostiese of entstof kandidate. In TST negatiewe 
kontakte, kan M.tbPPD, Rv1737c of Rv2029c nuttig wees voorspellers van die tempo van 
infeksie in TST negatiewe huishoudelike kontakte. Die meervoudige cytokine profiel studies 
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kan waardevolle platform aanbod vir die begrip van die gasheer-patogeen Aangeleenthede 
wat kan lei tot die identifisering van potensiële entstof of diagnostiese kandidate. 
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CHAPTER 1: INTRODUCTION 
1.1. The epidemiology of tuberculosis (TB) 
Mycobacterium tuberculosis (M.tb) is one of the oldest human pathogens known, and causes 
tuberculosis (TB), which continues to cause a major global health problem. In 2008 there 
were 9.4 million new TB cases detected, with 1.2 million reported fatalities across the world 
(WHO, 2009a). The incidence of TB in South Africa has continued to rise from 109 000 in 
1990 to 461 000 in 2007 (Kritzinger et al., 2009; Shanaube et al., 2009; WHO, 2009a). There 
are many factors that drive the TB epidemic. Individuals who are infected with HIV are at 
greater risk of developing active TB (Narain et al., 1992). South Africa has an estimated 5.7 
million people infected with HIV (UNAIDS, 2008) and in 2008, 72% of TB cases were co-
infected with HIV (WHO, 2009a). TB is also associated with several other serious illnesses 
including diabetes mellitus, renal failure and drug and/or alcohol abuse (American Thoracic 
Society, 2000). It has been observed that the risk of developing TB increases with decreasing 
social capital (van Rie et al., 1999; Holtgrave & Crosby, 2004; Baker et al., 2008; Harling et 
al., 2008). It is believed that between 18% and 22% of South Africans are chronically poor 
(Aliber, 2003). South Africa takes 5th place in the 22 countries that carry 80% of the global 
burden of TB (WHO, 2009a).  It is probably the country’s prevailing socioeconomic 
conditions that have contributed to South Africa being in such an unenviable position.  
The problematic global TB situation has remained unresolved because of various other 
limitations, which include high rates of latent TB infection, lack of understanding of the 
relationship between the mycobacteria and the host, emergence of drug resistant bacilli and 
poor adherence to treatment (Ruhwald & Ravn, 2009; Tsara et al., 2009; Lönnroth et al., 
2010).  
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1.2 TB prevention 
The structural challenges that are found in health systems have contributed to the continued 
scourge of TB. Also previous infection with M.tb is not protective. The currently used TB 
prevention methods, diagnostic tools as well as treatment regimens are old and inadequate 
(Lönnroth et al., 2010). Koch unsuccessfully tried to develop a TB vaccine soon after 
discovering M.tb in 1881(Brock, 1988). Bacillus Calmette Guérin (BCG), an attenuated live 
Mycobacterium bovis vaccine that is used in several countries including South Africa was 
developed by Calmette and Guérin and was first used in humans in 1921 (Clarke & Rudd, 
1992). Whereas BCG is capable of preventing disseminated forms of TB in infants and 
children (Rodrigues et al., 1993; Trunz et al., 2006) it has been found to be ineffective in 
adults (Fine, 1995). Guwatudde et al., (2003) have shown that BCG vaccination is associated 
with reduced risk of active TB among contacts. Knowledge about what constitutes an 
appropriate and effective immune response to M.tb is limited and there are presently no 
robust immune biomarkers of protection against TB. Lin and Ottenhoff (2008) argue that the 
current vaccine development initiatives have to overcome the challenges that are posed by 
pathogen strain heterogeneity and have to take account of the global host diversities. Several 
anti-TB vaccines have already undergone phase III clinical trials and others are in the 
pipeline. Recently, a promising BCG boosting recombinant novel vaccine that comprises 
Ag85A, Ag85B, and TB10.4 was tested on BCG vaccinated adults and has been found to be 
safe, immunogenic as well as capable of inducing polyfunctional CD4+ cells as well as 
enduring CD8+ cells (Abel et al., 2010). MVA85A, which expresses Ag85A, is another BCG 
boosting vaccine that has been shown to induce polyfunctional CD4+ cells in adolescents and 
children (Scriba et al., 2010).  Whether this translates to protection is yet to be discovered 
when the efficacy studies have been done. 
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1.3 TB Detection, diagnosis and treatment  
Early detection, diagnosis and effective treatment is central to the control of TB because it 
decreases transmission and the force of infection.  
1.3.1 Detection   
Several socio-economic barriers to early TB detection and treatment have been identified. 
These include alcohol and/or substance abuse, poverty, low access to health care facilities, 
old age, cultural beliefs and poor knowledge about TB (Storla et al., 2008). Some argue that 
delays in TB detection could be reduced through active case finding (Sekandi et al., 2009). 
Previously, it has been shown in one high incidence South African rural community that there 
were two undiagnosed TB cases for every nine cases of sputum positive pulmonary 
tuberculosis being treated at any one time (Pronyk et al., 2001).  
1.3.2 Diagnosing TB disease 
The importance of timely and quality diagnostic results in TB control cannot be over-
emphasized. Ineffective diagnostic tools as well as inadequate follow-up routines are central 
to delays in treatment initiation and once diagnosis was ascertained, treatment was promptly 
initiated (Storla et al., 2008). 
 
Clinical Signs and symptoms 
At the point of patient care, the identification of presenting clinical symptoms such as fever, 
chronic cough, loss of appetite, night sweats, and malaise among others by the health 
personnel is an important first line of TB diagnosis (American Thoracic Society, 2000). 
However, symptoms alone are not sufficient to diagnose and treat TB as other illnesses 
including bacterial and viral upper and lower respiratory tract infections, mycoses, 
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paragonimiasis and non-infectious conditions such as chronic obstructive pulmonary disorder 
may also cause some of these symptoms (Rosen, 2006).  
Chest X-ray 
The lungs are the primary sites of M.tb infection (Monack et al., 2004). Post-primary TB 
disease is characterized by the development of cavities in the lungs (Kritski & Fiuza de Melo, 
2007). The presence of cavitary disease in TB cases is associated with bacillary burden as 
well as with the clinical characteristics of the index case (Guwatudde et al., 2003). Other 
pulmonary abnormalities that may develop include infiltrations as well as calcification, which 
may be detected by a chest X-ray (American Thoracic Society, 2000).  However, a study in 
the Gambia observed that chest examinations alone were not wholly reliable in the diagnosis 
of TB as approximately 1% of sputum smear positive TB cases were reported to have a 
normal chest X-ray (Rathman et al., 2004).   
Microscopy using acid fast stain 
The identification of mycobacterial bacilli in sputum is critical for the diagnosis of active TB 
when not using culture (American Thoracic Society, 2000). M.tb and non tuberculous 
mycobacteria (NTM) are called acid-fast because they have an ability to resist de-
colourization with acid-alcohol solutions after staining with arymethane dyes such as carbol 
fuchsin because of the mycolic acid residues (Barrera, 2007). Acid fast bacilli (AFB) are 
detected from a sputum by a process that is initiated by the fixation of the smear, followed by 
the staining with carbol-fuchsin (a pink dye), and decolorization with acid-alcohol and 
counterstaining with methylene-blue with the AFB appearing pink in a contrasting 
background (Eisenstadt & Hall, 1995). Preliminary confirmation of mycobacteria through 
acid fast sputum smear is an easy, fast investigative tool that also provides a semi-
quantitative indication of the bacterial load even though it does not confirm M.tb because all 
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NTMs are acid fast and thus has to be complemented by culture; other limitations include the 
high number of bacilli required (at least 5 000 bacteria/mL), the high number of fields that 
have to be counted per specimen (at least 300 fields), which could lead to fatigue and error in 
high work-load situations (de Waard & Robledo, 2007). Sputum quality is also central to the 
success of the diagnosis. Poor quality sputum can lead to false negative findings (Hirooka, 
2004) while improved results may be attained through an induced sputum or a high-quality 
sputum (Alisjahbana, 2005). 
Culture 
 In order to confirm the presence of M.tb, the sputum has to be cultured in solid or liquid 
media, a process which also involves decontamination, antimicrobial susceptibility testing 
and confirmatory biochemical analysis or polymerase chain reaction (PCR) (Eisenstadt & 
Hall, 1995). While the benefits of sputum culture cannot be over-emphasized because of 
greater sensitivity, M.tb grows slowly, takes up to 48 days, with resultant delays in the 
confirmation of diagnosis. In addition the processes are costly, require complex laboratory 
settings and are potentially bio-hazardous. Furthermore there is always a possibility of cross-
contamination which would produce false positive results (de Waard & Robledo, 2007). 
Nucleic Acid Amplification Tests (NAAT) 
Nucleic acid amplification tests are quick and highly specific diagnostic tools that 
differentiate M.tb from other NTMs and involve a two-step, PCR method that is based on the 
genomic regions of difference (RD) corresponding to the presence of the different M. 
tuberculosis complex members (Warren et al., 2006). The PCR methods such as such as the 
GenoType® MTBDRplus assay have facilitated fast detection of resistant strains enabled 
(Evans, 2009). 
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Immunological diagnostic tools 
Markers of immune responses to M.tb antigens may provide invaluable diagnostic 
information.  It is well established that after inhalation, M.tb or its products are recognized by 
macrophage and dendritic cell (DC) toll like receptors (TLR), with a resulting process that 
induces intricate inflammatory responses including the secretion of cytokines and 
chemokines (van Crevel et al.,2002). The discovery of an immunological bio-signature 
resultant from M.tb infection may present an opportunity for the finding of diagnostic tools if 
specific enough. 
Serologic tests are simple to use and are relatively inexpensive and are based on antibody 
production to M.tb or some of its antigens is yet to be proven (Lighter et al., 2009a). Most 
serologic tests have proved disappointing (Pai et al., 2009). 
1.3.3 TB treatment 
Treatment of active TB is based on the World Health Organisation (WHO) guidelines which 
advocate for the use of fixed-dose combination drugs for 6 months and passive case finding 
(WHO, 2009b). In South Africa a combination of potent anti-tuberculosis isoniazid, 
rifampicin, pyrazinamide, streptomycin and ethambutol is used, with an initial intensive 
phase of 2-3months, and a continuation phase of 4-7 more months .Recently, another South 
African study conducted in a rural setting emphasizes the importance of active case finding as 
a strategy for timely treatment, especially in HIV infected individuals (Houlihan et al., 2010), 
but active case finding has not been implemented.  The efficacy of TB treatment however, 
depends on the susceptibility of the mycobacterial strain to the prescribed anti-TB drugs. TB 
control programmes are faced with the growing problem of multi-drug resistant TB which 
usually necessitates intensive and toxic drugs (Tsara et al., 2009). Inappropriate 
chemotherapy, poor adherence to treatment and prolonged periods of infectiousness due to 
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delays in susceptibility testing have been found to play a role in the spread of MDR-TB 
(Victor et al., 2007).The center for diseases control and prevention defines multidrug-
resistant TB (MDR TB) as TB that is resistant to at least two anti-TB drugs, isoniazid and 
rifampicin which are first-line drugs in the treatment of TB disease; and Extensively drug 
resistant TB (XDR TB) is described as is a type of MDR TB which in addition to being ris 
resistant to isoniazid and rifampin, it is also resistant to any fluoroquinolone and at least 1 of 
3 injectable second-line drugs (http://www.cdc.gov/tb/publications/factsheets/drtb.htm). 
Singh and co-workers (2007) argue that the emergence of XDR-TB in South Africa is a 
failure of the health system. The South African government states that MDR is both 
expensive to manage with a morbidity rate of at least 30% (The National Department of 
Health (1999).  A number of South African patients with active MDR-TB have been found to 
have had a prior TB episode (Calver et al., 2010). It is possible that these patients may have 
not adhered to treatment protocol or may have been re-infected with drug resistant strains.   
1.4 Diagnosing Latent TB infection (LTBI) 
M.tb is transmitted in aerosols from person to person. Close contact with an active TB case 
increases vulnerability to infection (Guwatudde et al., 2003; Hussain et al., 2007). It has been 
observed that the duration of contact with an active TB case is associated with risk of disease 
(Guwatudde et al., 2003). Approximately one third of the world’s population has 
asymptomatic sub-clinical and non-contagious TB infection (Dye et al., 1999). It is 
established that between 5%–10% of HIV negative individuals with LTBI will develop active 
TB in their lifetime (Horsburgh et al., 2004). These figures are higher in TB endemic areas. A 
recent study set in a crowded Western Cape community in South Africa reported a latent TB 
infection rate of 28% in the 5-10 year old group, increasing up to 88% among HIV negative 
individuals between 31 and 35 years of age (Wood et al., 2010). Hanifa et al., (2009) have 
also observed LTBI rates of 89% among South African miners. 
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In order to reduce the pool of latently infected persons, the WHO recommends that countries 
should implement policies which enable the tracing and diagnosis of people who are at risk of 
acquiring LTBI and concludes that citizens of those countries have benefitted from a 
significantly reduced prevalence of tuberculosis (WHO, 2009b). It has been suggested that 
TB endemic countries would also benefit from programmes that trace contacts of TB patients 
as an essential aspect of identifying and treating latent TB infection and to thereby reduce the 
incidence of TB (Morrisson et al., 2008). At present, tests that are available for LTBI 
diagnosis are based on demonstrating immunologic memory to mycobacteria (Ruhwald & 
Ravn, 2009). Because of the large numbers of people with LTBI and the pressing need to 
treat TB only children under 5 years who test TST positive are given a chemoprophylaxis 3 
months in South Africa (National Department of Health, 2000).  
The tuberculin skin test (TST)  
The tuberculin skin test (TST), which is commonly used to diagnose past or present 
tuberculosis infection, utilizes a purified protein derivative (PPD) of the tubercle bacilli. PPD, 
which is also known as tuberculin, is introduced into the skin by intradermal injection and the 
resulting delayed type hypersensitivity reaction (DTH; type IV) causes an induration to 
appear on the surface of the skin 48-72 hours later ((MMWR, 2000). In most studies that use 
the TST to determine infection with M.tb in HIV negative people an induration of > 10mm is 
taken as a positive result.  It has been observed that there is higher risk of being TST positive 
in household contacts of TB cases with higher smear grades (Lienhardt et.al, 2003; Okada et 
al., 2008). Cells and cytokines of both the innate and the adaptive immune systems are 
known to play a role in mounting the DTH reaction (Kobayashi et al., 2001). Many of the 
antigens that are present in PPD are also found in BCG and other mycobacteria, rendering 
TST non-specific (Lalvani & Pareek, 2009). A study that investigated household contacts in 
Gambia found that BCG vaccination may have an influence on TST (Lienhardt et al., 2003). 
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TST sensitivity and specificity is thus determined by a cut-off point; with a lower cut-off 
point resulting in higher sensitivity but lower specificity for M.tb (Mack et al., 2009). There 
are several other disadvantages to a TST. Individuals have to make 2 visits to a health facility 
which may be expensive and inconvenient. Furthermore the intradermal administration of 
tuberculin and the measurement of the DTH reaction induration are subjective (MWWR, 
2010).  
Interferon gamma release assays (IGRAs) 
Although mainly used in developed nations, interferon gamma release assays (IGRAs) are 
LTBI diagnostic tests that have recently gained widespread use. These diagnostic tools are 
also based on cell-mediated immune recognition of mycobacterial antigens and measure in 
vitro interferon gamma (IFN- production as part of effector immune response induced by 
stimulation with M.tb- specific antigenic such as 6 kilodalton (kDa) early secretory antigenic 
target (ESAT-6) and 10kDA culture filtrate protein 10 fusion protein (CFP-10) (Mack et al., 
2009; Ruhwald & Ravn, 2009). The main advantages of the IGRA are the availability of 
results within 24 hours without the need for a second visit as well as the objectivity in the 
results (MWWR, 2010). IGRAs are becoming accepted as accurate indicators of LTBI in low 
TB prevalence settings (Diel et al., 2008).  IGRAs have been found to be more specific when 
compared to TSTs in populations that use BCG vaccination (Mack et al., 2009). While there 
is not enough evidence available about the utility of these instruments in high prevalence 
settings, researchers that used ELISPOT to diagnose LTBI in Gambia advise that a negative 
ELISPOT result in the diagnosis of M.tb infection should be treated with caution ( Hill et al., 
2008). The Gambia has a TB prevalence rate of 404/100 000 (WHO, 2008). A major 
drawback of the IGRAs is that they require a blood sample to be tested within 6 hours of 
collection and in settings where the distances between the laboratory and the sample 
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collection points are large, delays in processing may decrease IGRA accuracy (Al-Orainey, 
2009). 
1.5 Latent TB infection in household contacts of active TB cases 
Studies of TB contacts offer an invaluable research platform in the understanding of the 
natural progression of M.tb infection. Although neither TST nor IGRA can distinguish 
between active and latent tuberculosis (Mack et al., 2009), the difference in their sensitivities 
for predicting progression to active TB was not found to be statistically significant (MWWR, 
2010). Consequently, the recent guidelines for detection of LTBI in vulnerable persons in the 
United States of America recommend the utilization of either a TST or IGRA for diagnostic 
purposes. Large longitudinal research studies into Human immunodeficiency Virus (HIV) 
negative household contacts of TB index cases in the developing world have found 
progression rates to active TB to be between 4% and 6.7% within 2 years of the initial contact 
(Teixeira et al., 2001; Wang & Lin, 2000; Hussain et al., 2007).  
1.6 The immune system 
1.6.1 The innate immune system 
The presence of a pathogen is recognized by immune receptors (pattern recognition 
receptors), which are present on surfaces of various cells including macrophages, dendritic 
cells (DCs), mast cells, neutrophils, eosinophils and natural killer (NK) cells, triggering the 
innate immune system (Janeway & Medzhitov, 2002). The main purpose of these pattern 
recognition receptors is to incite inflammatory responses including opsonization, activation 
of complement and coagulation cascades, phagocytosis, activation of proinflammatory 
signaling pathways, and induction of apoptosis (Medzhitov & Janeway, 1997). In TB, as an 
example, M.tb binds monocytes/macrophages via the complement receptors, the mannose 
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receptors and this process is facilitated by lipoarabinomannan, a glycolipid found on the 
mycobacterial surface which leads to phagolysosome fusion (Raja, 2004). A number of other 
receptors, such as Toll-like receptors (TLRs), recognize conserved pathogen associated 
molecular patterns (PAMPs) that are present among groups of microorganisms leading to the 
activation of the host innate inflammatory response (Flynn & Chan, 2001; Takeda et al., 
2003). TLR 2 is one of the most important TLRs in TB and gene polymorphisms in this TLR 
have been associated with increased susceptibility to TB (Yim et al., 2006; Chen, et al., 
2010).   
Circulating precursor dendritic cells (DCs)  enter tissues as immature DCs or directly 
encounter pathogens that induce secretion of cytokines which, in turn, can activate 
eosinophils, macrophage and natural killer (NK) cells (Banchereau et al., 2000). DCs are the 
initiators as wells as the modulators of the immune response and are involved in a complex 
system which begins with the recognition and capture in peripheral tissues of antigens which 
bind to the molecules of the major histocompatibility complex (MHC) that are on their 
surfaces (Banchereau & Steinman, 1998). These allow for the selection of rare circulating 
antigen-specific lymphocytes. After encounter with M.tb, DCs undergo maturation after-
which they migrate to the draining lymph nodes where they play a critical antigen presenting 
function (Bhatt & Salgame, 2007). DCs are not only vital for T-cell stimulation as well as for 
B-cell growth and immunoglobulin secretion, but are also critical in preventing autoimmunity 
(Banchereau & Steinman, 1998). The microenvironment determines the effector function of 
the DCs. They may differentiate and become involved in enhanced antigen presentation; or 
escalate antigen degradation; induce either immunity or tolerance; or may lead to the 
polarization of T cell responses towards type 1 or type 2.  
Macrophages are the first line of non-specific host defenses; recognize invading pathogen or 
antigen via cell-surface receptors; binding them and ingesting them in a process called 
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phagocytosis and producing a number of cytokines and chemokines which in turn influence 
the immune responses (Bhatt & Salgame, 2007). 
NK cells are bone-marrow derived lymphocytes that have been shown to lyse tumor-derived, 
virus-infected cells in the absence of previous sensitization or activation (Trinchieri, 1989). 
They are mainly activated by interleukin-12 (IL-12) and play an important role in the innate 
immune system (Trinchieri, 1995), producing large quantities of IFN‐,  Tumor Necrosis 
Factor  (TNF  as well as Macrophage inflammatory protein (MIP-1) chemokines (Biron et 
al., 1999). NK cells are activated via two types of receptors which either recognize MHC 
class I–like ligands or do not and thus have multiple recognition systems that are able to 
respond to diverse abnormalities arising from various situations (Raulet et al., 2001). 
Neutrophils are cells of the innate immune system that are granular and have large vacuoles. 
The pathogens are killed and digested by the protein found in the granules which is released 
by the neutrophils after they have phagocytozed the microbe (Segal, 2005).  
Although gamma delta (T cells are plastid and play a role in innate immunity, antigen 
presentation and regulation of the DC function (Casetti & Martino, 2008) they are thought 
play an important bacterical role in M.tb (Dagna et al., 2002). 
1.6.2 The adaptive immune response 
There are 3 different Th cells: Th1, Th2 and Th17 cells. IL-12 is an important factor for the 
differentiation of naive T cells into IFN--producing Th1 cells. Both IL-12 and IL-23 are 
critical in linking the innate and the adaptive immune responses and continue to exert their 
effects after the adaptive immune system has been activated either through the classical Th1-
type response or the IL-23/IL-17 immune pathway to create Th17 cells (Langrish et al., 
2004).  
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It is now established that after T cell receptor activation has been triggered by the antigen-
presenting cells (APCs), the cytokine milieu decides the direction of CD4 T cell 
differentiation to Th1, Th2,  Th17 or induced iTreg effector cells through a complex process 
that is determined by several transcription factors, master regulators, as well as STAT family 
proteins; Th1, Th2, and Th17 cells are important for eradicating intracellular pathogens, 
helminthes, and extracellular bacteria/fungi, respectively (Zhu et al., 2010). The expansion of 
complex T cell populations after bacterial infection is accompanied by an increase in their 
overall affinity for the antigen (Busch & Pamer, 1999). 
CD4 T cells are critical for the outcome of any infection because they direct the ongoing 
immune response through the secretion of cytokines; and for a long time were classified into 
Th1 and Th2 subsets until a third set, Th17 cells was discovered (Szabo et al., 2003).  Th1 
and Th17 cells are also involved in many types of autoimmune diseases, whereas Th2 cells 
contribute to allergic responses (Zhu & Paul, 2008). In TB, it has recently been shown by 
Scriba and co-workers (2008) that there was a population of CD4+ T cells that expressed 
either IL-17 or IL-22 and that IL-17 producing cells were found to be lower in TB patients 
compared to persons that have been exposed to mycobacteria. 
There are several populations of regulatory T cells (Tregs) that play a role in the maintenance 
and control of immune responses by regulating the magnitude of effector immune responses 
and are thus able to control the intensity of secondary responses to infections. These include 
IL-10 producing Tregs as well as Foxp3+ Tregs, which are critical in maintaining self-
tolerance and in modulating immune responses to infections (Belkaid & Tarbell, 2009). 
CD8+ T cells often play a major role in immunity to viral and intracellular bacterial 
infections (Zinkernagel et al., 1996) and identify pathogen-derived peptide epitopes which 
are presented by MHC class I molecules on the surface of infected cells (Germain, 1994). 
14 
 
Antigen-naive CD8+ T cells that are exposed to stimuli and increase chemokine receptor 5 
(CCR5) expression, wait for the DC to present the appropriate antigen, adhere and begin to 
secrete Chemokine ligand 3 (CCL3) and CCL4 leading to attraction of more DCs as well as 
CD8+ cells (Castellino & Germain, 2006).   
1.7 The host immune response to M.tb  
The tipping of the balance during the interaction between M.tb and its human host determines 
the outcome of infection. It is understood that although several factors may be responsible, 
the ability of the host’s innate immune system to contain the initial infection is critical (van 
Crevel et al., 2002). IFN- alone is not sufficient to protect against M.tb but this cytokine 
does play an important role in the fight against tuberculosis (Flynn et al., 1993; van Crevel et 
al., 2002; MacMicking et al., 2003; Abebe et al., 2005; Flynn & Chan, 2005).  Once M.tb is 
established within alveolar macrophages, it is thought that an interplay between TNF- and 
IFN- induces the infected macrophages to differentiate into epitheliod cells which fuse 
together to form multinucleated cells. The resulting giant cells form the centre of the 
granuloma, a system that is still poorly understood, but believed to be maintained by 
chemokines and cytokines (Ruhwald & Ravn, 2009). These mediators of inflammation are 
thus important tools in the understanding of the M.tb infection and their measurement could 
be used as a biomarker or biosignature for infection.  
 
1.8 The M.tb antigens – proteomics 
The advent of genomics has brought with it the possibility of advancing knowledge in the 
sphere of TB prevention, diagnosis and treatment. Consequently, 16 genetic regions of 
differences (RD1 to RD16) between M. tuberculosis and M. bovis have been elucidated (Behr 
& Small, 1999). It has been observed through the use of synthetic peptide pools that proteins 
encoded by some regions of difference may play a role in immune protection against TB, 
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while other regions may be responsible for pathogenesis (Al-Attiyah & Mustafa, 2008).  
Proteins that are encoded by RD1 (ESAT-6 and CFP-10) and RD11 (TB7.7) have been used 
successfully as LTBI diagnostic tools (Mack et al., 2009).  
Several studies have attempted to simulate the micro-environment of M.tb under different 
stress conditions, including oxygen depletion, nutrient reduction, changes in pH and 
accumulation of growth limiting products. These studies have led to the discovery of 48 
specific genes encoded by the dormancy (DosR) regulon that are expressed during non-
replicating persistence (NRP), a state in which the bacteria slows its metabolic activity and 
stops replicating (Wayne & Hayes, 1996; Boon & Dick, 2002; Voskuil et al., 2003; Murphy 
& Brown, 2007). It has been suggested that conditions that are favourable to the growth of 
the mycobacteria lead to the expression of a family of 5 genes called Resuscitation Promotion 
Factors (RPFs) (Mukalomova et al., 2002; Downing et al., 2005; Hett et al., 2007; Kana et 
al., 2008). Studies of the immunogenicity of the proteins expressed by M.tb during different 
stages of growth have ushered an era that could lead to the discovery of improved vaccine, 
diagnostic, and anti-mycobacterial products.   
1.9 Cytokine bio-signatures – Luminex technology 
Luminex is a fluorescent bead based time-saving technique that operates on the sandwich 
principle similar to that of the ELISA assay. This tool presents an opportunity to study and to 
quantify immune responses by simultaneously measuring up to 100 cytokines in theory in 
small samples which in most cases are precious. Although Luminex is a new technology, 
there are several research studies focusing on TB that have been published using this 
platform.  Recently it has been shown that TST conversion is associated with early increases 
in IFN-γ and IL-10 responses and that this phenomenon preceded latency by several months 
post exposure (Hussain et al., 2009). Chegou et al., (2009) have recently shown that the 
combinations of (Epidermal growth factor) EGF, Soluble CD 40 Ligand (sCD40L), Vascular 
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endothelial growth factor (VEGF), Transforming growth factor alpha (TGF and IL-1 
differentiate between latent and active infection. In the Gambia, IL-13, IL-17 and IL-18 have 
also been shown to discriminate between latent and active TB (Sutherland et al., 2009). In a 
study done in Guinea Bissau Monocyte chemotactic protein-1(MCP-1), MCP-2, MCP-3, 
Interferon inducible protein 10 (IP10) and Interleukin-1 receptor antigen (IL-1RA), all could 
discriminate between unexposed healthy controls and active TB cases (Ruhwald et al., 2009). 
1.10 The current study  
The whole blood assay (WBA) is an in vitro technique that enables circulating T cells to 
respond to antigenic stimulation by producing cytokines which can be quantified (Weir et al., 
1994). In the current study, novel M.tb antigens were used to stimulate diluted whole blood in 
culture for 7 days in order to measure cytokine production in harvested supernatants. All 
participants included in the current studies were HIV-1 antibody negative. The first aim of 
the study was to cross-sectionally compare the IFN- response to classical and novel M.tb 
antigens in TST negative household contacts, TST positive household contacts and newly 
diagnosed active TB index cases prior to treatment. This was done in order to identify 
antigens that could significantly differentiate between active TB and latent M.tb infection (as 
measured by the TST). As IFN- is a central cytokine associated with a protective immune 
response to M.tb infection, an IFN-ELISA was used for this purpose. The results of this 
work are described in Chapter 2. The second aim was to longitudinally assess immune 
responses in the group that was TST negative at recruitment; multiple cytokine responses 
were measured using Luminex technology at recruitment and 6 months later, by which time a 
proportion of the TST negative subjects had converted to TST positive. This was done in 
order to ascertain whether there is a multi-cytokine profile that is associated with fast TST 
conversion versus slow TST conversion assuming the TST negative subjects would convert at 
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some point. Understanding the cytokine signature that is associated with recent M.tb infection 
may facilitate the future discovery of improved biomarkers for disease progression. 
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CHAPTER 2: Interferon gamma responses to novel M.tb antigens in active TB cases 
and TB contacts with different tuberculin skin test reactions  
2.1 Introduction 
It is well established that close contacts of active tuberculosis (TB) patients are most 
vulnerable to infection (Guwatudde et al., 2003; Hussain et al., 2007). After inhalation, M.tb 
and its human host engages in a continuous struggle, which may lead to sub-clinical disease 
and, in some instances, may continue to symptomatic clinical disease (Young et al., 2009). 
The initial response to the M.tb challenge involves the host’s innate immune cells including 
alveolar macrophages, dendritic cells and monocytes, resulting in the induction of 
phagocytosis and the production of cytokines as well as chemokines (van Crevel et al., 2002).  
Whereas in some cases the innate immune system can eliminate M.tb effectively, in others 
the involvement of the adaptive immune system may become necessary to kill or to control 
the invading mycobacteria (Bhatt & Salgame, 2007). Should asymptomatic sub-clinical 
disease become established, it is said that individuals have latent TB infection (LTBI, which 
is currently accepted as a continuum or dynamic state (Young et al., 2009; Barry et al., 
2009). For a long time LTBI has been defined according to the results of a tuberculin skin test 
(TST), also known as the Mantoux skin test, and is diagnosed using Tuberculin, a purified 
protein derivative (PPD) which is injected intradermally and causes a delayed type IV 
hypersensitivity reaction in individuals that are infected with mycobacteria (Mack et al., 
2009).   
The centuries of co-existence between M.tb and humans have led the mycobacteria to evolve 
and to devise mechanisms that enable it to evade the host’s immune assault (Flynn & Chan, 
2005). While not completely understood, it is widely accepted that, upon being challenged by 
adverse conditions, which are part of the immune response, including oxygen depletion, 
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nutrient reduction, changes in pH, as well as accumulation of growth limiting products, M.tb 
may progressively reduce its metabolic activity, stop replicating and enter a phase known as 
Non Replicating Persistence (NRP) (Wayne & Sohaskey, 2001; Monack et al., 2004).  This 
stage is preceded by an up-regulation of 48 specific genes encoded by the DosR /Rv3133c 
regulon (Wayne & Hayes, 1996) (Boon & Dick, 2002; Voskuil et al., 2003; Murphy & 
Brown, 2007).  
NRP creates a reservoir of bacilli that could be reactivated when conditions become favorable 
for growth (Monack et al., 2004). Prior to reactivation, bacilli express genes that are 
associated with chromosomal division (Bacon & Marsh, 2007). Reactivation is also 
associated with granuloma enlargement (Kaufmann, 2006). Progression from NRP to a state 
of increased metabolic activity and replication is also preceded by the expression of a family 
of 5 genes called Resuscitation Promotion Factors (RPFs), (Mukalomova et al., 2002; 
Downing et al., 2005; Hett et al., 2007; Kana et al., 2008) which are regulated independently 
of one another (Kana & Mizhari, 2010). These RPF genes, namely rpfA (Rv0867c), rpfB 
(Rv1009), rpfC (Rv1884c), rpfD (Rv2389c), and rpfE (Rv2450c) are also thought to be 
important for bacterial virulence (Kana et al., 2008), and have been detected in bacilli during 
acute infection as well as throughout the stationary growth phase (Tufariello et al., 2004), 
even though they are not critical for bacterial growth (Downing et al., 2005; Hett et al., 2007; 
Kana et al, 2008). Kana and Mizhari (2010) posit that the main function of RPFs is to enable 
the bacilli to recover from the host’s immune damage by re-modelling the bacterial cell wall. 
The significance of RPFs in in vivo processes has been enhanced by the recent detection of 
RPF-dependent cells in human clinical sputum which illustrates the presence of non-
replicating bacilli in these samples (Mukalomova et al., 2010).   
In spite of recent advances in this field, the exact mechanisms of reactivation remain 
unknown. The expression of Rv3407, Rv1131 and Rv1471 by M.tb is thought to be 
20 
 
associated with reactivation. A recent study by Schuck et al. (2009) has shown that Rv3407 
could discriminate between LTBI and active TB cases. Rv3407 encodes an antitoxin (Golby 
et al., 2007) and is influenced by RPFs which interact with RipA (Hett et al., 2007). Rv1131 
encodes a citrate synthase which is an enzyme of the TCA (Krebs) cycle (Cole et al., 1998). 
Rv1131 protein has a role in the methylcitrate pathway (Munoz-Elias et al., 2006), and is also 
implicated in the pathogenicity of M.tb (Fontán et al., 2009). Rv1471 belongs to the 
thioredoxin family and functions as a disulfide reductase, maintaining the redox state of 
cytosol during oxidative stress (Akif et al., 2008).  
 
Stellenbosch University is one of seven African field sites involved in an international 
collaborative effort to identify biomarkers of protection against TB in the context of HIV.  
This collective venture, known as GC6, is the 6th in a series of Grand Challenges in Global 
Health, an initiative launched in 2003 by the Bill & Melinda Gates Foundation 
(http://www.gcgh.org). One of the goals of the GC6 project is to determine the natural 
immune profile of latently infected individuals by investigating their IFN-responses to a 
panel of novel M.tb antigens. IFN-production is widely accepted to be one of the most 
significant cytokines produced in a protective immune response against TB (Flynn & Chan, 
2001; Raja, 2004; Monack et al., 2004).  To achieve this objective, 86 M.tb antigens 
including proteins associated with latency, starvation, resuscitation and reactivation, were 
screened for their ability to induce IFN-responses in TST positive HIV negative adults 
across the African sites (Black et al., 2009). A final panel of the 22 most promising antigens 
was selected for inclusion in the longitudinal study.   
The present M.Sc. project was conducted as a sub-study of GC6. Using the 7-day diluted 
WBA that was developed by Weir and colleagues (1994) we have examined the in-vitro IFN-
 response elicited by all 22 M.tb antigens routinely tested in the GC6 study. This has been 
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done in TST negative and TST positive household contacts (HHC) as well as in untreated 
active TB patients, at the time of recruitment into the GC6 study. This study was done in 
order to 1) expand the body of knowledge that seeks to identify M.tb derived candidate 
proteins for inclusion in post-exposure vaccines which may offer protection against 
progression to active TB disease 2) provide additional information about putative immune 
correlates of protection against tuberculosis.  
2.2 Study Design and Methods 
2.2.1 Setting 
The study participants were recruited from the suburbs of Uitsig, Ravensmead, Elsiesriver 
and Adriaanse in Tygerberg District, Western Cape Province, South Africa. This is an area 
with low HIV prevalence but a high incidence of TB of 764/100 000 (Kritzinger et al., 2009). 
2.2.2 The tuberculin skin test (TST)  
The TST was done on HHC immediately after collection of blood. Two tuberculin units of 
M.tb PPD RT23 for in vivo use (Statens Serum Institute, Denmark) were administered 
intradermally on the distal forearm and read 48 -72 hours later by trained study nurses. The 
TST was considered positive if the induration was > 10mm, and negative if there was no 
visible induration (0mm). The skin test was repeated only in HHC that were TST negative at 
recruitment; at each subsequent study time point (6 and 18 months, see 2.2.3 below) until 
conversion was observed.    
2.2.3 Study population 
HHC were recruited from the 4 suburbs mentioned above. For inclusion in the study, contacts 
had to be between 10 and 60 years old; have been residing with a sputum positive adult TB 
case diagnosed within the past 2 months; agree to the tuberculin skin test procedure and; to be 
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tested for HIV. HHC were actively followed up at months 6, 18 and 24. An assisted sputum 
sample for microscopy and culture was obtained from the contacts by physiotherapy trained 
nursing assistants using percussion. Exclusion criteria for the study were presence of cancer, 
diabetes mellitus, chronic emphysema/ bronchitis/ asthma requiring steroid therapy or any 
steroid therapy within the past 6 months; previous or current treatment of TB or HIV; current 
or recent (within 6 months) participation in a vaccine/clinical trial; pregnancy and; absence of 
a permanent physical address or if the individual had not been living in the study area for at 
least 3 months. All participants gave informed consent and the study was approved by the 
ethics committee of Stellenbosch University. 
 
By May 2009, 893 HIV negative HHC had been recruited into the GC6 study. At study 
enrollment, 829 participants (92.8%) tested TST positive (induration > 10mm) and 64 (7.2%) 
were TST negative (no visible reaction). At month-6 follow up, of the 64 participants who 
had tested TST negative at recruitment, 29 (45.4%) were not skin tested again. Consequently, 
their TST status at month 6 is not known. Twenty six originally TST negative participants 
had converted to TST positive by month 6 (40.6%) while 9 (14%) remained TST negative. 
These 9 participants were skin tested again at month 18 by which time 8 (88.9%) had 
converted to TST positive with only 1 individual remaining TST negative (Figure 2.1). This 
participant was not tested again at month 24.  
New active TB cases between the ages of 10 and 60 years were identified through the 
Department of Health community clinics in the 4 suburbs mentioned above, and introduced 
into the GC6 study by research nurses. Eligibility as a TB index case was based on pre-
defined case definitions (Table 2.1). Sputum ZN smears, liquid culture and chest x-rays were 
done and the likelihood of the disease recorded by a study clinician. After enrolment into the 
study, all patients diagnosed with TB received chemotherapy as per national guidelines. 
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At recruitment 
    
Month 6 
   
  Month 18 
Figure 2.1 TST status at recruitment, 6 months and 18 months in study participants 
enrolled into the GC6 household contact study. All household contacts recruited into the 
GC6 study were skin tested with M.tb PPD at enrollment. In TST negative subjects the TST 
was repeated at months 6 and again at month 18 if there was no reaction at 6 months. 
  
893 HHC  
829 TST + 64 TST -  
29 TST not done 26 TST +  9 TST -   
1 TST -   8 TST +   
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Table 2.1 GC6-74 Clinical Case Definition For TB diagnosis. Table 2.1:  Definite TB had 
to have one of (a) > two positive culture sputum results with acid fast bacilli in liquid culture; 
or (b) > one positive sputum culture with a chest X-ray suggestive of TB. Probable TB  had 
to have one of (a) > one culture positive, with > one symptom compatible with TB and a 
chest X-ray not suggestive of TB; or (b) negative cultures and a chest x-ray suggestive of TB; 
or (c) negative cultures and 2 positive sputum smears.  Possible TB had to have one of (a) 
>one positive culture and chest X-ray not suggestive of TB; or (b) negative cultures and a 
chest X-ray suggestive of TB or (c) negative culture and a chest X-ray not suggestive of TB, 
but >2 positive or scanty smear with symptoms compatible with TB. An unlikely TB case 
had to have negative cultures and a chest X-ray not suggestive of TB.   
  
Culture 
1 
Culture 
2 AFB 1 AFB 2 CXR Symptoms
Treatment 
response Class 
+ + Irrelevant Irrelevant Irrelevant Irrelevant Irrelevant Definite 
+ Negative Irrelevant Irrelevant + Irrelevant Irrelevant Definite 
+ Negative + Irrelevant Negative + Irrelevant Probable
+ Negative Negative Negative Negative + + Probable
Negative Negative + Negative + + Irrelevant Probable
Negative Negative + Negative + Irrelevant + Probable
Negative Negative Negative Negative + + + Probable
Negative Negative + + + Irrelevant Irrelevant Probable
Negative Negative + + Negative + + Probable
+ Negative + Irrelevant Negative Negative Negative Possible 
+ Negative Negative Negative Negative + Negative Possible 
+ Negative Negative Negative Negative Negative Negative Possible 
Negative Negative + Negative + Negative Negative Possible 
Negative Negative Negative Negative + + Negative Possible 
Negative Negative Negative Negative + Negative + Possible 
Negative Negative + Negative Negative + + Possible 
Negative Negative + Negative Negative + Negative Unlikely 
Negative Negative Negative Negative Negative + + Unlikely 
Negative Negative Negative Negative Negative + Negative Unlikely 
Negative Negative Negative Negative Negative Negative Negative Unlikely 
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Of the 26 participants that were TST negative at recruitment and converted to TST positive 6 
months later, whole blood assay supernatants were available for 17 (see 2.2.5 below). The 
same number of age and gender matched recruitment TST positive contacts and active TB 
cases that also had whole blood supernatants available were identified using the project 
database. The clinical and demographic data of the study population is shown in Table 2.2.   
The median ages of the study participants were 25 years for the TST negative group, 30 years 
for the TST positive group and 23.5 years for the TB index cases.  Males comprised 36.8% of 
participants in both the TST negative and the TB index case groups while they made up 
30.7% of the TST positive group. TST positive participants had skin test indurations ranging 
between 10mm and 33mm (median 17mm) at recruitment. A visible BCG scar was recorded 
in 41.1% of the TST negative group, 52.9% of the TST positive group and 56.3% of the TB 
index cases.  
The degree of exposure of the HHC to their respective index cases was determined using a 
contact score (Table 2.4). The total contact score was calculated by adding the weights for 
infectivity of the index case (based on smear grade), duration of exposure to the index case, 
proximity of exposure, and relationship of the contact to the index case (Hesseling et al., 
2009). 
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Table 2.2 Clinical and demographic information of study population. Characteristics of 
the three study groups at study recruitment, with details on BCG scar status, TST induration 
and, for HHC, the gradient of exposure to the TB index case. For those study participants that 
were TST negative at recruitment, the median TST size (and range) as measured at the 6 
month time point is shown.   
 
2.2.4 Blood Samples and HIV testing 
Peripheral blood was obtained in 10ml heparinised tubes at recruitment from each study 
participant (Becton Dickinson (BD), San Diago, USA). Blood was transported to the 
laboratory and processed under sterile conditions within 2 hours of collection in a laminar 
flow hood. Each participant was tested for HIV using a rapid test after pre- and post-test 
counseling (First Response HIV Card 1–2.0, PMC Medical India Pty Ltd, Daman, India).   
2.2.5 Whole blood assay 
The WBA followed a previously described method (Weir et al., 1994).  Diluted whole blood 
(1:10 with RPMI 1640 1% (Sigma)  + L-glutamine) was incubated in triplicate with 
recombinant protein antigens (10g/ml final) in 96-well tissue culture plates (Nunc) (370 C, 
5% CO2) in a volume of 200l per well.  Supernatants were harvested on day 7 and stored at 
 TST Negative  
at study recruitment 
TST positive  
at study recruitment 
TB  index 
case 
Number of participants 17 17 16 
Age median in years,  
(range)  
25 (10 - 52) 30 (14 - 51) 23.5 (17 - 
49) 
Male/female ratio 7 /10 7/10 5/11 
BCG vaccine documented or 
scar present, n(%) 
7(41.1) 9 (52.9) 9(56.3) 
Median TST induration  
at recruitment,  
(range, mm) 
0 17(10 - 33) Not done 
Median TST induration at 
month 6, (range, mm) 
17 (10 - 24) Not done Not done 
Median M.tb contact score 12 (10 - 12) 12 (8 -12)  
BCG vaccine documented  
or scar present, n(%) 
7 (41.1) 9 (52.9) 9(56.3) 
27 
 
-800 C. The negative control was RPMI alone. Phytohemagglutinin (PHA) (Sigma) (5g/ml) 
and SEB (1g/ml) were used as positive controls. 
2.2.6 Antigens 
All antigens were produced and quality controlled by Leiden University Medical Center 
(LUMC) as described previously (Leyten et al., 2006). Purity and size were checked by gel 
electrophoresis and Western blotting with anti-His antibodies and anti-E.coli antibodies. 
Residual endotoxin levels were determined with a Limulus amebocyte lysate assay 
(Cambrex) and found to be below 50 IU/mg recombinant protein. A total of 17 recombinant 
antigens were tested; 11 DosR regulon encoded proteins, 3 antigens associated with the 
reactivation of M.tb and 3 RPFs. All recombinant antigens were tested at 10g/ml. Five 
‘classical’ TB antigens were also included.  All antigens and controls and their final dilution 
in blood was 1 in 10 and are listed in Table 2.3.1 - Table 2.3.4. 
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Table 2.3.1 Classical M.tb antigens 
Table 2.3.1 List of classical M.tb antigens tested. Rv-numbers denote the names of the 
protein products. 
Mehta et al, 2007  
Zvi et al, 2008 
Rogerson et al, 2006 
Black et al, 2009 
Lin et al, 2009 
*Borsuk et al, 2009 
 
  
ANTIGEN 
NAME M.tb GENE 
PROTEIN SIZE 
(a.a) DESCRIPTION 
M.tb PPD   173 proteins* 
Esat6/CFP10 fusion product - ESAT-6 and CFP-10 fusion protein 
Rv3019 esxR 96 TB10.3; Secreted ESAT-6-like protein 
TB10.4 
(Rv0288) esxH 96 
Low molecular weight protein 
Antigen 7 
Ag85A 
(Rv3804c) fbpA 338 Secreted Antigen 85A 
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Table 2.3.2 Dos-R regulon antigens  
ANTIGEN NAME M.tb GENE  OR 
PROTEIN FUNCTION 
PROTEIN SIZE (a.a.) 
Rv1737c narK2 395 
Rv2029c pfkB 339 
Rv1733c  Possible transmembrane 
protein 
210 
Rv1735c CHP 165 
Rv0081 Transcriptional regulator 114 
Rv0569 CHP 88 
Rv2028c CHP 279 
Rv2031c acr (HSPX) 144 
Rv3131 Two component response 
regulator 
332 
Rv2659c phiRV2 integrase 375 
Rv2660 peptide 
pool  
HP 75 
Table 2.3.2: List of DosR regulon Latency Antigens tested. Rv-numbers denote the names of 
the protein products. Italicised names designate the gene region and capitals the protein 
function. HSP indicates heat shock protein, and CHP and HP indicate conserved hypothetical 
and hypothetical proteins 
Wayne & Hayes, 1996 
Wayne & Sohaskey, 2001 
Boon & Dick, 2002 
Voskuil et al., 2003 
Monack et al, 2004 
 Voskuil et al., 2004 
Leyten et al, 2006 
Murphy & Brown, 2007  
Roupie, et al, 2007 
Black et al, 2009 
Lin et al, 2009 
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Table 2.3.3 Resuscitation Promotion Factors 
 
Table 2.3.3 List of all the Resuscitation-promoting Factors tested. Rv-numbers denote the 
names of the protein products. Italicised names designate the gene region and capitals the 
protein function. 
Mukalomova et al, 2002  
Tufariello et al, 2004 
Downing et al, 2005  
Hett et al, 2007 
Kana et al, 2008  
Kana and Mizhari 2010  
Mukalomova et al, 2010   
Table 2.3.4 Reactivation Antigens 
ANTIGEN 
NAME M.tb GENE or PROTEIN FUNCTION 
PROTEIN SIZE 
(a.a.) 
Rv1131 gltA1 393 
Rv1471 trxB 123 
Rv3407 * CHP 99 
Table 2.3.4: List of all Reactivation Antigens, produced by the Wayne model, tested. Rv-
numbers denote the names of the protein products. Italicised names designate the gene region 
and capitals the protein function. HSP indicates heat shock protein, and CHP and HP indicate 
conserved hypothetical and hypothetical proteins. NB*: This antigen was provided by the 
Max Planck Institute for Infection Biology, Berlin, Germany. 
Cole et al, 1998 
Downing et al, 2004 
Munoz-Elias et al, 2006 
Golby et al, 2007 
Akif et al, 2008 
Fontán et al, 2009 
Schuck et al,2009   
  
ANTIGEN 
NAME 
M.tb 
GENE  
PROTEIN SIZE 
(a.a.) DESCRIPTION 
Rv2450 rpfE 172 Probable Resuscitation-promoting factor 
RPFE 
Rv0867c rpfA 407 Possible Resuscitation-promoting factor 
RPFA 
Rv1009 rpfB 362 Possible Resuscitation-promoting factor 
RPFB 
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2.2.7 IFN- ELISA response cut-off 
The IFN- ELISA followed a previously described method (Black et al., 2001).  Briefly, 
antibody pairs from Becton Dickinson were used for cytokine (IFN-) assessment by ELISA. 
Supernatants were analyzed in duplicate in 96 well plates, which had been coated overnight 
at 4 0C with a primary antibody. Ag-Ab complex reacted with avidin peroxidase and 
enzymatic activity was measured with OPD at 490nm using a 4 parameter log curve (4PL). 
The lower detection limit of the standard curve was 31pg/ml and the upper detection limit 
4000pg/ml. Low undetectable responses were assigned a value of 15pg/ml. The negative 
control value for each study participant was subtracted from the antigen-induced IFN- 
values so that all response values could be considered over and above the background 
response. 
 A standard method that has been used by others (Lewinsohn et al., 2008) to determine the 
cut-off for a positive IFN- response is to add the average of the negative control values of all 
participants included in the analysis to two times their standard deviation. However, all 
negative control values in our data set were read off the standard curve as 0pg/ml, which was 
converted to 15pg/ml (as described above). A value of 15pg/ml could not be considered to 
discriminate between responders and non-responders to antigenic stimulation because it was 
out of range of the standard curve. Therefore, following subtraction of the negative control, a 
positive response was defined as an IFN- concentration greater than 62 pg/ml, which 
represents twice the lowest detection limit of the ELISA (lowest point on the standard curve 
is 31pg/ml). This method of defining a cut-off has been published by ourselves and others 
previously (Black et al., 2003; Lin et al., 2007).  
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2.2.8 Statistics  
The Mann-Whitney test (two tailed) was used to investigate differences in the median 
responses between study groups. Correlations between antigen responses were assessed with 
the Spearman correlation coefficient.  Fisher’s exact test was used to establish differences 
between groups. A p value of < 0.05 was considered significant. Power calculations were not 
done. 
2.2.9 Research Questions 
 In the initially TST positive group: 
Is TST induration size associated with either gender, age or BCG scar at recruitment? 
 In the group that convert from TST negative to TST positive at 6 months:  
Is the 6 month TST induration size associated with gender, age or BCG scar? 
 Are there differences in the TB exposure gradients between HHC who are TST 
negative at recruitment and those who are TST positive at recruitment? 
 Is there a relationship between the TST status of the HHC and the smear grade of their 
respective TB index case? 
 Can antigen induced whole blood cytokine responses distinguish between the 3 
distinct groups of HIV negative adults included in this study: TST negative HHC 
(0mm), TST positive (> 10mm) HHC and new active TB disease prior to initiation of 
therapy.  
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2.3 Results 
2.3.1 Comparison of the clinical and demographic information 
In the group that were TST positive at recruitment, no association was observed between TST 
induration size and either age or gender.  All study participants that were TST negative at 
recruitment had converted their skin test by month 6 and, again, TST induration was not 
associated with gender or age in this group.  BCG scar status (presence or absence) was not 
associated with TST induration size in the TST positive group at recruitment or the TST 
negative group following conversion at 6 months. Furthermore, the BCG status did not have 
an influence on TST grouping of contacts (Fisher’s Exact Test, p=0.11).  
No differences were observed in total contact scores between the TST positive and TST 
negative participants at recruitment. 
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Table 2.4 TB Contact Score of Household Contacts To TB Index Cases. The degree of 
exposure of the HHC to the TB index case was determined by adding the weight of each of 
the variables. From Hesseling et al., 2009. 
 
 
 
Variable Weight 
Relationship to index case (relation)  
 No known TB contact 0 
 Non-household TB contact 1 
 Other relative/friend in household with TB 2 
 If a child: secondary caregiver (care provider during day) in household 
with TB 
3 
 If a child: primary caregiver in household with TB 4 
Infectivity of index case (infectivity)  
 No known TB contact 0 
 Sputum acid-fast negative 2 
 Sputum acid-fast positive 4 
Type of exposure to index case (proximity)  
 No known exposure 0 
 Lives and sleeps in different house (e.g. different structure on same plot or 
completely different plot and house) 
1 
 Lives and sleeps in same house  2 
 Sleeps in same room 3 
Duration (total hours) contact per day with TB index case (duration)  
 No known contact 0 
 0-3 h 1 
 4-7 h 2 
 8-11 h 3 
 ≥ 12 h 4 
Total contact score (maximum score = 15)  
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As Shown in Table 2.4 the contact score considers positive sputum as a single factor but does 
not consider the grading of the smear. In our setting, sputum smears are graded according to 
the World Health Organization recommended grading system, which has five (5) groups. A 
negative smear grade indicates that no acid fast bacilli were seen in at least 100 fields; scanty 
indicates between 1 and 9 bacilli were observed in 100 fields; 1+ indicates between 10 and 99 
bacilli were detected in 100 fields; 2+ indicates 1 to 10 bacilli per high power field and 3+ 
indicates more than 10 bacilli per higher power field (Rieder et al., 2007).  We investigated 
whether there was an association between the TST status of the HHC at recruitment (positive 
vs negative) and the smear grade (scanty, 1+, 2+ and 3+) of their respective TB index cases. 
Although two sputum samples were obtained per TB case, only the highest smear grade was 
considered in the analysis. Sputum smear information for 3 TB index cases (for 1 TST 
negative and 2 TST positive contacts) was not available. A sputum smear of 2+ or higher was 
documented for 83% of the TB index cases in contact with TST positive participants 
compared to 72% of cases in contact with TST negative subjects (Figure 2.2). These 
differences were not statistically significant.   
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Figure 2. 2: Acid-fast bacilli sputum smear grade of TB index cases in contact with TST negative
and TST positive study participants.83% of the TST positive contacts were exposed to TB cases with
higher grade sputum smears compared to 72% of TST negative contacts. Scanty means that between 1 and
9 bacilli were observed in 100 fields; 1+ represents 10 -99 bacilli observed in 100 fields; 2+ stands for 1 to
10 bacilli per high power field and 3+ greater than 10 bacilli per higher power field (Rieder et al, 2007).
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2.3.2 Reproducibility control 
IFN-  ELISAs were done on a total of 62 ELISA plates. Of the 62, 23 plates were assayed 
with a positive control supernatant obtained from the PHA stimulated blood of a healthy 
donor. The supernatant was generated using the whole blood assay protocol described above 
and PHA was used at a final concentration of 5ug/ml. The resulting positive control 
supernatant (hereafter called positive control 1) was tested in duplicate on the 23 plates. 
Figure 2.3a shows the IFN-concentrations detected in positive control 1 on each plate. For 
positive control 1, the average IFN-concentration was 1503.8pg/ml (range 847pg/ml – 
2285pg/ml).  The inter-plate and inter-well variability were determined using the coefficient 
of variation (CV). The average inter-well variation was 3.6% (range 0.15% - 18.9%) whereas 
the average inter-plate variation was calculated to be 27.2%.  
Positive control 2, a recombinant human IFN- standard was obtained from Pharmingen (cat 
554616, lot 33306) and diluted to 750pg/ml following the manufacturer’s recommendations. 
This second positive control was tested in duplicate on the remaining 39 plates. Figure 2.3b 
shows the IFN-concentrations detected in positive control 2 on each plate. The average 
IFN-concentration detected in positive control 2 was 1381pg/ml (range: 790pg/ml – 
3098.5pg/ml).  The inter-plate and the inter-well variability were determined using the 
coefficient of variation (CV). The average inter-well variation was 3% (range: 0.14% - 
16.6%) whereas the inter-plate variation was calculated to be 32.8%.  
2.3.3 Standardization and normalization of the IFN-γ ELISA results 
While the inter-well variation was within acceptable levels, the inter-plate variation was high 
for both positive control 1 (PC1, 27.2%) and positive control 2 (PC2, 32.8%). The results 
from each of the ELISA plates were corrected as follows: For the 23 plates tested with PC1, a 
reference curve (reference curve 1) was created from the average optical densities (ODs) of 
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four curves with the closest fit to the required four-parameter logistic (4PL) shape. The 4PL 
model is recommended for immunoassay calibrations (Findlay, 2006). Four (4) plates that 
were chosen had their standard curves showing constantly decreasing trends with respect to 
concentration levels and OD signal responses. The mean of the internal positive control 1 
value on the 4 selected plates (mean = 1423pg/ml) was plotted onto reference curve 1, and 
the emerging reference OD of 2.64 was used to determine a correction factor for all the test 
samples that were assayed on these 23 plates.  Each plate assayed with PC1 had its own 
correction factor. For example, the average optical density of the duplicate positive control 
supernatants tested on plate number X was 2.83; this value was divided by the reference OD 
of 2.64, giving a correction factor for of 0.93 for plate X.  The test supernatant derived from 
seven day whole blood stimulation with Rv3019c was assayed on plate X and had an OD of 
2.43 was obtained. When read with the original plate X curve, this OD translated to a 
concentration of 2052pg/ml. However, when the test OD of 2.43 was multiplied by the 
correction factor (0.93) this resulted in an OD of 2.27 which, when read of the reference 
curve, gave rise to a corrected concentration of 1175.5pg/ml. In a similar process, reference 
curve 2 was created from the average ODs of seven curves with the closest fit to the required 
4PL shape on plates with internal positive control results closest to the known value of 
750pg/ml (790-850pg/ml). The mean of the internal positive control 2 value of the seven 
selected plates (819pg/ml) was plotted on reference curve 2, and the emerging reference OD 
of 1.80 was used to determine a correction factor for the samples that were assayed on all 39 
plates containing positive control 2. As for PC1, each PC2 plate had its own correction factor. 
Graph Pad prism (version 5) was used to produce the corrected values for both sets of plates.  
It was not possible to run to both PC1 and PC2 in the same plate because when the study 
commenced, a PHA stimulated positive control was used (PC1) which was later changed to a 
diluted standard curve positive control (PC2).   
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Figure 2.3 a –b : Interferon gamma level in internal positive controls 1 and 2, per plate. Log10
interferon gamma level detected in internal positive control supernatants, per plate.. Control supernatants
were tested in duplicate on each of the 62 ELISA plates. (a) In 23 plates the positive control was obtained
from PHA stimulated supernatant from a healthy control (b) In 39 plates the positive control was from
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2.3.4 Responses to negative and positive controls 
Figure 2.4a illustrates that none of the study participants in any of the groups produced an 
IFN- response to the negative control (RPMI). All participants across all three study groups 
responded to whole blood stimulation with the positive control, SEB, at the recruitment time 
point, with the exception of 2 subjects in the TB index case group (Figure 2.4b), which may 
be due to anergy or lymphopenia in the blood. Stimulation with SEB resulted in positive 
responses (>62pg/ml) in 100% of TST negative (n=17) and TST positive (n=17) contacts 
respectively as well as in 86.7% (n=13/15) of TB cases. The median response to SEB in the 
TST negative subjects was significantly higher than that observed in the TB index cases 
(p=0.04, Mann-Whitney test).  
 All subjects except for 1 in both the TST negative (n=15/16) and TST positive groups 
(n=16/17) responded to PHA at recruitment (Figure 2.4c), compared to 69% (11/16) of the 
TB cases. Median responses to PHA were significantly higher in both the TST negative and 
TST positive groups when compared to the TB index cases (p=0.01; Mann-Whitney test). 
SEB is a superantigen and PHA a mitogen, and that is why both of them are used as positive 
controls.  
2.3.5 Comparing response frequencies to classical M.tb antigens between study groups at 
recruitment 
M.tb PPD 
Figure 2.5a illustrates that 100% of the TST positive contacts responded to M.tb PPD 
stimulation at recruitment, whereas 87.5% (n=13) and 60% (n=9) of TB index cases and TST 
negative HHC respectively responded to this antigen. The median response of the TST 
positive contacts was significantly higher than that of both the TST negative contacts and TB 
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index cases (p=0.0002 and p=0.04 respectively), and the median response of the TB cases 
was significantly higher than that of the TST negative HHC group (p=0.01). This indicates 
that ELISA is more sensitive than the TST.  
ESAT6/CFP10 fusion protein  
ESAT6/CFP10 fusion protein induced responses in 100% of TST positive HHC and 87.5 % 
(n=13) of the TB cases (Figure 2.5b), whereas there were responses in only 26.7% (n=4) of 
the TST negative participants. In the TST negative group 3 of the 4 subjects that responded to 
ESAT6/CFP10 also responded to M.tb PPD. Median responses in both the TST positive 
group and the TB cases were markedly higher than those of the TST negative group 
(p<0.0001 and p< 0.0001, respectively).  
Rv3019c (TB10.3) 
Figure 2.5c shows that in the TST positive group the median IFN- response to TB10.3 
(343pg/ml) was  significantly lower than that induced by M.tb PPD (1625pg/ml, p<0.0001) or 
ESAT6/CFP10 fusion protein (1973pg/ml, p<0.0001) indicating that this recombinant antigen 
was less immunogenic than PPD or the fusion protein. Both the proportion of responders 
(47%, n=8) and the median response to this antigen was greater in the TST positive 
participants compared to the TB index cases (6.25%, n=1; median 15pg/ml; p=0.008), and 
TST negative participants (5.9%, n=1; median 15pg/ml; p = 0.01).  
TB10.4 
In the TST positive group the median IFN- response to TB10.4 (43.7%, n=7) was similar to 
that observed for TB10.3 (47%, n=8). In the TST positive group, 6 out of the 7 participants 
that responded to TB10.4 also responded to TB10.3. In TB cases 37.5% (n=6), and in TST 
negative subjects, 11.7% (n=2), responded to TB10.4 stimulation (Figure 2.5d). TST positive 
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subjects had a significantly higher median response compared to TST negative contacts, 
(p=0.03).  
NEGATIVE CONTROLS100
m
l)
(a)
NEGATIVE POSITIVE TB 
10
Lo
g 
IF
N
 (
pg
/m
SEB
1000
10000
p=0.04
*
N
 (
pg
/m
l)
(b)
NEGATIVE POSITIVE TB 
10
100
Lo
g 
IF
N
PHA(c)
100
1000
10000 **
p=0.01
p=0.01
Lo
g 
IF
N
 (
pg
/m
l)
NEGATIVE POSITIVE TB 
10
Figure 2.4a-c: Negative control and positive controls used in the  interferon- ELISA. The ELISA was 
done on 7-day whole blood culture supernatants of HIV negative participants who were TST negative 
(n=17), TST  positive (n=17) and TB index cases (n=16). The negative control was RPMI alone (a). SEB 
(1mg/ml), (b) and PHA (5mg/ml), (c) were used as positive controls. The line denotes the median. 
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Ag85A 
Ag85A (Figure 2.5e) elicited responses in 20% (n=3) of the TST positive contacts, 2 of 
which also responded to TB10.3, while all 3 also responded to TB10.4.  Neither the TST 
negative subjects nor the TB index cases responded to this antigen. 
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Figure 2.5 a-e: Interferon gamma responses to classical M.tb antigens: M.tb PPD, ESAT6/CFP10 fusion 
protein, Rv3019c, TB10.4 and Ag85A. IFN- ELISA was performed on 7-day whole blood culture 
supernatants of TST negative HHC (n=17), TST positive HHC (n=17) and TB index cases (n=16). 
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Figure 2.6 a-d: Comparison of IFN- responses to DosR regulon-encoded latency antigens in TST
negative household contacts, TST positive household contacts and TB cases. IFN- levels were measured
by ELISA in culture supernatants following 7 day whole blood stimulation with the DosR regulon-encoded
antigens. The data shown is for antigens Rv1737c, Rv2029c, Rv1733c and Rv1735c which are antigens that
displayed discriminating abilities between disease states. Data of 7 other DosR regulon-encoded antigens
tested including Rv0081, Rv0569c, Rv2028c, Rv2031c, Rv3131c, Rv2659 pool C and Rv2660 is not
shown.
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2.3.6 Comparison of responses to DosR regulon encoded antigens within and between 
study groups at recruitment 
In this section, data is only shown for antigens Rv1737c, Rv2029c, Rv1733c and Rv1735c as 
they were all able to discriminate between infection and disease states. Data from the other 7 
DosR regulon-encoded antigens tested i.e. Rv0081, Rv0569c, Rv2028c, Rv2031c, Rv3131; 
Rv2659 pool C and Rv2660 is not shown.  
TST negative HHC 
As shown in Figures 2.6a-d, 35.3% (n=6) of the TST negative subjects responded to 
Rv1737c, 13.3% (n=2) to Rv2029c. 17.6% (n=3) to Rv1733c and 23.5% (n=4) to Rv1735c. 
All 3 subjects that responded to Rv1733c also responded to both Rv1735c and Rv1737c. One 
of the 2 subjects responding to Rv2029c also responded to Rv1733c, Rv1735c and Rv1737c.  
One subject (5.9%), each responded to Rv0081, Rv2660 and HspX/Rv2031c in the TST 
negative HHC group (data not shown). No responses were observed to Rv0569, Rv2028c, 
Rv2659 pool C and Rv3131 in this study group (data not shown). 
 
TST positive HHC 
The frequencies of responses to Rv1737c, Rv2029c, Rv1733c and Rv1735c in the TST 
positive group were 76.5% (n=12), 60% (n=9), 53.3% (n=8) and 47% (n=6) respectively 
(Figures 2.6a-d). Participants that responded to Rv1735c also responded to Rv1737c, 
Rv2029c, and Rv1733c; subjects responding to Rv1733c also responded to Rv1737c and 
Rv2029c; and subjects that responded to Rv2029c also responded to Rv1737c. There were 
29.4% (n=5) TST positive participants that responded to Rv0569, whereas 2 subjects (11.7%) 
responded to Rv2028c in this group and only 1 (5.9%) responded to both Rv0081 and to 
HspX/Rv2031c. One participant (5.9%) also responded to Rv2659poolC and another (5.9%) 
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to Rv2660 (data not shown). No responses were observed upon stimulation with Rv3131 in 
this group (data not shown). 
TB cases  
Two (12.5%) TB cases responded to stimulation with Rv1737c (Figure 2.6a). The same 
subjects also responded to Rv1735c (Figure 2.6c).  Rv2029c elicited responses in 37.5% 
(n=6) of the subjects in this group (Figure 5b) and only 1 (6.25%) participant responded to 
Rv1733c (Figure 2.6d). A single positive response (6.25%) to each of Rv2659 pool C and 
Rv3131was also observed (data not shown) and no IFN- was produced in response to 
Rv0081, Rv0569, Rv2028c, HspX/Rv2031c or Rv2660 (data not shown).   
Significantly higher IFN- levels were secreted in response to Rv1737c in TST positive 
contacts compared to both the TB index cases and the TST negative subjects (Figure 2.6a, 
p<0.0001 and p=0.01). Responses to Rv2029c (Figure 2.6b) were significantly enhanced in 
TST positive participants when compared to TST negative subjects only (p=0.01). In 
contrast, Rv1733c and Rv1735c (Figures 2.6c and 2.6d) induced significantly higher IFN- 
concentrations in TST positive subjects when compared to the TB cases only (p=0.001 and 
p=0.02). 
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Figure 2.7 a-c: Comparison of TST negative subjects, TST positive subjects and TB index cases in 
response to stimulation with resuscitation promotion factors. Significant differences in IFN- ELISA 
levels observed between the study groups measured in 7-day whole blood culture supernatants stimulated 
with (a) Rv2450c, (b) Rv0867c and (c) Rv1009.
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2.3.7 Comparison of responses to resuscitation promotion factors between study groups 
TST negative household contacts 
Figures 2.7a shows that 6.25% (n=1) of TST negative participants responded to Rv2450c and 
18.75% (n=3) responded to Rv0867c and Rv1009. The individual that responded to Rv2540c 
also responded to Rv0867c and Rv1009, whereas the 2 (12.5%) others responded to both 
Rv0867c and Rv1009 in this study group.  
TST positive HHC 
In Figures 2.7 a-c, 41.1% (n=7) of TST positive subjects responded to Rv2450c; 29.4% (n=5) 
to Rv0867c and 23.5% (n=4) to Rv1009. Four subjects responded to both Rv2450c and 
Rv0867c, with 2 (11.25%) of them also responding to Rv1009. Three of the 4 participants 
that responded to Rv1009 also responded to Rv2450c. 
TB cases 
Only 1 TB index case (6.25%) responded to both Rv0867c and Rv1009 (Figures 2.7 b and c).  
The median response to Rv2450c was significantly higher in the TST positive contacts 
compared to both the TB cases and the TST negative subjects (p=0.007 and p=0.01). Also, 
TST positive contacts produced significantly enhanced IFN- levels to both Rv0867c and 
Rv1009 when compared to TB index cases (p=0.01 and p=0.02). 
  
Table 2.5: Correlations between M.tb antigens in TST negative contacts
RV1733c RV1735c RV1737c RV0569 RV1131 RV0867c RV1009 RV2450c TB10.4 RV3019c
RV1735c 0.78**
RV1737c 0.63*
HspX/RV2031 0.64*
RV1131 0.65* 0.70* 0.61*
RV0867c 0.82*** 0.83*** 0.73* 0.84***
50
RV1009 0.82*** 0.83*** 0.73* 0.84*** 1.00***
RV2450c 0.51* 0.51* 0.73* 0.62* 0.62*
RV3019c 0.65* 0.70* 0.61* 1.00*** 0.84*** 0.84*** 0.73*
TB10.4 0.49 0.77** 0.56* 0.77** 0.62* 0.62* 0.77**
M.tb
PPD
0.62* 0.59* 0.57* 0.62* 0.62* 0.66*
Table 2.5: Associations between M.tb antigens in TST negative HHC were determined using the Spearman Rank Correlations Test. #
denotes p< 0.05; * denotes p< 0.01:** p<0.001;*** p<0.0001
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2.3.8 Comparison of responses to reactivation antigens 
Two (12.5%) TST negative subjects responded to Rv1131. No responses to Rv3407 or 
Rv1471 were observed in this group (data not shown).  Rv1131, Rv3407 and Rv1471 elicited 
responses in 17.6% (n=3), 11.8% (n=2) and 5.9% (n=1) respectively of the TST positive 
contacts (data not shown).  One TB index case (6.25%) responded to Rv1131 (data not 
shown).   
2.3.9 Associations between IFN- responses to classical and novel M.tb antigens 
The Spearman rank correlations test for non parametric samples was used to determine the 
associations between variables and antigens. Due to the large number of antigens tested (22 
in total), only positive (r>0.5) and significant (p<0.05) correlation co-efficients are shown in 
all correlation matrices (Tables 2.5 – 2.9).  
TST negative HHC 
Table 2.5 shows the Spearman correlation co-efficients that were observed between the IFN- 
responses induced by stimulation with all tested M.tb antigens in the TST negative HHC. 
Within the set of 11 Dos-R encoded antigens tested, a very strong and significant association 
was observed between responses to Rv1733c and Rv1735c (r =0.78, p<0.01). Rv1735c was 
also significantly associated to Rv1737c (r =0.63, p<0.05). In addition responses to Rv0569 
were significantly correlated with responses to Rv2031c (r=0.64, p<0.05). Pair-wise 
responses to each of the 3 tested RPFs were significantly correlated with a particularly strong 
association observed between Rv0867c and Rv1009 (r=1, p<0.0001). Responses to Rv2450c 
were significantly correlated with responses to both Rv0867c and Rv1009 (r=0.62, p<0.05 
respectively). Responses to the classical TB antigen TB10.4 were strongly and significantly 
associated with responses to Rv3019c (TB10.3; r=0.77, p<0.01), while also significant to 
those stimulated by M.tb PPD (r=0.66, p<0.05). Classical M.tb antigen Rv3019c was strongly 
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and significantly associated with all 3RPFs Rv0867c, Rv1009 and Rv2450c (r=0.84, 
p<0.0001; r=0.84, p<0.0001 and r=0.73, p<0.05 respectively). TB10.4 and M.tb PPD, on the 
other hand, were each significantly associated with both Rv0867c and Rv1009 (both r=0.62, 
p<0.05).  All 3RPFs: Rv2450c, Rv0867c and Rv1009 in this study group were strongly and 
significantly associated with the reactivation antigen Rv1131 (r=0.73, p<0.05; r=0.84, 
p<0.0001 and r=0.84, p<0.0001 respectively). Furthermore, Rv1131 was strongly and 
significantly associated with classical TB antigens Rv3019c and TB10.4 (r=1, p<0.0001 and 
r=0.77, p<0.01). A strong and significant relationship was also observed between Rv1131 
and Rv1735c, while significant associations between this antigen and both Rv1733c and 
Rv1737c were observed too (r=0.65, p<0.05 and r=0.61, p<0.05). The Dos-R encoded 
antigens Rv1733c, Rv1735c and Rv1737c, each had strong and significant associations with 
both Rv0867c and Rv1009 (r=0.82, p<0.0001 and r=0.82, p<0.0001; r=0.83, p<0.0001 and 
r=0.83, p<0.0001; and r=0.73, p<0.05 and r=0.73, p<0.05 respectively). Rv1733c and 
Rv1735c, each was significantly associated with Rv2450c (r=0.51, p<0.05). Rv1733c was 
also significantly correlated with Rv3019c and M.tb PPD (r=0.65, p<0.05 and r=0.62, p<0.05. 
Rv1735c was strong and significantly correlated with Rv3019c and TB10.4, while 
significantly correlated with M.tb PPD (r=0.70, p<0.05; r=0.77, p<0.01 and r=0.59, p<0.05).  
Rv1737c was also significantly correlated with Rv3019c, TB10.4 and M.tb PPD (r=0.61, 
p<0.05; r=0.56, p<0.05 and r=0.57, p<0.05).   
TST Positive HHC 
In Table 2.6 the relationships between the clinical data and M.tb antigens in TST positive 
HHC are shown. IFN-responses to Rv2029c and TB10.4 were stronger in TST positive 
HHC with a higher TB contact score (r=0.56, p<0.05 and r=0.68, p<0.05). The older the 
subjects the stronger their responses to TB10.4 and M.tb PPD responses in this study group  
Table 2.6: Correlation between the clinical data and M.tb antigens in TST positive contacts
 Contact score Age BCG Scar R+ 
RV2029c 0.56*   
RV0867c   0.63* 
TB10.4 0.68* 0.50*  
M.tb PPD  0.77 **  
 Table 2.6: Associations between age, TB contact score, BCG scar, M.tb antigens in TST positive HHC were determined using the Spearman
Correlation. # denotes p< 0.05; * denotes p< 0.01:** p<0.001;*** p<0.0001
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Table 2.7: Correlation between the M.tb antigens in TST positive contacts
 RV1733c RV1735c RV1737c RV0569
RV1735c 0.66*    
RV1737c 0.63* 0.86 ***   
RV2028c 0.59*
RV2029c   0.75 *  
RV2660 0.51*   0.66* 
RV1131 0.52* 0.60 * 0.53 *  
RV0867c  0.90*** 0.73**  
RV1009 0.68* 0.71 * 0.61 *  
RV2450 0 77 0 74 0 70c . *** . ** . *
RV3019c  0.76 ** 0.56 *  
TB10.4   0.63*  
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The presence of a BCG scar was significantly associated with higher responses to Rv0867c 
(r=0.63, p<0.05).  
Table 2.7 illustrates the associations observed in the responses between M.tb antigens in TST 
positive HHC. Rv1733c was significantly correlated to both Rv1735c and Rv1737c in TST 
positive subjects (r=0.66, p<0.05 and r=0.63, p<0.05). A significant and strong correlation 
was observed between Rv1735c and Rv1737c (r=0.86, p<0.0001). Rv1733c was significantly 
correlated to Rv2660c (r=0.51, p<0.05); Rv1735c was significantly correlated to Rv2028c 
(r=0.59, p<0.05); Rv0569 was significantly correlated to Rv2660c (r=66, p<0.05) and 
Rv2028 was significantly correlated to Rv3131 (r=64, p<0.05). Strong and significant 
associations were observed between responses to Rv1737c and Rv2029c (r=0.75, p<0.05); 
Rv2028c and Rv2031c (r=0.73, p<0.01) as well as between Rv2659 peptide pool C and 
Rv3131 (r=1, p<0.0001) in TST positive HHC. When the relationship between the RPFs 
were investigated, it was observed that there was a strong and significant association between 
Rv0867c and Rv1009 (r=0.72, p<0.05); whereas Rv2450 was significantly correlated to both 
Rv0867 and Rv1009 (r=0.62, p<0.05 and r=0.54, p<0.05 respectively). Correlations were 
observed between antigen responses elicited by RPFs and those caused by other M.tb 
antigens. Strong and significant correlation were observed between Rv0867c and the 
following antigens: Rv1735c (r=0.90, p<0.0001); Rv1737c (r=0.73, p<0.001) and; Rv3019c 
(r=0.73, p<0.01).  Significant associations were also observed between Rv0867c and the 
following antigens: Rv2028c (r=0.56, p<0.05); Rv1131 (r=0.65, p<0.05) and; ESAT6/CFP10 
fusion protein (r=0.63, p<0.05). A strong and significant correlation was observed between 
responses caused by Rv1009 and those elicited by Rv1735c (r=0.71, p<0.01). Significant 
correlations were also observed between Rv1009 and the following antigens: Rv1733c 
(r=0.68, p<0.05); Rv1737c (r=0.61, p<0.05); Rv2028c (r=0.62, p<0.05); Rv1131 (r=0.52, 
p<0.05) and; Rv3019c (r=0.56, p<0.05). Rv2450c was strongly and significantly associated 
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to Rv1733c (r=0.77, p<0.0001); Rv1735c (r=0.74, p<0.01) and Rv1737c (r=0.70, p<0.05). 
Rv2450c was found to be significantly correlated to Rv2028c (r=0.56, p<0.05); Rv2029c 
(r=0.51, p<0.05); Rv1131 (r=0.66, p<0.05) and; Rv3019c (r=0.63, p<0.05). A significant 
association was observed between reactivation antigens Rv1131 and Rv1471 in this study 
group (r=0.61, p<0.05). While Rv1131 was strongly and significantly associated with 
Rv2660c (r=0.72, p<0.05), this antigen was also significantly correlated to Rv1733c (r=0.52, 
p<0.05); Rv1735c (r=0.60, p<0.05); Rv1737c (r=0.53, p<0.05); Rv2659 peptide pool C 
(r=0.61, p<0.05); Rv3131 (r=0.61, p<0.05) and; Rv3019c (r=0.60, p<0.05). Rv1471 was 
strongly and significantly associated with Rv2659 peptide pool C (r=1, p<0.0001) and 
Rv3131 (r=1, p<0.0001). Rv1471 was also significantly correlated to 2028c (r=0.64, p<0.05).  
Reactivation antigen Rv3407 was strongly and significantly associated with Rv2031c 
(r=0.73, p<0.01) and significantly correlated to Rv2028c (r=0.50, p<0.05). When the 
relationship between the responses caused by M.tb classical antigens and those produced by 
both other M.tb classical as well as M.tb antigens in other categories were investigated, it was 
observed that M.tb PPD responses were significantly correlated to those elicited by TB10.4 
(r=0.5, p<0.5). Rv3019c was strongly and significantly associated with Rv1735c (r=0.76, 
p<0.01) and this antigen (Rv3019c/TB10.3) was observed to be significantly correlated to 
both Rv1737c and Rv2028c (r=0.56, p< 0.05 and r=0.5, p<0.05 respectively). TB10.4 was 
significantly associated with Rv1737c (r=0.63, p<0.05) and strongly significantly correlated 
to Rv2029c (r=0.71, p<0.05).      
  
RV1131 RV0867c RV1009 RV2450c RV3019c Ag85A ESAT6/
CFP10
TB10.4
RV1471 0.61*
RV0867 0 65* 0 63*c . .
RV1009 0.52* 0.72*
RV2450c 0.66* 0.62* 0.54*
RV3019c 0.60* 0.73** 0.56* 0.63*
TB10.4 0.48 0.46
M tb PPD 0 48 0 50*. . .
RV2028c RV2029c HspX/ RV2659 RV2660 RV3131
56
RV2031 pool C
HspX/RV2031 0.73**
RV2659
pool C
0.64*
RV3131 0.64* 1.00***
RV1131 0.61* 0.72* 0.61*
RV1471 0.64* 1.00*** 1.00***
RV3407 0.50* 0.73**
RV0867c 0.56*
RV1009 0.62*
RV2450c 0.56* 0.51*
RV3019c 0.50*
Table 2.7: Associations between M.tb antigens in TST positive HHC were determined using the Spearman Correlation. # denotes p< 0.05; *
denotes p< 0.01:** p<0.001;*** p<0.0001
ESAT6/CFP10 0.54*
Table 2.8: Correlations between demographic data and M.tb antigens in TB cases
Sex Age
RV2029c 0.5*
M.tb PPD 0.69*
Table 2.8: Associations between age, sex and M.tb antigens in TB index cases were determined using the Spearman Correlation. # denotes
p< 0.05; * denotes p< 0.01:** p<0.001;*** p<0.0001
Table 2.9: Correlations between M.tb antigens in TB cases
57
RV1733c RV1735c RV1737c RV2029
c
RV3131 RV1131 RV0867c RV3019c Esat6/CFP10
RV1735c 0.53*
RV1737c 0.73* 0.84
RV2029c
RV3131
RV3407 1.00*
RV0867c 1.00*** 0.53* 0.73*
RV1009 1.00*** 0.53* 0.73* 1.00*
RV2450c 1.00*
Esat6/CFP10 0.60*
TB10.4 0.46 0.71*
Table 2.9: Associations between M.tb antigens in TB index cases were determined using the Spearman Correlation. # denotes p< 0.05; *
denotes p< 0.01:** p<0.001;*** p<0.0001
M.tb PPD
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TB cases 
The correlations between age, gender and M.tb antigens are described in Table 2.8. Females 
were more likely to elicit strong IFN- responses to Rv2029c (r=0.50, p<0.05). Older TB 
cases elicited stronger responses to M.tb PPD (r=0.69, p<0.05).  
Table 2.9 shows the association observed between M.tb antigens in TB index cases.  Rv1733c 
and Rv1735c, both displayed strong and significant correlations with Rv1737c (r=0.73, 
p<0.05 and r=0.84, p<0.0001 respectively), and Rv1733c was significantly correlated to 
Rv1735c (r=0.53, p<0.05).  RPFs Rv0867c and Rv1009 were strongly associated with each 
other (r=1, p<0.0001). In this study group, ESAT6/CFP10 fusion protein was strongly and 
significantly associated with TB10.4 (r=0.71, p<0.05). Reactivation antigen Rv1131 was 
strongly and significantly associated with Rv2450c (r=1, p<0.0001) and Rv3407 was strongly 
and significantly associated with Rv3131 (r=1, p<0.0001). When the DosR regulon encoded 
antigens were investigated for associations with RPFs, strong and significant correlations 
were observed between Rv1733c and both Rv0867c and Rv1009 (r=1, p<0.0001 and r=1, 
p<0.0001). Furthermore, strong and significant associations between Rv1737c and both 
Rv0867c and Rv1009 (r=0.73, p<0.05 and r=0.73 p<0.05). Rv1735c was also significantly 
correlated to both Rv0867c and Rv1009 (r=0.53, p<0.05). A significant correlation was 
observed between responses to Rv2029c and those resulting from ESAT6/CFP10 fusion 
protein in this group (r=0.60, p<0.05).  
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2.4 Discussion 
In this study we wanted to investigate whether there were differential immunologic responses 
to M.tb antigens in TST negative household contacts, TST positive household contacts and 
active TB cases. We did not perform an IGRA because it was part of the study design. We 
made several assumptions: Firstly, we assumed that the TST negative subjects were not 
infected with M.tb and that TST positive subjects had LTBI. Secondly, we presupposed that 
TST negative subjects were more protected than both TST positive subjects and TB index 
cases, and that TST positive subjects were more protected that the TB cases assuming they 
had been exposed to M.tb. Thirdly, we assumed that in TST positive subjects M.tb 
transmission had occurred within the household and that therefore the strain of M.tbwould be 
the same. In this investigation we observed that novel M.tb antigens could differentiate 
between non infected, M.tb infected and active TB disease.  
In the main GC-6 study, 92.8% (n=829) of the 893 HIV negative HHC of TB index cases had 
tested TST positive at baseline, suggesting a high rate of TB transmission in these 
communities.  A recent study conducted within the same geographical region by Kritzinger et 
al. (2009) has noted the continued escalation of TB incidence. Similar proportions of TST 
positive subjects (89%) were also observed in a recent study that was conducted in South 
African gold mines (Hanifa et al., 2009) even though that study was not designed as a TB 
contact study and both the both HIV negative and HIV positive participants were included in 
it. On the other hand, a TB contact study that was conducted in Pakistan has shown high rates 
(80%) of TST positive contacts (Hussain et al., 2007), while in Brazil the proportion of TST 
positive HHC observed was 43% (Cailleaux-Cezar et al., 2009) and that of The Gambia 27% 
(Jackson-Sillah, 2007).  Several studies have demonstrated that the proportion of healthy HIV 
negative household contacts of TB index cases that develop active TB within two years of 
exposure to respective TB cases is between 4 and 6.7% (Teixeira et al., 2001; Wang & Lin, 
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2000; Hussain et al., 2007). Countries that have successfully minimized TB transmission 
have used tracing of contacts of active TB patients as a vital prevention strategy which 
involves provision of treatment to those found to be latently infected (Morrisson et al., 2008). 
These authors assert that the treatment and elimination of latent TB infection may be 
paramount in the eradication of global TB. Others, however, note that, for developing 
countries it is the treatment of active TB cases which urgently requires attention in spite of 
the understanding of the greater need for treatment of LTBI (Baltussen et al., 2005). 
However, this is true only if the force of infection would decrease, which is not the case in 
the communities in our study where we have observed a high incidence of both LTBI and 
active TB.  In our investigation with 893 study participants, the proportion of TST negative 
subjects at baseline was only 7.2% (n=64). At month 6, of the 64 participants, 29 (45.4%) 
were not skin tested again, 26 (40.6%) had converted to TST positive, while 9 (14%) 
remained TST negative. The 26 TST negative subjects under investigation in this study, 
which had converted their TST status by month 6, suggests that they may have been fighting 
the bacterial challenge before the establishment of the infection or had not been infected for 
some reason such as increased ventilation within the household or due to anergy.  
In our study groups the gradient of exposure to the TB index case did not play a role in the 
TST results of contacts. The exposure gradient, however, does not include ventilation, which 
is important in TB transmission. Several studies have observed a positive association between 
the risk of being TST positive in TB contacts and the extent of exposure to the TB index case 
(Lienhardt et al., 2003; Adetifa et al., 2007; Gustafson et al., 2007).  In our setting, maybe 
non household exposure such as in the public transport, sheebens, schools etc. is more 
important.  Age did not affect the TST result in our investigation, but our cohort was 
comprised of adults. Which may part explain why Gustafson et al. (2007) observed that there 
was a tendency for adult household contacts to test TST positive.  In our study, we observed 
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that older subjects produced stronger IFN- responses to TB10.4 and M.tb PPD in TST 
positive contacts. In TB index cases age was positively associated with stronger responses to 
M.tb PPD only. In this study group we also observed that females were more likely to elicit 
stronger responses to Rv2029c. The BCG scar status (presence or absence) did not have an 
influence on the TST results in our study. This is in agreement with other studies (Lienhardt 
et al., 2003; Machado et al., 2009; Adetifa et al., 2010). Further, we did not observe a 
relationship between BCG status and induration size in the TST positive group at recruitment 
or the TST negative group following conversion at 6 months. Whereas Lewinshon et al., 
(2008) did not observe any association between BCG status and IFN- responses to M.tb 
antigens, we did observe a positive association between the BCG scar and responses to 
Rv0867c in the TST positive group only. BCG vaccination has also been shown to lead to 
increased IFN- responses to PPD and Ag85A in TST negative subjects (Lin et al., 2007). 
The differences that we observed in our study compared to those of others may be due to 
regional differences or genetics or some other variable.  Although not significant, 83% of 
TST positive subjects had been exposed to 2+ or higher graded sputum smear TB cases 
compared to 72% observed with TST negative contacts. The increased risk of being TST 
positive in HHC of TB cases with higher smear grades has been observed in other studies 
(Lienhardt et al., 2003; Okada et al., 2008; Akhtar & Rathi, 2009). Chee et al., (2004) have 
observed a trend for contacts that were exposed to more infectious TB index cases to have 
greater TST induration.  
We observed that TST induration in TST positive contacts was not associated with antigen 
stimulated IFN- production. Earlier, Arend and colleagues (2001) showed that T cell 
responses to M.tb culture filtrate protein, PPD, ESAT-6, CFP10 and TB10.4 were associated 
with TST results. Recently, the size of the TST induration in TST positive subjects has been 
linked to antigenic stimulation including stimulation with M.tb culture filtrate protein 
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(Lewinshon et al., 2008), TB10.3 in Uganda and ESAT6/CFP10 fusion protein in South 
Africa (Black et al., 2009).  
There was no spontaneous IFN- production from unstimulated whole blood across all the 
groups tested in our study. With the exception of 2 TB cases, all participants elicited positive 
responses to SEB. We observed that stimulation with PHA resulted in higher levels of IFN- 
in both TST negative and TST positive groups compared to TB cases. Previously, it has been 
demonstrated that responses to PHA by TB patients was significantly lower than those 
produced by household contacts (Vekemans et al., 2001). Our results also show significantly 
lower levels of IFN- production in response to PHA in active TB cases. 
We investigated IFN- responses in TST negative contacts, TST positive contacts and TB 
index cases and observed that M.tb PPD stimulation elicited higher IFN- responses in TST 
positive contacts when compared to both TST negative contacts and TB index cases. In 
concordance, it has been shown that IFN- responses to M.tb PPD were elevated in TST 
positive subjects compared to TST negative subjects (Arend et al., 2001; Ordway et al., 
2004). It has also been shown that latently infected individuals had high IFN- responses to 
PPD compared to TB cases (Demissie et al., 2006). TST positive subjects have also been 
shown to elicit stronger IFN-responses compared to active TB cases when stimulated with 
M.tb antigens (Leyten et al., 2006; Schuck et al., 2009).   While Ribeiro-Rodrigues and co-
workers (2006) have observed that M.tb specific T cell responses were suppressed in TB 
cases when compared to TST positive subjects, they observed higher CD4+ cells in TB cases 
than in TST positive subjects. Others have shown that IFN-producingT cells were 
elevated in TST positive subjects compared to TST negative subjects when stimulated with 
heat killed M.tb (Ordway et al., 2004). Recently, Sutherland et al., (2009) did not find 
significant differences in IFN-CD4+ producing cells between TST positive and TST 
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negative contacts, nor between TB index cases and TST positive contacts, due to stimulation 
with PPD. The source of increased IFN- that we observed in our study may be due to the 
T cells.  In TST positive subjects, T cells are thought play an important anti-bacterical 
role in M.tb (Dagna et al., 2002). In our study, we noted that the TB cases produced higher 
IFN- responses to M.tb PPD when compared to TST negative contacts. Higher IFN-
CD4+cells have been observed in active TB cases compared to TST negative HHC in 
response to PPD (Sutherland et al., 2009). We observed that 60% (9/15) of the TST negative 
household contacts responded to M.tb PPD. While responses to M.tb PPD have previously 
been observed in M.tb unexposed, non-BCG vaccinated TST negative controls (Lin et al., 
2007), in our study, we cannot rule out the possibility of responses being as a result of BCG 
vaccination as 4 participants that responded to M.tb PPD had evidence of prior vaccination, 
although it is not known how long ago they had been vaccinated.  Of the 9 participants that 
responded to M.tb PPD, 2 also responded to ESAT6/CFP10 suggesting that they may have 
become infected with M.tb without mounting a DTH response at that time point because 6 
months into the study TST indurations were observed in those subjects. It has been 
hypothesized that BCG vaccination or possible exposure to environmental mycobacteria, 
many of which share M.tb PPD antigens, may be responsible for some of the responses to 
M.tb PPD (Lin et al., 2009). The observation of a stronger in vitro response to M.tb PPD in 
the TST positive group in this investigation is not surprising because the tuberculin skin test 
also uses M.tb PPD. However there was no correlation between TST induration and the IFN- 
response to PPD in the TST positive group.  
ESAT6/CFP10 fusion protein 
As expected all TST positive HHC responded to ESAT6/CFP10 fusion protein, 87.5 % of the 
TB cases, and just 26.7% (n=4) of the TST negative participants. Both TST positive HHC 
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and TB cases exhibited markedly higher responses to the fusion protein compared to the TST 
negative group. ESAT6 is an immuno-dominant M.tb antigen (Rogerson et al., 2005). IFN- 
producing CD4+ cells have been shown to increase in response to ESAT6/CFP10 fusion 
protein and M.tb PPD in latently infected individuals (Schuck et al., 2009). It is interesting to 
note that in the TST negative group 3 of the 4 subjects that responded to ESAT6/CFP10 
fusion protein also responded to M.tb PPD. While we did not use the IGRA to test the 
participants for LTBI, ESAT6 and CFP10, a combination of antigens that was used in this 
study are used to diagnose LTBI in IGRA (Ruhwald & Ravn, 2009). A positive IGRA result 
is thought to be indicative of recent exposure to M.tb (Nakaoka et al., 2006; Arend et al., 
2007). In this investigation, the TST negative subjects that produced IFN- in response to 
ESAT6/CFP10 fusion protein may be an indication of an early infection which could not be 
picked up by a TST, a phenomenon that may be partly explained by the current opinion that 
suggests the existence of the presence of a spectrum of events from inhalation to infection 
which may or may not lead to active disease (Young et al., 2009; Barry et al., 2009). All TST 
negative subjects in this cohort converted their TST status to positive by month 6, indicating 
that they may have become latently infected by the follow up time point, 6 months later.   
In the TST positive group the median IFN- response to TB10.3 (343pg/ml) was significantly 
lower than that induced by M.tb PPD (1625pg/ml), or ESAT6/CFP10 fusion protein 
(1973pg/ml) indicating that this recombinant antigen was less immunogenic than PPD or the 
fusion protein. Significantly higher IFN- levels were observed in response to TB10.3 
between the TST positive participants and both TB index cases and TST negative 
participants. M.tb PPD is a mixture of 173 proteins (Borsuk et al., 2009), which may explain 
the strength of its immunogenicity compared to other classical M.tb antigens.  
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TB10.3 and TB10.4 are part of a family of ESAT proteins that are highly expressed during 
M.tb infection (Rogerson, 2006). The percentage of IFN- responders to TB10.4 (41.2%) in 
TST positive HHC was similar to that observed for TB10.3 (47%). In this group 6 out of the 
7 participants that responded to TB10.4 also responded to TB10.3. TB10.4 has been observed 
to be more inmmunogenic than TB10.3 in TB patients (Skjøt et al., 2002). Also, a recent 
mouse model has demonstrated the immunogenicity of TB10.4 with the evidence of highly 
expressed CD8 and CD4 T cells during M.tb infection (Hoang et al., 2009). While that study 
did not compare the immunogenicity of TB10.3 to that of TB10.4, and TB10.4 we observe in 
our study that TB10.3 was more immunogenic than TB10.4 in TST positive household 
contacts, whereas it was similar in TST negative HHC and in TB cases. These differences 
may be as a result of population differences or M.tb strain differences.  
Of the classical M.tb antigens, Ag85A was the least immunogenic in this study, producing 
responses in 20% of the TST positive contacts only. Positive responses to Ag85A have been 
observed in TST negative, M.tb unexposed BCG vaccinated adults (Lin et al., 2007). The 
differences in the responses to this antigen may be population specific. 
We investigated the differential responses to 11 DosR regulon antigens in our study groups. 
Rv1737c elicited higher IFN- levels in TST positive contacts compared to both TB index 
cases and TST negative subjects. Furthermore, we observed higher responses to this antigen 
in TST negative subjects compared to TB cases. Both Rv1733c and Rv1735c induced 
significantly higher IFN- concentrations in TST positive subjects when compared to the TB 
cases only. Rv2029c resulted in enhanced IFN- production in TST positive participants 
when compared to TST negative subjects only. Rv2029c has been shown to discriminate 
between ESAT6/CFP10 responders and non-responders (Lin et al., 2007). Also, it has 
previously been demonstrated that IFN- responses to both Rv1733c, Rv2029c were 
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enhanced in TST positive subjects compared to TB cases (Leyten et al., 2006). Schuck et al., 
(2009) have also observed higher IFN- responses to Rv1733c in TST positive subjects 
compared to TB cases. With respect to Rv1733c, our results are in agreement with those seen 
by others. However, in this study Rv2029c could discriminate between TST positive and TST 
negative participants only. The other 7 DosR regulon-encoded antigens tested including 
Rv0081, Rv0569c, Rv2028c, Rv2031c, Rv3131, Rv2659 pool C and Rv2660 did not display 
abilities to discriminate between the study groups in our study.  
IFN- responses to resuscitation promotion factors Rv2450c, Rv0867c and Rv1009 were 
compared between TST positive and TST negative contacts as well TB cases. We observed 
higher IFN- concentration in response to Rv2450c in TST positive contacts compared to 
both the TB cases and the TST negative subjects. Also, both Rv0867c and Rv1009 elicited 
higher IFN- levels to TST positive contacts compared to TB index cases. While this is in 
line with what has been shown previously with respect to Rv1009 and Rv2450c and their 
abilities to elicit higher IFN- levels in TST positive subjects than in TB cases (Schuck et al., 
2009), in our investigation, we also observed higher responses to Rv2450c in TST positive 
subjects than those of TST negative subjects. Perhaps, Rv2450c may offer a possibility for 
further investigations in our setting.    
We also investigated immunologic responses to reactivation antigens Rv1131, Rv1471 and 
Rv3407 in our study groups. Schuck et al. (2009) have shown Rv3407 elicited IFN-
production in latently infected subjects but not in TB cases, but we did not observe these 
properties in our investigation. The differences in the results may be explained by the 
population differences or M.tb strains.   
We investigated the associations between variables and between antigens in all the study 
groups. As expected Rv1733c, Rv1735c and Rv1737c were positively associated in all study 
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groups. The same pattern was observed with all RPFs Rv2450c, Rv0867c and Rv1009. In the 
TST negative group, the classical M.tb antigen TB10.4 was positively associated with both 
TB10.3 (Rv3019c) and M.tb PPD, whereas ESAT6/CFP10 fusion protein did not correlate 
with any of the novel antigens tested in this study.  
When investigating correlations between antigens in TST positive contacts, we observed a 
positive association between TB10.4 and M.tb PPD. It has been recently demonstrated in TB 
contacts that strong responses to both M.tb PPD and ESAT6/CFP10 were associated with 
inferior mycobacterial killing abilities, compared to ESAT6/CFP10 non-responders that 
responded to M.tb PPD (Kang et al., 2010).  These authors suggest that the capacity to kill 
mycobacteria could be indicative of the strength of adaptive immunity against M.tb. While all 
TST positive subjects responded to both M.tb PPD and ESAT6/CFP10 fusion protein, no 
significant correlation was observed between these antigens in this study group. This suggests 
that subjects that elicited strong responses to M.tb PPD did not produce equally strong 
responses to ESAT6/CFP10 and may be falling outside of the group with purported inferior 
mycobacterial killing capabilities. In TST negative participants we observed that 3 of the 4 
subjects that responded to ESAT6/CFP10 fusion protein also responded to M.tb PPD. 
Although none of the participants in both contact groups in our study had progressed to active 
disease in the two year follow up period, their susceptibility to active future disease cannot be 
ruled out. We did not observe any significant correlation between Rv3019c (TB10.3) and 
TB10.4 in the TST positive group in this study even though we noted that there was a similar 
proportion of responders to these classical M.tb antigens (TB10.3, 47%, n=8; TB10.4, 43.7%, 
n=7); moreover 6 out of the 7 participants that responded to TB10.4 also responded to 
TB10.3. In TB index cases we observed a positive correlation between ESAT6/CFP10 fusion 
protein and both TB10.4 and Rv2029c.  
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In our investigation we discovered that there were some antigens that displayed 
discriminating abilities between non-infection, infection and TB disease which were also 
significantly correlated. In both TST positive subjects and TB cases, ESAT6/CFP10 was 
significantly correlated to Rv2029c. The work of Lin and others (2007) also demonstrated 
that 81% of TST positive subjects that responded to ESAT6/CFP10 fusion protein also 
responded to Rv2029c. Both Rv2029c and the fusion protein could distinguish between TST 
negative and TST positive subjects. It is important to note that none of the ESAT6/CFP10 
responders in the TST negative group responded to Rv2029c which is a DosR-regulon 
encoded antigen. As Rv2029c is a Dos R encoded antigen, this could mean that these subjects 
had been recently infected and the bacteria were still actively replicating and had not yet 
entered dormancy. In addition, Rv2029c was positively correlated to Rv2450c in the TST 
positive group. Within the TST negative study group there was 1 participant that responded 
to Rv2029c and another 1 responded to Rv2450c.  While the positive responder to R2029c in 
the TST negative group did not respond to ESAT6/CFP10 fusion protein, the responder to 
Rv2450c also responded to the fusion protein, suggesting the latter responder may have been 
latently infected. Our results suggest that a combination of Rv2029 to ESAT6/CFP10 fusion 
protein may be useful in distinguishing between latently infected and non infected 
individuals.  
In conclusion, 11 antigens could discriminate between the not infected, M.tb infection and 
active TB including M.tb PPD, Rv3019c, ESAT6/CFP10 fusion protein, TB10.4, Rv1737c, 
Rv1733c, Rv1735c, Rv2029c, Rv2450c, Rv0867c and Rv1009. The capability of both 
Rv2029c and Rv2450c antigens to distinguish between infection and disease states and their 
positive association in the TST positive group only may be important in the identification of 
possible diagnostic or vaccine candidates. It is important to be able to distinguish between 
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LTBI and active TB. In our investigation, however, we did not find any promising candidates 
for distinguishing between LTBI and active TB. 
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CHAPTER 3: MULTI-PLEX CYTOKINE ANALYSIS IN ADULT HIV NEGATIVE 
FAST AND SLOW TST CONVERTORS 
3.1 Introduction  
For a long time it was believed that IFN-was the single most critical cytokine required for 
protection against TB (Flynn et al., 1993). There is mounting evidence which indicates that 
while its importance cannot be disputed,  IFN-alone cannot confer protection against M.tb 
and that there may be additional cytokines and chemokines that may be protective against this 
pathogen (Flynn & Chan, 2001).  
Cytokines are simple polypeptides that are produced in response to antigens. They act in an 
autocrine or paracrine manner which may lead to an increase or decrease in the rate of cell 
proliferation, changes in cell differentiation states and/ or a change in the expression of some 
functions (Vilcék, 2003).  
Studies into the host immune response have been made possible by cell culture systems with 
recombinant purified proteins used to stimulate the production of cytokines. This study was 
intended to supplement the findings of chapter 2, where IFN-was utilized as a marker of the 
immune profile of TST negative and TST positive contacts as well as TB cases in response to 
11 latency antigens, 3 reactivation associated antigens and 3 RPFs (LUMC) plus 4 classical 
TB antigens. In chapter 2 we observed that 11 stage-specific antigens of M.tb had the ability 
to discriminate between participants that were TST negative and those who were either TST 
positive and/ or had active TB and between TST positive and active TB. Those antigens 
include M.tb PPD, ESAT6/CFP10 fusion protein, Rv3019c, TB10.4, Rv1733c, Rv1735c, 
Rv1737c, Rv2029c, Rv2450c, Rv0867c and Rv1009. 
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 In this investigation we used the Luminex platform to study multi-cytokine immune 
responses to M.tb antigens in the TST negative group described in Chapter 2. Cytokine 
responses were measured at recruitment and 6 months later, after 17 of the 26 subjects had 
converted to TST positive.  Luminex technology is a fluorescent bead based time-saving 
technique that operates on the sandwich principle similar to that of the ELISA assay. This 
tool presents an opportunity to study and to quantify immune responses by simultaneously 
measuring up to 100 cytokines in theory in small samples, which in most cases are precious. 
Because this platform is expensive, only the conditions with the strongest discriminating 
abilities were included in this investigation, namely:- M.tb PPD, ESAT6/CFP10 fusion 
protein, Rv1733c, Rv1737c, Rv2029c and Rv2450c. As stated in the previous chapter at 
study recruitment M.tb PPD and Rv1737c could discriminate between TST negative and TST 
positive contacts; between TST negative contacts and TB cases as well as between TST 
positive contacts and TB cases.  ESAT6/CFP10 fusion protein could discriminate between 
TST negative and TST positive contacts as wells as between TST negative contacts and TB 
cases. Rv2450c was able to differentiate between TST negative and TST positive contacts as 
well as between TST positive contacts and TB cases. Even though both Rv1733c and 
Rv1735c could distinguish between TST negative and TST positive contacts, Rv1733c 
elicited the most significant differences and on that basis was included in this study.    
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3.2 Materials And Methods 
3.2.1 Study population 
Table 3. 1 summarizes the demographic data of the participants included in the Luminex 
study. The two study groups investigated in this chapter, consisting of 17 fast TST convertors 
and 9 slow TST convertors, are a sub-set of the 64 subjects that tested TST negative at 
recruitment. All the fast convertors tested in this chapter had also been assayed for IFN- 
production levels in response to M.tb antigens in the previous chapter. In the slow TST 
convertor study group, 6 participants had supernatants available for the recruitment time 
point, 8 had samples available for the 6 month time point. The one study participant that 
remained TST negative at month 18 was included in the slow TST convertor study group. 
The median age of the fast TST convertors (25 years) was significantly greater than that of 
the slow TST convertors (15 years, p=0.04) with a BCG scar present in 41.1% of fast TST 
convertors compared to 77.7 % of slow TST convertors.  Exposure of the study participants 
to their respective TB index cases measured with the contact score described in the previous 
chapter was similar (12) between slow and fast convertors.  
  
Table 3.1 Clinical and demographic data of the study population. 26 HIV negative, TST
negative subjects were enrolled into the study and followed for 6, 18 and 24 months. 17
participants converted to TST positive by month 6 (fast TST convertors), while 9 remained
TST negative (slow TST convertors) By month 18 all but 1 had converted to TST positive, . , .
TST was not done at month 24.
 Fast 
convertors 
Slow 
convertors 
Number of participants 17 9    
Age median in years, (range) in years 25 (10-52) 15(10-55) 
Male/female ratio 6/11 5/4 
BCG vaccine documented or scar present, n 
(%) 
17 (41.1) 7 (77.7) 
Median TST induration at month 6, mm 
(range, mm)
16 (10-24) 0 
  
Median M.tb contact score 12 (8-14) 12 (10-13) 
Number with contact score not available, n 
(%) 
1 (5.8) 0 
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Table 3.2.1 Cytokines and chemokines included in the 27-plex Luminex kit and secreted by cells of the innate immune system.  
   
Cytokine/ 
chemokine 
Major source Target cells Function 
VEGF 
 
 
Endothelial cells 
 
Hematopoietic cells 
Endothelial  & dendritic cells 
 
Hematopoietic cells & 
Monocytes 
Proliferation, angiogenesis, increased vascular permeability 
 
 Promotes differentiation and chemo-attraction 
TGFα  
 
Macrophages& epithelial cells Macrophages Mitogenic 
Stimulates cell adhesion and proliferation  
EGF Macrophages & 
epithelial cells 
 Epithelial cells  Cell proliferation, migration, differentiation 
Up-regulates VEGF induction   
Eotaxin Endothelial cells & fibroblasts Eosinophils, mast cells, 
basophils 
Proliferation, differentiation, chemo-attractant for fibroblast and 
epithelial cells 
Fractalkine 
 
Endothelial cells Epithelial cells,  
Dendritic cells 
NK cells, lymphocytes, 
monocytes 
Mediates cell adhesion, enhances NK cell cytotoxicity, stimulates 
cell migration, induces  activation of phosphoinositide3 kinase & 
mitogen activated protein kinase and stimulates calcium 
mobilisation  
G-CSF Bone marrow stromal cells, 
fibroblasts, endothelial, 
macrophages 
Bone marrow stromal cells 
 
Neutrophils 
Proliferation and maturation of granulocyte progenitors and 
precursors 
Promotes and survival of  neutrophils 
IP-10 Macrophages Neutrophils,  
Activated T cells 
Endothelial cells 
Monocytes 
Chemo attractant for neutrophils 
Enhances neutrophil degranulation 
Promotes growth and enhances inflammatory properties 
Promotes chemotaxis 
MCP-1 Monocytes, endothelial cells, 
keratinocytes, fibroblasts & 
neutrophils 
T cells, hematopoietic 
progenitor cells.  
Endothelial cells 
Proliferation of hematopoietic progenitor cells, chemo-attractant 
for T cells macrophages & neutrophils 
Responsible for angiogenesis  
MIP-1/ 
CCL3 
Monocytes,  NK cells, 
macrophages, epithelial and 
endothelial cells, fibroblasts 
Neutrophils, macrophages, 
NK cells 
Chemo attractant for neutrophils, macrophages & NK cells 
MIP-1β/   
CCL4/LAG-1 
Macrophages Granulocytes & macrophages Activation of granulocytes, induction of pro-inflammatory 
cytokines, proliferation of hematopoietic progenitor cells 
IL-1RA 
 
Monocytes, macrophages, 
neutrophils, fibroblasts  
and epithelial cells 
Macrophages 
T cells, islet cells 
Inhibits release of IL-1 and TNF-α from macrophages 
Inhibits release of IL-2 and expression of IL-2R in T cells 
Blocks proliferation of T cells 
IL-12  
(IL-12p70) 
 
 
(IL-12p40) 
Monocytes, macrophages and 
dendritic cells 
T cells  
NK cells 
B cells 
Macrophages and DCs 
Hematopoietic stem cells & 
antigen presenting  cells 
Promotes differentiation and proliferation of T cells.  
Stimulates cytotoxic effects 
Promotes antibody production.  
Enhances the antigen presenting function.  
Activates early hematopoiesis.  
Determines IL-12 production: Antagonist to IL-12p70 
Langrish et al., 2004; Xia &Sui, 2009; 
Gabrilovich & Dikov, 2003; Mukaida et al., 2003 
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3 2.2 The Luminex Assay 
Luminex technology is an immunoassay that uses fluorescent beads to determine the profile 
of multiple cytokines and chemokines in a single sample. Four 27-plex kits were obtained 
from Millipore (Cat. No. MPXHCYTO-60K-27, Lot no. 1643604, expiry date 30/09/2010). 
Tables 3.2.1 – 3.2.3 show the 27 chemokines/ cytokines measured and which cell types have 
been reported to produce them. A plate layout template was designed for each Luminex plate 
and the assay was done according to the manufacturer’s instructions. The experiments and all 
incubation steps were done at room temperature. A standard curve ranging from 3.2 pg/ml – 
10 000 pg/ml was generated by serial dilution of reconstituted standard.  
Each multiplex kit contains two pre-mixed quality control solutions, namely QC-I and QC-II, 
which are used to validate the results of each assay. These control solutions are included in 
duplicate on every plate and have pre-determined acceptable measurement ranges for each 
analyte.  
Study samples were supernatants derived from 7-day culture of diluted whole blood, with 
M.tb antigens M.tb PPD, ESAT6/CFP10 fusion protein, Rv1733c, Rv1737c, Rv2029c and 
Rv2450c. As described in the previous chapter, the supernatants were harvested and stored at 
– 80 0C. For this investigation culture supernatants were thawed at room temperature, mixed 
by vortexing and then centrifuged for 10 minutes at 1500rpm in order for cellular debris to 
settle. Supernatants were tested undiluted and in single wells. For each participant, 
unstimulated culture supernatant was added in single wells, as per plate layout template. The 
blank, with RPMI (containing 1% L-glutamine) only was included on each plate in duplicate. 
The filter of each well was first blocked with 200lof the assay buffer for 10 minutes on a 
plate shaker. The buffer was removed by vacuum aspiration and 25l of the assay diluent was 
added to wells designated for samples while RPMI was added to those wells selected for 
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standards. Samples and standards were added as per template, followed by the addition of 
25l antibody coated fluorescent beads, after which plates were incubated for an hour on a 
plate shaker. After the fluid was removed by vacuum aspiration, a biotinylated secondary 
antibody and streptavidin-phycoerythrin labeled antibodies were added with alternate 
incubation and washing steps between the additions of each antibody.  The last step was the 
addition of 100l of sheath fluid for 5 minutes, followed by reading on the Bio-plex assay 
reader using a 5 parameter logistic regression (5PL) curve. The channel through which the 
fluorescent beads flow for measurement into the assay reader is called RP1. Fluorescence 
detected in samples and controls was read using both low RP1 and high RP1fluorescent 
channels. It is important to read the results with both channels because while the low RP1 
channel measures a broad range of cytokines/chemokines with a large array of 
concentrations, the high RP1 channel has greater sensitivity and is valuable when measuring 
cytokines/chemokines present in low concentrations.  
The negative control value was subtracted from all antigen induced responses prior to 
analysis.  
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Table 3.2.2 Cytokines and chemokines included in the 27-plex Luminex kit and secreted by cells of both the innate and the adaptive immune systems.  
Cytokine/ 
Chemokine
Major source Target cells Function 
IL-1: 
IL-1α,  
IL-1β 
Monocytes, macrophages, 
dendritic cells, T and B cells, 
NK cells.  
Monocytes, eosinophils, dendritic 
cells & fibroblasts.  
Vascular endothelial cells.  
T and B cells 
Pro-inflammation: Initiation of COX-2, type2 phospholipase A and iNOS 
Co-stimulatory for lymphocyte proliferation. Involved in antigen presentation. 
Increase the expression of ICAM-1 and VCAM-1.  
Increases T-cell dependent antibody production 
IL-4 CD 4+, CD8+ T cells, NK cells, 
basophils, and mast cells and 
eosinophils 
B cells  
 
T cells 
 
NK cells 
Mast cells 
Endothelial cells 
Increases MHC-II antigens and co-stimulatory molecules on B- cells. 
Induces isotype switching. Enhances antibody production & CD3 expression.  
Induces CD40 – CD40L dependent proliferation. Growth of T helper cells and 
cytotoxic T cells 
Promotes TH1 and TH2 cell proliferation.  
Promotes histamine release.  
Up-regulates VCAM1 expression 
IL-6 T cells 
fibroblasts 
Hematopoietic stem cells 
Hepatocytes 
B cells, T cells 
Eosinophils 
Induces hematopoiesis 
Stimulates acute phase protein production.  
Induces proliferation and differentiation.  
Promotes activation, growth and differentiation 
IL-8 Monocytes, T cells, neutrophils, 
NK cells, endothelial and 
epithelial cells 
Neutrophils 
T cells 
Basophils 
Promotes chemotaxis, increases intracellular calcium, respiratory burst, endothelial 
cell adhesion and migration. 
Promotes degranulation &  Histamine release 
IL-10 T cells, B cells, monocytes and 
macrophages, NK cells 
B & Tcells, monocytes, 
macrophages, Dendritic cells, NK 
cells
Suppress immune responses on T cells, B cells, antigen presenting cells and to 
skew the immune responses from TH1 to TH2 
IL-13 Macrophages, dendritic cells, B 
and T cells, NK cells, basophils, 
eosinophils, mast cells 
B cells 
Monocytes/ macrophages 
DCs, macrophages & Eosinophils 
Endothelial cells, Epithelial cells. 
Enhances antibody production.  
Up-regulates expression of adhesion molecules. Promotes VCAM-1 expression. 
IFN 
 
T cells, NK cells, Lymphocytes, 
dendritic cells, macrophages 
 
Macrophages 
Phagocytes  
T cells 
B cells 
T and B cells 
Stimulates TNF- & IL-12 production 
Promotes macrophage activation killing of non specific intracellular and 
extracellular pathogens. Assists in TH1 development.  
Regulates B-cell development, proliferation & antibody secretion.  
Isotype switching, promotes antigen processing and presentation 
TNF-α 
 
Macrophages, monocytes, NK 
cells, B cells, T cells, basophils, 
mast cells, neutrophils, 
fibroblasts 
Monocytes/ Macrophages 
Neutrophils 
NK cells 
Vascular endothelial cells 
Induction of IL-1, IL-8,GM-CSF, IFN, TGF, EG2, Chemotaxis,   
Phagocytosis 
NK cell function 
Modulates angiogenesis & increased permeability 
GM-CSF T cells, neutrophils, 
macrophages, NK cells,  
fibroblasts, epithelial cells. 
Neutrophils,  
Macrophages & dendritic cells 
Stimulation of anti-microbial properties. Enhances uptake of opsonized pathogens. 
Increases phagocytosis 
Enhances microbial killing.  
 
 
Enzler &Dranhoff, 2003;  
De la Barrera et al., 2004 
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Table 3.2.3 Cytokines and chemokines included in the 27-plex Luminex kit and secreted by cells of the adaptive immune system 
 
 
 
 
 
 
 
 
Cytokine/ 
chemokine
Major source Target cells Function 
IL-2 CD4+ T  cells T and B cells 
NK cells 
 
Monocytes 
Enhances proliferation and differentiation  
Augments cytolytic activity of NK cells. Stimulates cytolytic activity. 
Promotes the production of GM-CSF, IL-1, IL-6. 
IL-5 T cells Eosinophils 
Basophils  
B cells 
Activates eosinophils.  
Stimulates histamine 
Stimulates IgA production.  
IL-17 T cells  Bone marrow cells, 
macrophages, NK cells 
fibroblasts T cells,  
Proliferation and differentiation of T cells, activation of NK cells; induces hematopoiesis 
Augments the production of pro-inflammatory chemokines and cytokines 
Kok et al., 2003; Boyman et al., 2007. 
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3. 2.3 Results of Kit Validation and Quality Control (QC)  
The quality control validation results indicated that the 4 kits used in this study had 
performed optimally (Figure 3.1 A and B). The recoveries of the 27 chemokines/ cytokines 
were all within the desired 70% - 130% range. In both QC-I and QC-II the observed values 
were within the expected ranges for all analytes in all plates with the exception of plate 4 
where IL-6 levels were higher (257pg/ml and 928pg/ml) than the expected maximum values 
of 176pg/ml and 918pg/ml respectively. For QC-II in plate 4, the observed sCD40L level 
(396pg/ml) was found to be slightly lower than the minimum expected concentration 
(416pg/ml).  
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Cytokines/ chemokines
Figure 3.2: Cytokine profile in supernatant from unstimulated 7-day whole blood at study recruitment
Box plot of the negative control condition using the 27-plex kit. Supernatant from 17 fast TST convertors
and 6 TST convertors was tested with a 27-plex cytokine assay kit at recruitment. Minimum and maximum
values, error bars and median concentrations are shown. The highest unstimulated median cytokine levels
were seen for MCP-1, MIP-beta, sCD40L and IL-8at baseline .
81
82 
 
3. 2.4 Statistical Analysis 
The Mann-Whitney U test was used to measure differences between medians. The mixed 
model of the analysis of variance (MANOVA) was used to determine differences between 
fast and slow TST convertors at recruitment and over time. A p value <0.05 was considered 
statistically significant. The Spearman correlation test was used to investigate the association 
between variables.  
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3.3 Research Questions 
The main research questions that were addressed in this chapter were: 
1. At study recruitment, is there a difference in the multi-cytokine response to M.tb 
antigens in HIV negative household contacts with a prolonged negative skin test 
reaction compared to those that TST convert earlier? 
2. Can the antigen-induced cytokine expression profile at recruitment predict the rate of 
TST conversion? 
3. Do cytokine levels change in fast and/or slow TST convertors over 6 months?  
3.4 Results 
3.4.1 Magnitude of response in fast versus slow TST convertors at recruitment 
3.4.1.1 Negative control at recruitment   
Of the 26 TST negative participants, supernatants from 3 slow TST convertors were not 
available at study recruitment. Unstimulated culture supernatants from the recruitment time 
point of 23 subjects included in the study were tested with the 27-plex cytokine assay (Figure 
3.2). At this time point all subjects were TST negative. The values of 19 of the 27 analytes 
were below detectable levels (<3.2pg/ml). The concentrations of the remaining 8 analytes 
were as follows: EGF, 7.7pg/ml (0.01pg/ml – 36pg/ml); IP10, 32.8pg/ml (0.01- 477pg/ml); 
Fractalkine, 41.9pg/ml (0.01 – 123pg/ml); IL-1ra , 5.6pg/ml (0.01pg/ml – 20.2pg/ml); MIP-
1beta, 60.7pg/ml (11pg/ml – 363.8pg/ml); IL-8, 81.6pg/ml (4pg/ml - 442.8pg/ml); MCP-1, 
104.8pg/ml (21pg/ml - 1857pg/ml) and sCD40L, 112.5pg/ml (21pg/ml - 560pg/ml).   
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3.4.1.2 Fast versus slow TST convertors at recruitment 
Fast TST convertors produced higher levels of GM-CSF, IP-10, IL-8, IL-2, IL-5 and IL-13 
than slow TST convertors when diluted whole blood was stimulated with M.tb PPD at 
recruitment (Figure 3.3 A-F; p=0.0003, p=0.003, p=0.01, p=0.02, p=0.0007 and p<0.0001 
respectively). Slow TST convertors produced markedly enhanced median levels of IL-12p70 
(Figure 3.4: A) in response to both of the DosR regulon-encoded antigens Rv1737c and 
Rv2029c (p=0.02 and p=0.01). These antigens produced a similar response with VEGF 
(p=0.03 and p=0.03; data not shown). Figure 3.4: B illustrates that  MCP-1 levels were 
significantly enhanced in slow convertors when compared to fast convertors in response to 
Rv1733c, Rv1737c, Rv2029c and ESAT6/CFP10 fusion protein (p=0.009, p=0.001, p=0.002 
and p=0.004). IL-10 production (Figure 3.5) was also significantly higher in slow TST 
convertors following stimulation with Rv2029c (p=0.01). 
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Figure 3.3 A - F: Cytokine responses to M.tb PPD at recruitment: fast versus slow TST convertors.
Diluted whole blood from 17 fast TST convertors and 6 slow TST convertors was stimulated with M.tb PPD
for 7 days at recruitment Significantly higher median levels of (A) GM-CSF were observed in fast
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convertors when compared to slow convertors (p=0.0003). A similar observation was made for IP-10 (B) and
IL-8 (C) which are pro-inflammatory chemokines (p=0.003, p=0.01). TH2 cytokines IL-13 (D), IL-5 (E) and
IL-2 (E) produced the same pattern (p<0.0001, p=0.0007 and p=0.02 respectively).
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Figure 3.6: Cytokine profile in supernatant from unstimulated 7-day whole blood at month 6. Box plot
of the negative control condition using the 27-plex kit. 6 months into the study supernatant from 17 fast TST
convertors and 8 slow TST convertors was tested on a 27-plex cytokine assay. The box plot shows minimum,
median and maximum values with error bars. The highest unstimulated median cytokine levels were seen for
IP10, MCP-1, MIP-1 beta, sCD40L and IL-8 at 6 months.
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3.4.2 Magnitude of response in fast and slow TST convertors over time  
Differential cytokine production over time was investigated by measuring the same 27 
cytokines/ chemokines described above in whole blood assay supernatants collected at the 
month 6 time point in fast (n=17) and slow convertors (n=8). The emerging 6 month 
cytokine/chemokine profile was compared to the recruitment cytokine/ chemokine profile. 
The results are described according to cytokines that changed over time in fast convertors 
only, in slow convertors only, or in both fast and slow convertors.  
3.4.2.1 Negative control at 6 months 
Figure 3.6 shows the production levels of the 27 cytokines measured in unstimulated culture 
supernatants at month 6. Seventeen subjects had converted to TST positive and 9 remained 
TST negative.  The values of 18 of the 27 analytes were below detectable levels (<3.2pg/ml). 
The concentrations of the remaining 9 analytes were as follows: MIP-1alpha, 3.2pg/ml 
(0.01pg/ml – 43.7pg/ml); EGF, 7.6pg/ml (0.01pg/ml – 19.4pg/ml); IL-1ra, 9.4pg/ml 
(0.01pg/ml – 125.2pg/ml); Fractalkine, 26.4pg/ml (0.01pg/ml – 77.8pg/ml); IL-8, 50.9pg/ml 
(8.6pg/ml – 8890pg/ml); IP10, 58.7pg/ml (2.1- 1003pg/ml); sCD40L, 73.7pg/ml (18.1pg/ml – 
690.6pg/ml); MCP-1, 77.1pg/ml (15.2pg/ml – 5719pg/ml); and MIP-1beta, 87.9pg/ml 
(7.1pg/ml – 505pg/ml). 
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Figure 3.7A - D: Cytokines that increase over time in response to classical Mtb antigens only and in fast
convertors only. Whole blood from 17 fast TST convertors was stimulated in fast convertors with M.tb
antigens Rv1733c, Rv1737c, Rv2029c, ESAT6/CFP10 fusion protein and M.tb PPD for 7 days at recruitment
and at 6 months. GM-CSF (A) was induced only by M.tb PPD at recruitment and the response was enhanced
at 6 months (p<0.0001). A similar pattern was observed for IL-2 (p=0.001, data not shown). (B) IL-8 was
strongly expressed in response to all antigens at both time points. At 6 months IL-8 responses to M.tb PPD
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(p=0.004, data not shown). (C) IL-4 levels in response to all antigens were very low with the exception of
M.tb PPD at month 6 (p=0.0008). The same pattern was seen for sCD40 ligand, IL-5, IL-13, fractalkine and
IL-17 (p <0.0001, p<0.0001 , p<0.0001, p=0.003 and p=0.005 respectively, data not shown). (D) IFN
production had significantly increased by 6 months upon stimulation with both ESAT-6/CFP10 fusion protein
and M.tb PPD (p=0.02, p= 0.002). This presentation was also observed for IP-10 (p= 0.003, p<0.0001, data
not shown).
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3.4.2.2 Cytokines that change over time in fast convertors only 
Only M.tb PPD elicited both pro-inflammatory chemokines and adaptive immune system 
cytokines at recruitment in fast TST convertors, which were enhanced at 6 months (Figure 
3.7A–D). GM-CSF was induced in fast convertors at recruitment and the response was 
enhanced at 6 months (Figure 3.7A, p<0.0001). A similar pattern was observed for IL-2 
(p=0.001, data not shown).  Figure 3.7B demonstrates that IL-8 was strongly expressed in 
response to all antigens at both time points. At 6 months IL-8 responses to M.tb PPD were 
significantly increased when compared to recruitment (p=0.0008). EGF displayed the same 
pattern (p=0.004, data not shown).  IL-4 levels in response to all antigens were very low with 
the exception of M.tb PPD at month 6 (Figure 3.7C, p=0.0008). The same pattern was seen 
for sCD40 ligand, IL-5, IL-13, Fractalkine and IL-17 (p <0.0001, p<0.0001, p<0.0001, 
p=0.003 and p=0.005 respectively, data not shown). Stimulation with all antigens except for 
M.tb PPD resulted in very low IFN- production at recruitment. Stimulation with ESAT-
6/CFP10 fusion protein and M.tb PPD resulted in significantly increased IFN-production 6 
months (Figure 3.7D, p=0.02, p= 0.002). This presentation was also observed for IP-10 (p= 
0.003, p<0.0001, data not shown). 
Figure 3.8: A-B shows that both MIP-1and IL-1 were markedly elevated in response to 
Rv1737c at 6 months in fast convertors only when compared to recruitment (p=0.02 and 
p=0.02). Stimulation with DosR regulon-encoded antigens Rv1733c, Rv1737c and Rv2029c 
resulted significantly higher IL-1ra responses only in fast convertors at 6 months compared to 
recruitment (Figure 3.8C, p=0.006, p=0.03 and p=0.02).  
At 6 months, stimulation with Rv2029c and ESAT-6/CFP10 fusion protein elicited 
significantly higher MCP-1 levels when compared to recruitment (Figure 3.9, p=0.006 and 
p=0.04). 
Figure 3.8
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Figure 3.8A - C: Cytokines that increase over time in response to DosR regulon-encoded antigens only
and in fast convertors only. Whole blood from 17 fast TST convertors was stimulated with M.tb antigens
Rv1733c, Rv1737c, Rv2029c, ESAT6/CFP10 fusion protein and M.tb PPD for 7 days at recruitment and at 6
months. (A-B) MIP-1 and IL-1 were markedly elevated in response to Rv1737c at 6 months in fast
convertors only when compared to recruitment (p=0.02 and p=0.02). (C) Significantly higher IL-1ra
responses to Rv1733c, Rv1737c and Rv2029c were observed only in fast convertors at 6 months compared
to recruitment (p=0 006 p=0 03 and p=0 02). , . . .
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Figure 3.9: Cytokines that increase over time in response to classical Mtb antigens and
DosR regulon-encoded antigens in fast convertors only. Whole blood from 17 fast TST
convertors was stimulated with M.tb antigens Rv1733c, Rv1737c, Rv2029c, ESAT6/CFP10
fusion protein and M.tb PPD for 7 days at recruitment and at 6 months. Significantly higher
MCP-1 levels in response to Rv2029c and ESAT-6/CFP10 fusion protein at 6 months when
d t it t ( 0 006 d 0 04)compare o recru men p= . an p= . .
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3.4.2.3 Cytokines that change over time in slow convertors only  
Rv2029c elicited significantly lower IL-10 and G-CSF at month 6 when compared to 
recruitment (Figure 3.10: A- B, p=0.002 and p=0.01). In this study group, lower VEGF 
production was observed in response to Rv1737c at month 6 when compared to recruitment 
(Figure 3.10C, p=0.04). 
3.4.2.4 Cytokines that change over time in both fast and slow convertors  
 In Figure 3.11A, significantly higher IL-12p40 responses were observed at month 6 
compared to recruitment when both fast and slow convertors were stimulated with Rv1733c 
(p=0.01, 0.02) and Rv1737c (p=0.003, p=0.006).  However, stimulation with Rv2029c 
elicited higher IL-12p40 concentrations at 6 months in fast TST convertors only (p=0.02). 
Significantly higher IL-12p70 responses to Rv1737c were seen at month 6 compared to 
recruitment in both fast and slow convertors (Figure 3.11B, p=0.005 and p= 0.006).  
TGFproduction displayed a distinct pattern in fast and slow TST convertors due to 
stimulation with M.tb antigens. Figure 3.12 illustrates that fast convertors produced enhanced 
TGF levels to M.tb PPD stimulation at 6 months (p=0.005) whereas slow convertors 
produced significantly lower cytokine responses to Rv2029c at 6 months (p=0.04).  
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Figure 3.10A - C: Cytokines that decrease over time in response to DosR regulon-encoded antigens only
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and in slow convertors only Whole blood from 6 slow TST convertors was stimulated with M.tb antigens
Rv1733c, Rv1737c, Rv2029c, ESAT6/CFP10 fusion protein and M.tb PPD for 7 days at recruitment and in
subjects at 6 months. Slow convertors produced significantly lower (A) IL-10 and (B) G-CSF upon
stimulation with Rv2029c at month 6 when compared to recruitment (p=0.002 and p=0.01). (C) Lower VEGF
production was observed in response to Rv1737c at month 6 when compared to recruitment (p=0.04).
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Figure 3.11A-B: Cytokines that increase over time in response to DosR regulon-encoded antigens only
in fast and slow convertors Whole blood from 17 fast TST convertors and 6 and 8 slow TST convertors (at
recruitment and at month 6 respectively) was stimulated with M.tb antigens Rv1733c, Rv1737c, Rv2029c,
ESAT6/CFP10 fusion protein and M.tb PPD for 7 days at recruitment and at 6 months. (A) Significantly
higher IL-12p40 responses were observed at month 6 compared to recruitment when (i) both fast and slow
convertors were stimulated with Rv1733c (p=0.01, 0.02) and Rv1737c (p=0.003, p=0.006) (ii) fast
i l d i h R 2029 ( 0 02) (B) Si ifi l hi h IL 12 70convertors were st mu ate w t v c p= . . gn cant y g er - p responses were
observed at month 6 compared to recruitment when both fast and slow convertors were stimulated with
Rv1737c (p=0.005 and p= 0.006).
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Figure 3.12: Cytokines that change over time in response to classical or DosR regulon-encoded M.tb
antigens in fast and slow convertors.Whole blood from 17 fast TST and 8 slow convertors was stimulated
with M.tb antigens Rv1733c, Rv1737c, Rv2029c, ESAT6/CFP10 fusion protein and M.tb PPD for 7 days at
recruitment and at 6 months (6 slow TST convertors at month 6). Fast convertors produced significantly
higher cytokine responses to M.tb PPD stimulation at 6 months (p=0.005) whereas slow convertors produced
significantly lower cytokine responses to Rv2029c at 6 months (p=0 04). .
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3.4.3 Percent responders: fast TST convertors versus slow TST convertors  
A response was considered positive for an analyte if the antigen-induced concentration was 
greater than the mean of the negative control value plus 2 standard deviations. If this cut-off 
value was lower than the lowest point on the standard curve (3.2pg/ml), the cut-off point for 
the analyte was set to 3.2pg/ml. Table 3.3 shows the response cut-off values for each analyte.  
Table 3.4 A - E shows the frequency of responses to M.tb antigens in fast and slow 
convertors at recruitment and after 6 months for each of the 27 cytokines tested. 
3.4.3.1 Classical TB antigens: M.tb PPD 
In fast convertors at recruitment, M.tb PPD induced positive responses for 22 of the 27 
cytokines, and for 10 cytokines this antigen induced responses in over 50% of the study 
group. 6 Months into the study this antigen induced positive responses for 23 of the 27 
cytokines and for 12 cytokines this antigen induced responses in over 50% of fast convertors 
(Table 3.4 A).  
In slow convertors at recruitment, M.tb PPD induced positive responses for 11 of the 27 
cytokines, and for 2 cytokines this antigen induced responses in over 50% of the study group. 
6 Months into the study, this antigen also induced positive responses for 11 of the 27 
cytokines, and for the same 2 cytokines this antigen induced responses in over 50% of the 
study group.  The positive cytokine responses at the different time points were not from the 
same cytokines. While there were no IL-10, IL-2 and IL-17 produced in response to M.tb 
PPD in slow convertors at recruitment, these cytokines were produced at month 6 in response 
to this antigen. On the other hand whereas there were IL-12p40, MIP-1 and VEGF 
responses to M.tb PPD at recruitment in this study group these cytokines were not produced 
at month 6.  
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Table 3.3 Cut-off point per cytokine/chemokine in the 27-plex Luminex kit. A distinct 
cut-off value for each cytokine in the 27-plex Luminex kit was determined as the mean of the 
negative control value plus 2 standard deviations. Where this cut-off fell below the lowest 
detection limit of the assay (3.2pg/ml), the value was changed to 3.2pg/ml. Cytokines are 
kinetic and therefore measuring these 27 cytokines/chemokines at 7 days only is a biased 
picture.   
 
 
  
Cytokine/Chemokine Cut-off values (pg/ml) 
EGF 24.9 
Eotaxin  394.8 
Fractalkine 96.0 
G-CSF  34.3 
GM-CSF  3.2 
IL-1ra 53.5 
IL-1alpha  24.5 
IL-12p40 15.3 
IL-17 3.2 
IP-10  433.0 
MCP-1  2192.4 
MIP-1alpha  34.3 
MIP-1beta  273.8 
sCD40L  388.0 
TGF-alpha  3.2 
TNF-alpha  18.0 
VEGF  36.1 
IFN-gamma  8.0 
IL-2 3.2 
IL-4 3.2 
IL-5  3.2 
IL-10  5.3 
IL-13 3.2 
IL-1beta 14.2 
IL-6  810.6 
IL-8 2830.0 
IL-12p70 3.2 
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Table 3.4 A. Percentage of responders to classical M.tb antigen M.tb PPD per cytokine/ 
chemokine in the 27-plex Luminex kit.at recruitment and at month 6. Diluted whole 
blood of fast TST convertors (n=17 at recruitment, n=16 at month 6) and slow TST 
convertors (n=6 at recruitment, n=8 at month 6) was stimulated with M.tb PPD for 7 days and 
cytokines were measured in harvested supernatants using the 27-plex Luminex kit. The 
percentage of responders was determined using pre-determined, cytokine specific response 
cut-off values.  
 
 
  
Cytokine /Chemokine  Fast  TST 
convertors 
At 
Recruitment 
Slow TST 
convertors 
At 
Recruitment 
Fast TST 
convertors  
At Month 6 
Slow TST 
convertors  
At Month 6 
Innate cytokines      
EGF 0 0 5.8 0 
Eotaxin 0 0 0 0 
Fractalkine 0 0 5.8 0 
G-CSF 5.9 0 5.8 0 
IL-1ra 70.5 50 94.1 57.1 
IL-12p40 17.6 16.7 23.5 0 
IL-12p70 0 0 0 0 
IP10 70.5 16.7 94.1 42.8 
MCP-1 100 83.3 100 85.7 
MIP-1alpha 76.4 16.7 82.3 14.2 
MIP-1beta 29.4 16.7 47 0 
TGF alpha 52.9 0 0 0 
VEGF 5.9 16.7 0 0 
Innate and adaptive 
cytokines/chemokines
    
GM-CSF 64.7 16.7 94.1 42.8 
IFN gamma 64.7 16.7 94.1 42.8 
IL-1alpha 29.4 0 41.1 0 
IL-1 beta 17.6 0 41.1 0 
IL-6 29.4 0 23.5 0 
sCD40L 0 0 5.8 0 
IL-4 5.9 0 11.7 0 
IL-8 52.9 33.3 94.1 14.2 
IL-10 35.2 0 64.7 28.5 
IL-13 29.4 0 76.4 0 
TNF alpha 70.5 16.7 88.2 14.2 
Adaptive cytokines     
IL-2 52.9 0 82.3 14.2 
IL-5 5.9 0 35.2 0 
IL-17 17.6 0 64.7 14.2 
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Table 3.4 B. Percentage of responders to classical M.tb antigen ESAT6/CFP10 fusion 
protein per cytokine/ chemokine in the 27-plex Luminex kit at recruitment and at 
month 6. Diluted whole blood of fast TST convertors (n=16 at recruitment, n=17 at month 6) 
and slow TST convertors (n=6 at recruitment, n=8 at month 6) was stimulated with 
ESAT6/CFP10 fusion protein for 7 days and a cytokine/chemokine profile of the percentage 
of responders determined using a 27-plex kit. 
 
 
 
  
Cytokine /Chemokine  Fast  TST 
convertors  
at 
Recruitment  
Slow TST 
convertors at 
Recruitment 
Fast 
convertors  
At Month 
6 
Slow 
convertors 
At Month 6 
Innate cytokines      
EGF 17.6 0 17.6 0 
Eotaxin 0 0 0 0 
Fractalkine 0 0 0 0 
G-CSF 41.2 16.7 35.3 37.5 
IL-1ra 88.2 100 100 87.5 
IL-12p40 47 66.7 52.9 62.5 
IL-12p70 0 33.3 17.6 25 
IP10 58.8 66.7 82.3 62.5 
MCP-1 100 100 92.1 100 
MIP-1alpha 58.8 66.7 64.7 37.5 
MIP-1beta 58.8 66.7 64.7 75 
TGF alpha 17.6 16.7 41.1 25 
VEGF 35.2 33.3 23.5 37.5 
Innate and adaptive 
cytokines/chemokines
    
GM-CSF 56.3 75 70.5 50 
IL-1alpha 52.9 83.3 70.5 62.5 
IL-1 beta 76.4 83.3 82.3 87.5 
IL-4 0 0 0 0 
IL-6 58.8 66.7 64.7 62.5 
IL-8 82.3 83.3 94.1 87.5 
IL-10 58.8 66.7 64.7 75 
IL-13 0 0 11.7 0 
IFN gamma 70.5 50 88.2 75 
sCD40L 0 0 0 0 
TNF alpha 94.1 83.3 94.1 87.5 
Adaptive cytokines     
IL-2 0 0 47 25 
IL-5 0 0 11.7 12.5 
IL-17 12.5 0 29.4 12.5 
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3.4.3.2 Classical TB antigens: ESAT6/CFP10 Fusion Protein 
Table 3.4B shows that in fast convertors at recruitment ESAT6/CFP10 fusion protein induced 
positive responses for 19 of the 27 cytokines, and for 13 cytokines this antigen induced 
responses in over 50% of the study group. 6 Months into the study this antigen induced 
positive responses for 23 of the 27 cytokines and for 14 cytokines this antigen induced 
responses in over 50% of fast convertors.   
In slow convertors at recruitment ESAT6/CFP10 fusion protein induced positive responses 
for 18 of the 27 cytokines, and for 14 cytokines this antigen induced responses in over 50% 
of the study group. 6 Months into the study this antigen induced positive responses for 21 of 
the 27 cytokines and for 18 cytokines this antigen induced responses in over 50% of fast 
convertors.   
3.4.3.3 DosR regulon encoded antigens: Rv1733c 
Table 3.4C shows that in fast convertors at recruitment Rv1733c induced positive responses 
for 20 of the 27 cytokines, and for 16 cytokines this antigen induced responses in over 50% 
of the study group. All 20 cytokines that responded at recruitment also responded to this 
antigen 6 months into the study, and for 18 cytokines this antigen induced responses in over 
50% of the study group. 
In slow convertors at recruitment Rv1733c induced positive responses for 20 of the 27 
cytokines, and for 18 cytokines this antigen induced responses in over 50% of the study 
group. 6 Months into the study Rv1733c induced positive responses for 19 of the 27 
cytokines and for 18 of the same cytokines that this antigen induced responses in over 50% at 
recruitment, were also induced at month 6 in slow convertors.   
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Table 3.4C. Percentage of responders to Dos-R regulon encoded antigen Rv1733c per 
cytokine/ chemokine in the 27-plex Luminex kit at recruitment and at month 6. Diluted 
whole blood of fast TST convertors (n=16) and slow TST convertors (n=6 at recruitment, n=8 
at month 6) was stimulated with Rv1733c for 7 days and a cytokine/chemokine profile of the 
percentage of responders determined using a 27-plex kit. 
 
 
  
Cytokine /Chemokine  Fast  TST 
convertors at 
Recruitment 
Slow TST 
convertors at 
Recruitment 
Fast  TST 
convertors  
At Month 6 
Slow TST 
convertors  
At Month 6 
Innate 
cytokines/chemokines 
    
EGF 12.5 33.3 43.7 37.5 
Eotaxin 0 0 0 0 
Fractalkine 0 0 0 0 
G-CSF 100 100 87.5 87.5 
IL-1ra 100 100 100 100 
IL-12p40 100 100 87.5 100 
IL-12p70 12.5 50 62.5 75 
IP10 36.3 50 81.2 75 
MCP-1 100 100 87.5 100 
MIP-1alpha 100 100 93.7 100 
MIP-1beta 100 100 100 100 
TGF alpha 56.3 50 75 62.5 
VEGF 68.8 100 75 87.5 
Innate and adaptive 
cytokine/chemokines 
    
GM-CSF 87.5 100 93.7 100 
IFN gamma 62.5 66.7 75 100 
IL-1alpha 100 100 100 100 
IL-1 beta 100 100 100 100 
IL-4 0 0 0 0 
IL-6 100 100 100 100 
IL-8 100 100 93.7 100 
IL-10 100 100 100 100 
IL-13 0 0 0 0 
sCD40L 0 0 0 0 
TNF alpha 100 100 100 100 
Adaptive cytokines     
IL-2 0 0 0 0 
IL-5 0 0 0 0 
IL-17 6.25 16.7 12.5 0 
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3.4.3.4 DosR regulon encoded antigens: Rv1737c 
Table 3.4D shows that in fast convertors at recruitment Rv1737c induced positive responses 
for 20 of the 27 cytokines, and for 15 cytokines this antigen induced responses in over 50% 
of the study group. 6 months into the study, 21 cytokines responded to Rv1737c including all 
20 that had responded at recruitment to this antigen; and for 18 cytokines this antigen induced 
responses in over 50% of the study group. 
In slow convertors at recruitment Rv1737c induced positive responses for 20 of the 27 
cytokines, and for 17 cytokines this antigen induced responses in over 50% of the study 
group. 6 Months into the study Rv1737c induced positive responses for the same 20 of the 27 
cytokines and for 18 cytokines this antigen induced responses in over 50% were induced at 
month 6 in slow convertors. 
3.4.3.5 DosR regulon encoded antigens: Rv2029c 
Table 3.4E shows that in fast convertors at recruitment Rv2029c induced positive responses 
for 20 of the 27 cytokines, and for 16 cytokines this antigen induced responses in over 50% 
of the study group. 6 Months into the study, 23 cytokines responded to Rv2029c including all 
20 that had responded at recruitment this antigen, and for 17 cytokines this antigen induced 
responses in over 50% of the study group. 
In slow convertors at recruitment Rv2029c induced positive responses for 19 of the 27 
cytokines, and for 17 cytokines this antigen induced responses in over 50% of the study 
group. 6 Months into the study Rv2029c induced positive responses in 20 of the 27 cytokines 
and for 17 cytokines this antigen induced responses in over 50% that were induced at month 
6 in slow convertors. 
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Table 3.4 D. Percentage of responders to Dos-R regulon encoded antigen Rv1737c at 
recruitment and month 6, per cytokine/ chemokine in the 27-plex Luminex kit. Diluted 
whole blood of fast TST convertors (n=17) and slow TST convertors (n=6 at recruitment, n=8 
at month 6) was stimulated with Rv1737c for 7 days and a cytokine/chemokine profile of the 
percentage of responders determined using a 27-plex kit. 
   
Cytokine /Chemokine  Fast  TST 
convertors at 
Recruitment 
Slow TST 
convertors at 
Recruitment 
Fast TST 
convertors  
At Month 6 
Slow TST 
convertors  
At Month 6 
Innate 
cytokines/chemokines 
    
EGF 29.4 33.3 29.4 50 
Eotaxin 0 0 0 0 
Fractalkine 0 0 0 0 
G-CSF 88.2 83.3 88.2 87.5 
IL-1ra 94.1 100 94.1 100 
IL-12p40 94.1 100 88.2 100 
IL-12p70 47 50 58.8 50 
IP10 47.8 50 88.2 87.5 
MCP-1 94.1 100 88.2 100 
MIP-1alpha 82.3 100 88.2 100 
MIP-1beta 94.1 100 94.1 100 
TGF alpha 47.3 33.3 82.3 62.5 
VEGF 88.2 83.3 82.3 62.5 
Innate and adaptive 
cytokines/chemokines 
    
GM-CSF 76.4 100 88.2 100 
IFN gamma 82.3 100 82.3 100 
IL-1alpha 94.1 100 94.1 100 
IL-1 beta 94.1 100 94.1 100 
IL-4 0 0 5.8 0 
IL-6 94.1 100 94.1 100 
IL-8 94.1 100 88.2 100 
IL-10 94.1 100 94.1 100 
IL-13 0 0 0 0 
sCD40L 0 0 0 0 
TNF alpha 94.1 100 94.1 100 
Adaptive cytokines     
IL-2 0 0 0 0 
IL-5 0 0 0 0 
IL-17 17.6 16.7 11.7 12.5 
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Table 3.4E. Percentage of responders to DosR regulon-encoded antigen Rv2029c per 
cytokine/ chemokine in the 27-plex Luminex kit: at recruitment and month 6. Diluted 
whole blood of fast TST convertors (n=17 at recruitment, n=16 at month 6) and slow TST 
convertors (n=6 at recruitment, n=8 at month 6) was stimulated with Rv2029c for 7 days and 
a cytokine/chemokine profile of the percentage of responders determined using a 27-plex kit.  
Cytokine /Chemokine  Fast  TST 
convertors at 
Recruitment 
Slow TST 
convertors at 
Recruitment 
Fast TST 
convertors 
At Month 6 
Slow TST 
convertors 
At Month 6 
Innate 
cytokines/chemokines 
    
EGF 12.5 16.7 25 18.7 
Eotaxin 0 0 0 0 
Fractalkine 0 0 0 0 
G-CSF 75 75 62.5 50 
IL-1ra 93.8 100 100 100 
IL-12p40 68.8 100 87.5 87.5 
IL-12p70 25 33.3 37.5 50 
IP10 50 50 87.5 50 
MCP-1 93.8 100 93.7 100 
MIP-1alpha 68.8 83.3 81.2 62.5 
MIP-1beta 75 83.3 93.7 87.5 
TGF alpha 37.5 50 18.7 12.5 
VEGF 56.3 66.7 56.2 50 
Innate and adaptive 
cytokines/chemokines
    
GM-CSF 87.5 83.3 93.7 87.5 
IFN gamma 75 66.7 87.5 87.5 
IL-1alpha 93.8 100 100 75 
IL-1 beta 93.8 100 100 100 
IL-4 0 0 0 0 
IL-6 81.3 83.3 100 87.5 
IL-8 93.8 100 93.7 100 
IL-10 75 66.7 100 87.5 
IL-13 0 0 6.2 0 
sCD40L 0 0 0 0 
TNF alpha 93.8 100 100 100 
Adaptive cytokines     
IL-2 0 0 25 0 
IL-5 0 0 6.2 0 
IL-17 18.7 0 25 25 
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3.4.3.6 Resuscitation promotion factors: Rv2450c 
Table 3.4 F shows the frequency of responses to resuscitation promotion factor Rv2450c in 
fast and slow convertors at recruitment for each of the 27 cytokines tested. In fast convertors 
at recruitment Rv2450c induced positive responses for 18 of the 27 cytokines, and for 1 
cytokine this antigen induced responses in over 50% of the study group. In slow convertors at 
recruitment Rv2450c induced positive responses for 16 of the 27 cytokines, and for 4 
cytokines this antigen induced responses in over 50% of the study group.  
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Table 3.4F Percentage of responders RPF antigen Rv2450c at recruitment only: per 
cytokine/ chemokine in the 27-plex Luminex kit. Diluted whole blood of fast TST 
convertors (n=17) and slow TST convertors (n=6) was stimulated with Rv2450c for 7 days 
and a cytokine/chemokine profile of the percentage of responders determined using a 27-plex 
kit. 
 
 
Percentage of responders to 
Cytokine /Chemokine  
Fast  TST 
convertors at 
Recruitment  
Slow TST 
convertors at 
Recruitment 
Innate cytokines   
EGF 31.3  16.7 
Eotaxin 0 0 
Fractalkine 0 0 
G-CSF 5.9 0 
IL-1ra 58.8 100 
IL-12p40 5.9 50 
IL-12p70 0 0 
IP10 17.6 75 
MCP-1 5.9 16.7 
MIP-1alpha 23.5 0 
MIP-1beta 23.5 33.3 
TGF alpha 0 0 
VEGF 5.9 16.7 
Innate and adaptive 
cytokines/chemokines
  
GM-CSF 25 16.7 
IL-1alpha 23.5 16.7 
IL-1 beta 41.2 33.3 
IL-4 0 0 
IL-6 17.6 16.7 
IL-8 29 33.3 
IL-10 11.6 16.7 
IL-13 0 0 
IFN gamma 35.2 50 
sCD40L 0 0 
TNF alpha 35.3 33.3 
Adaptive cytokines   
IL-2 0 0 
IL-5 0 0 
IL-17 25 33.3 
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 3.4.4 Correlations between cytokines 
3.4.4.1 Correlations between cytokines in fast TST convertors at recruitment 
Cytokines that were significantly associated with each other are illustrated in Appendix 1. In 
this section only strong and highly significant correlations which are defined as association 
with r >.80 and p≤ 0.0001 are reported. 
Upon stimulation of fast TST convertors with M.tb PPD, IL-1 strongly associated with G-
CSF, IL-6 and IL-1 IL-17 was highly associated with IP10 and GM-CSF.  
Following stimulation with ESAT6/CFP10 fusion protein, G-CSF and IL-1were strongly 
associated with each other and with MIP-1IL-1IL-6, IL-8, TNF-and IL-10. Apart 
from being highly correlated to each other, TNF-and IL-10 were also strongly associated 
with MIP-1and MIP-1TNF-was also strongly associated with IL-1IL-6, IL-8 and 
IL-12p40. IL-10 was also highly correlated with IL-6. IL-1was highly correlated with both 
IL-6 and IL-8, while IL-6 was also highly correlated with IL-8.  IL-1ra strongly correlated 
with EGF. 
Rv1733c resulted in strong associations between MIP-1 and MIP-1as well as between 
TNF- and IL-6 only.   
Rv1737c stimulation produced strong association between G-CSF and IL-1 These two 
cytokines were also correlated with IL-6. IL-10 was strongly correlated with G-CSF, IL-1 
and IL-6. IL-12p70 was strongly associated with both TNF- and IP10.  
Following stimulation with Rv2029c, TNF- was strongly correlated with MIP-1 IL-6, IL-
10, IL-12p40 and IL-12p70. IL-10 also strongly associated with both IL-1 and IL-6. In 
addition, a strong association between MIP-1and MIP-1was observed. 
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Both IL-1 and TNF- were strongly associated with IL-1 and IL-6 when fast TST 
convertors were stimulated with Rv2450c at recruitment. IL-1 was also highly correlated 
with IL-6, whereas IL-1ra was strongly associated with both IL-6 and IL-1strong 
association between MIP-1and MIP-1was also observed as a result of this antigen.  
3.4.4.2 Correlations between cytokines in slow TST convertors at recruitment 
At recruitment, none of the antigens tested elicited strong correlations between cytokines 
measured in slow TST convertors. 
3.4.4.3 Correlations between cytokines in fast TST convertors at month 6 
Six months into the study, the fast TST convertors were stimulated with M.tb PPD resulting 
in a cytokine correlation profile that demonstrated strong association between GM-CSF and 
with IL-5, IL-8 and IL-13. IL-1was strongly correlated with G-CSF, IL-5 and IL-8. Strong 
associations were also observed between MIP-1and MIP-1as well as between IL-1 and 
IL-12p40.  
At this time point, stimulation with ESAT6/CFP10 fusion protein resulted in G-CSF and IL-
1 both being strongly associated with MIP-1 IL-1and IL-6. TNF was also strongly 
correlated with IL-1, IL-6, IL-10 and MIP-1. Whereas IL-1 was also strongly correlated 
with IL-6, IL-10, strong association also observed between GM-CSF and IL-2 as wells as 
between MIP-1and MIP-1 
Rv1733c responses led to strong associations between G-CSF and IL-1 with IL-
1Rv1737c at month 6 in fast TST convertors resulted in strong association observed 
between TGF and IL-6, IL-1 and IL-10, TNF and IP10 as well as with both IL-10 and 
IL-1 with G-CSF.   
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Stimulation with Rv2029c at month 6 resulted in strong associations being observed between 
MIP-1and MIP-1IL-1and IL-1 as well as between TNF and both IL-12p40 and IL-
12p70.   
3.4.4.4 Correlations between cytokines in slow TST convertors at month 6 
M.tb PPD stimulated 7-day diluted whole blood from slow TST convertors at month 6 did not 
result in a strongly correlation between cytokines. On the other hand, stimulation with 
ESAT6/CFP10 fusion protein resulted in a highly significant correlation between IFN- and 
IP10. 
Stimulation with latency antigens, Rv1733c, Rv1737c and Rv2029c did not yield strong 
cytokine associations in the slow TST convertor group 6 months into the study. 
3.4.5 Comparison of the ELISA and Luminex methods 
We wished to validate the results emanating from both assays by comparing the IFN- 
production that was determined using the ELISA and the Luminex upon stimulation of the 
fast TST convertors by 5 conditions at recruitment, when they were still TST negative. In 
Table 3.5 significant correlations in the interferon gamma production measured with both 
assays was observed as a result of stimulation with 4 out of 6 conditions tested.   
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Table 3.5 Correlation co-efficient between the ELISA and the Luminex Assay. The 
Spearman correlation test was performed in on order determined whether there was 
agreement between the 2 cytokine assays.  P<0.05 was considered significant.   
 
 
 
 
  
 ELISA 
Median (range 
in pg/ml) 
LUMINEX 
Median (range 
in pg/ml) 
r P 
M.tb PPD 174 (15 – 
1957pg/ml) 
33 (0.01 – 
5260pg/ml) 
.54 0.02 
ESAT6/CFP10 
fusion protein 
52 (15 – 
1574pg/ml) 
43pg/ml (0.01 – 
226pg/ml) 
0.56 0.02 
Rv1733c 15 (15 – 
1029pg/ml) 
27 (0.01 – 
116pg/ml) 
.72 0.002 
Rv1737c 49.2 (15 - 
1801pg/ml) 
109.6 (0.01 – 
1052pg/ml) 
.64 0.005 
Rv2029c 32.9 (15 - 
1360pg/ml) 
33 (0.01 - 
550pg/ml)  
-.09 0.74 
Rv2450c 15 (15 – 
226pg/ml) 
5 (0.01 – 
92pg/ml) 
.14 0.60 
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3.5 Discussion  
In this chapter we used the luminex assay to investigate multiple cytokine expression profiles 
of 26 HHC of TB index cases that were TST negative at study recruitment, followed them for 
6 months, when 17 (65.4%) of them had converted their status to positive, while 9 (34.6%) 
remained negative. The luminex platform has been recommended as a screening tool in order 
to determine markers that may be followed up using more senitive instruments (Djoba 
Siawaya, 2008). This report demonstrates that the cytokine expression patterns due to 
antigenic stimulation in fast convertors were significantly different to those of the slow 
convertors. Both the fast and the slow convertors had been equally exposed to their respective 
TB index cases. Others have observed that TST conversion in contacts was associated to the 
gradient of exposure to TB index cases (Whalen et al., 2006). The main variables that were in 
the contact gradient of that study were whether the contact was a spouse to the index case or a 
relative or a caregiver.  These authors also observed that 27% of initially TST negative HHC 
converted to TST positive within a year. In their study, del Corral et al., (2009) observed a 
TST conversion rate of 44.5% within a year in contacts that had tested negative at baseline. In 
the main GC-6 study we observed that 92.8% (829) of the HHC were already TST positive at 
baseline. We do not have the month 6 TST results of 29 (45.4%) of the 64 participants who 
had tested TST negative at recruitment and as a result, we cannot be sure about the TST 
conversion rate in the main study. We know, however, that of the available TST results at 
month 18, only 1 subject had remained TST negative, whom we had included in the slow 
convertor group. While a study that has been conducted in the same community that we 
conducted our own study in has previously shown that only 19% of TB had occurred within 
the household (Verver et al., 2004), in our study we assumed that transmission had occurred 
within the household. It is possible therefore that TB infection of as many as 81% (722) of 
the participants in our main population had taken place outside of the household. In our 
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investigation we observed that participants that converted faster were significantly older than 
those that converted later and that the BCG scar was present in 41.1% of fast TST convertors 
compared to 77.7 % of slow TST convertors.   
At the point of study recruitment, both pro-inflammatory and Th2 cytokines were 
significantly elevated in fast TST convertors in response to M.tb PPD. These included IP-10, 
IL-8, GM-CSF, IL-2, IL-5 and IL-13.  IP10 is a chemokine of the innate immune system, is 
mainly produced by the macrophages and attracts NK cells, neutrophils, monocytes and CD4+ 
memory T cells as well as promoting the growth of endothelial cells (Mukaida et al., 2003). 
IL-8, GM-CSF AND IL-13 are cytokines of both the innate and the adaptive immune 
systems. IL-8 is a potent neutrophil attractant (Mukaida et al., 2003). GM-CSF stimulates 
neutrophil antimicrobial activities, enhances phagocytosis in macrophages and stimulates the 
production of other pro-inflammatory cytokines (Enzler & Dranoff, 2003); and IL-13 down-
regulates and modulates inflammation and also induces TGF (Grüning et al., 2003). IL-2 
and IL-5, on the other hand, are produced by the cells of the adaptive immune system. IL-2 
plays a unique role in the expansion of Foxp3- suppressor cells (Zheng et al., 2007) and is 
essential for  optimizing CD8+ T-cell functions (Boyman et al., 2010). IL-5 is responsible for 
eosinophil localization, enhances the histamine releasing abilities of basophils and stimulates 
antibody production (Kok et al., 2003). The involvement of both the innate and the adaptive 
immune systems in response to M.tb PPD in fast convertors when they were still TST 
negative may be indicative of an innate immune system that is fighting the bacterial challenge 
and leading to the mobilization of the adaptive immune system. It is well established that 
while in some cases innate immunity may be able to effectively eliminate M.tb in other 
instances adaptive immunity may be required to fight and to contain the infection (Bhatt & 
Salgame, 2007).  
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In their review, Doherty and co-workers (2009) assert that cytokine expression profiling 
presents an important instrument in biomarker studies. The cytokine expression pattern that 
was revealed in response to M.tb PPD in TST negative HHC in our study demonstrates that it 
may be possible to predict whether TST negative HHC would convert their TST faster or 
lower. When fast convertors had become TST positive at month 6, all cytokines that had been 
produced in response to M.tb PPD at recruitment in this study group were enhanced. In 
addition, responses to M.tb PPD in fast convertors at this time point resulted in increased 
concentrations of innate immune system cytokines including TGF, EGF and MCP-1, those 
of both the innate and adaptive immune system such as IL-4, sCD40L and IFN-as well as 
IL-17, which is a cytokine of the adaptive immune system. When we investigated the 
relationship between cytokines in response to M.tb PPD in fast convertors, we observed that 
GM-CSF was associated with IP-10, IL-2, IL-5, IL-8 and IL-13 at both time points. While 
responses to ESAT6/CFP10 fusion protein did not result in significant differences between 
the study groups at recruitment, we observed that 6 months into the study the fusion protein 
resulted in significantly higher MCP-1, IP10 and IFN-concentrations in fast TST convertors 
only. This is in concordance with a previous study which showed that there was an 
association between TST conversion and increased IP10 levels as a result of stimulation with 
ESAT6/CFP10 fusion protein (Lighter, 2009b). Six months into our study there were no 
changes in IP10 levels due to ESAT6/CFP10 fusion protein in subjects that did not convert 
their TST status.  Further, no changes were observed in MCP-1, GM-CSF and IL-8 over time 
due to M.tb PPD in this study group.  
We have shown that, at recruitment, slow convertors produced significantly higher VEGF, 
IL-12p70 and IL-10 in response to Dos-R antigens only. VEGF is responsible for 
proliferation of dendritic cells, angiogenesis and increased vascular permeability of 
endothelial cells, differentiation of hematopoietic cells as well as chemo-attraction of 
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monocytes (Gabrilovich & Dikov 2003). IL-12p70 is produced by macrophages and dendritic 
cells within hours after the encounter with pathogens and acts on NK cells as well as on 
macrophages and dendritic cells (Langrish et al., 2004). IL-10 suppresses the immune 
responses on B cells, T cells as well as on antigen presenting cells (De la Barrera et al., 
2004), it seems that at the point of study enrolment slow convertors may have mounted a 
potent innate immune response through enhanced NK cytotoxic effects and may have been 
able to fight the M.tb onslaught. ESAT6/CFP10 fusion protein and all 3 Dos-R antigens 
tested in this chapter induced high levels of MCP-1 in both fast and slow convertors, and 
these responses were significantly higher in slow convertors. MCP-1 is one of the most 
important chemokines that is produced in response to M.tb and attracts monocytes, dendritic 
cells, NK cells and memory T cells (Xia & Sui, 2009). At the recruitment time point when all 
the HHC were TST negative, Dos-R antigens incited a potent innate immune response that 
was stronger in slow convertors than in fast convertors. 6 Months into the study, MCP-1 
levels, in response to Rv2029c and ESAT6/CFP10, had increased significantly in fast 
convertors only indicating that, not only were these subjects mounting adaptive immune 
responses, but they were also engaging vigorous innate immune responses in their endeavour 
to contain the infection. Both IL-12p40 and IL-12p70 were collectively expressed at higher 
levels at the 6 month time point in both fast and slow TST convertors but this was seen only 
in response to Dos-R regulon-encoded antigens indicating that in both study groups there was 
an on-going attempt to fight the enduring M.tb challenge as illustrated by the up-regulated 
adaptive responses in fast convertors and the sustained innate responses in slow convertors. 
With regards to other cytokine responses to Dos-R antigens over time, increased expression 
of MIP-1, IL-1and IL-1ra in fast convertors were observed, whereas these antigens 
resulted in decreased production of G-CSF, IL-10 and VEGF in slow TST convertors. These 
responses further demonstrate the differential cytokine responses of these study groups. We 
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did not perform another TST after this time point after fast convertors had become TST 
positive. All, but 1 of the slow convertors converted their TST to positive by month 18 and 
no other TST was performed on them as well. Therefore we do not know the TST status of 
either group at later time points. However, by month 24, none in either group had developed 
TB. 
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CHAPTER 4: MAIN FINDINGS AND CONCLUSIONS 
The present study demonstrates that, in our setting, there is a high rate of transmission of 
tuberculosis infection in household contacts of active TB cases. At the point of study 
recruitment, 92.8% of the household contacts were tuberculin skin test (TST) positive, and all 
but 1 out 893 contacts had converted to TST positive by month 18. The transmission rates of 
TB infection to household contacts vary widely from 27% in The Gambia, (Jackson-Sillah, et 
al., 2007), to 43% in Brazil (Cailleaux-Cezar et al., 2009) to 80% in Pakistan (Hussain et al., 
2007). It is possible that some of the TST positive individuals in our cohort had been exposed 
to environmental mycobacteria although in a highly TB endemic area it is likely to be M.tb. 
Antigens that are present in PPD are also found in BCG and in other mycobacteria, rendering 
the TST non-specific (Lalvani & Pareek, 2009). There is a possibility that the participants in 
our study had been infected outside of the household, in public transport such as taxis, which 
have no ventilation and that is used daily for travel. However, since all were exposed to 
recently diagnosed sputum positive TB case in the household, it is also likely that 
transmission had occurred within the household setting. Whereas IGRAs are said to have 
greater abilities to detect recent exposure, the TST has been shown to have greater abilities 
for detection of remote exposure (MWWR, 2010). IGRA testing was not done in this study; 
however we assumed that the 26 study participants that converted their TST status by month 
18 had been recently infected by M.tb. While both the TST and the IGRAs cannot distinguish 
between active and latent tuberculosis (Mack et al., 2009), during the period under 
investigation in this study active TB disease in HHC was excluded at all time points and none 
of the contacts had progressed to active TB after 24 months. After M.tb infection, it is not 
known who is most vulnerable to progression to disease.  Yet, future active disease cannot be 
excluded because the incidence of TB in this community has continued to rise due to 
increased transmission (Kritzinger, et al., 2009; Shanaube et al., 2009). This could be 
119 
 
attributed to the poverty levels that prevail within this setting as there is a causal link between 
the risk of developing TB and social capital (van Rie et al.,1999; Holtgrave and Crosby, 
2004; Baker et al.,2008; Harling et al., 2008). Several longitudinal studies involving healthy 
HIV negative household contacts of TB index cases have established that between 4 and 
6.7% of contacts developed active TB within 2 years of the initial contact (Teixeira et al., 
2001; Wang & Lin, 2000; Hussain et al., 2007). It is not surprising that the transmission of 
TB was 99.9% in our study setting because M.tb is transmitted in aerosols from person to 
person and those living in close contact to active TB cases are more vulnerable to infection 
(Guwatudde et al., 2003; Hussain et al., 2007). It has been shown that children living in close 
contact with a TB patient under conditions of overcrowding are more vulnerable to TB 
disease (Tornee et al., 2005). Active case finding is not implemented in South Africa. It is 
possible therefore that there could be more active TB cases that remain undetected within our 
setting, which could be fueling the high rate of LTBI and active TB in that community. 
Pronyk et al (2001) have shown in their study that there were 2 undetected active TB cases 
for every 9 that were detected.  
No differences were observed in the contact gradient to the TB index case of household 
contacts that were already TST positive at recruitment compared to those that were TST 
negative. It is important to note that ventilation is not included in calculating the contact 
score. Furthermore, of the 26 participants who were TST negative at recruitment and were 
successfully followed up, with 17 converting to TST positive by month 6 and 9 remaining 
TST negative, there were no differences between their gradients of exposure to respective TB 
index cases. Although our study has not investigated the risk of progression to active disease 
among the household contacts, others have observed that the duration of contact was 
associated with risk of disease and that the presence of cavitary disease in TB cases was 
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associated with bacillary burden as well as with the clinical characteristics of the index case 
(Guwatudde et al., 2003). 
Wood et al., (2010) found LTBI infection of 28% in the 5-10 year age group which increased 
to 88% in the 31-35 years age group. While our cohort was HIV negative, there are 5.7 
million South Africans living with HIV (UNAIDS, 2008). It is known that the risk of 
developing active TB is higher in HIV infected individuals (Narain, 1992). This means that 
should those contacts acquire HIV infection, they could be most vulnerable to active TB 
disease. TB infection levels are also high among South African miners (Hanifa et al., 2009).   
In this study we have observed that BCG scar status (presence or absence) did not have an 
influence on the TST results in our study because the force of infection is so high in our 
setting. This is in agreement with other studies (Marks et al., 2000; Lienhardt et al., 2003). 
Further, we did not observe a relationship between BCG scar status and induration size in the 
TST positive group at recruitment or the TST negative group following conversion at 6 
months. When all household contacts at recruitment were considered, we observed a trend for 
an association between TST status (positive or negative) at recruitment and the smear grade 
of the known TB index case because the bacillary burden is important for transmission to be 
successful. Is has previously been observed that there was higher risk of being TST positive 
in household contacts of TB cases with higher smear grades (Lienhardt et al., 2003; Okada et 
al.,2008).  
We measured interferon gamma production in response to a panel of classical and novel M.tb 
antigens to identify whether they could discriminate between TB infection states (as 
measured by the TST) and active TB cases. With regards to the classical TB antigens, as 
expected, all TST positive HHC responded to ESAT6/CFP10 fusion protein. In active TB 
cases, we observed an 87.5 % response rate to the fusion protein. Of the 17 TST negative 
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subjects, 4 (26.7%) responded to ESAT6/CFP10 fusion protein. All TST positive subjects 
also produced a positive IFN- response to M.tb PPD, even though there was no correlation 
between TST induration size at recruitment and IFN-responses to M.tb PPD (r=0.06, 
p=0.81). Three of the 4 TST negative subjects that responded to ESAT-6/CF10 fusion protein 
also produced a positive IFN- response to M.tb PPD. This may indicate that even though the 
DTH could not pick up the infection at the point of the study recruitment, it is possible that 
those participants were already infected. Both ESAT6 and CFP10 are found in IGRAs (Mack 
et al., 2009; Ruhwald & Ravn, 2009) and M.tb PPD has also previously been included as an 
antigen in these cell culture based tests for infection.  
The ability of a number of antigens across the growth phases of M.tb to differentiate infection 
and disease states as we have shown with Rv1737c, Rv2450c, Rv2029c, TB10.3, M.tb PPD 
may offer a possibility for the development of diagnostic or vaccine instruments using a 
combination of those antigens. Recently a combination of classical antigens, RPFs and Dos-R 
antigens has been used to generate a vaccine (Zvi et al., 2008).  Because M.tb changes gene 
expression in response to its microenvironment, a combination of antigens expressed at 
different growth phases which can differentiate between diseases states may offer 
possibilities for the development of diagnostic tools that may be able to discriminate between 
latent infection and active disease.  Also, there is a need for vaccines that can be used after 
individuals have been latently infected in order to minimise the risk of reactivation and 
reinfection (Kauffman et al., 2010). The combination of these antigens with discriminatory 
abilities may also offer an opportunity for the development of post-exposure vaccines.  
A prolonged ability to fight off infection may represent a marker of a protective phenotype 
against TB. In the household contacts that were TST negative at recruitment, we were 
interested in finding out whether we could identify differences in the cytokine responses to 
122 
 
M.tb antigens between those contacts that converted their TST status by month 6 to those that 
only converted later. In this study we observed that, at the point of study recruitment, M.tb 
PPD elicited higher pro-inflammatory and Th2 cytokines in fast TST convertors. The 
cytokines that were higher in fast convertors were GM-CSF, IP-10, IL-8, IL-13, IL-5 and IL-
2.  In addition, IL-12p70 and VEGF produced in response to Rv1737c and Rv2029c 
respectively were also significantly higher in the fast TST convertors. This suggests that M.tb 
PPD, Rv1737c or Rv2029c may be useful predictors of the rate of infection in TST negative 
household contacts. We also observed that in contacts that took longer to convert their TST 
status, Dos-R regulon-encoded proteins Rv1733c, Rv1737c and Rv2029c, all elicited much 
stronger MCP-1 responses compared to fast convertors at recruitment. To our knowledge this 
is the first study that investigates the predictive role of multiple cytokines in TST conversion 
rate using several novel M.tb antigens. Hussain et al., (2009) observed that TST conversion is 
associated with early increases in IFN γ and IL-10.  In our study we also observed that IL-10 
could discriminate between fast TST and slow convertors at recruitment, in response to 
Rv2029c. 
Over time, IL-8, fractalkine, EGF, IFN-, IL-2, IL-4, sCD40 ligand, IL-5, IL-13, and IL-17 
were all increased in fast convertors only in response to M.tb PPD. IFN- levels were also 
higher in fast convertors in response to ESAT-6/CFP10 fusion protein 6 months into the 
study.   
By the 6 month time point, IL-10 and G-CSF levels had decreased in response to Rv2029c in 
slow convertors, and VEGF had also decreased in response to Rv1737c. In the slow TST 
convertors, the immune responses appear to be mostly due to the innate immune system, 
therefore not specific.  
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A major limitation of this study is the small number of participants. Also, none of the subjects 
were tested for IGRA. The WHO has recently recommended that both the TST and an IGRA 
should be used in diagnosing LTBI (MWWR, 2010). The cost of conducting both tests may 
be limiting for a developing country, like South Africa. Another limitation of this study is 
that we did not ascertain the infecting M.tb strains of the index cases of HHC. It is possible 
that diferent strains may determine diferent diseases phenotypes. While we are still a long 
way from finding the exact immune correlates that may provide protection against M.tb, this 
study shows that the immune responses to M.tb in household contacts that differ in their TB 
infection and disease states  are distinct. Also, this study provides an insight into the different 
immune profiles that are associated with TST conversion over time. 
Mechanisms that are involved in determining the rate of infection with M.tb, as well as 
different states of TB infection and disease could be further elucidated through studies 
investigating phenotypic differences in cells of the innate and adaptive immune system using 
flow cytometry across different study groups. The immune response of the slow TST 
convertors by the time they convert to TST positive at month 18 not known. Answering these 
questions could lead to a better understanding of the protective immune response against M.tb 
and provide information leading towards the design of more effective diagnostic tests and 
vaccines against tuberculosis. In this exploratory study, we observed correlates that may be 
used to predict TST negative subjects that would convert their earlier when they were still 
TST negative. However, it is difficult to predict immune correlates of protection from this 
study as no household contacts had progressed to active disease 24 months into the study. 
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Appendix 1.1: Table of cytokine correlations: Fast TST convertors at recruitment in response to M.tb PPD  
Cytokine/ 
Chemokine 
G-CSF GM-CSF IL-1ra  IL-1 IL-
12p40  
IL-17  IP-10 MIP-1 MIP-1
IL-1ra 0.56*         
IL-1 0.61* 0. 54*        
IL-12p40   0.65* 0.55*      
IL-17  0. 85***  0.57*      
IP-10  0.88***    0.86***    
MCP-1 0.53*         
MIP-1   0.50*       
MIP-1     0.60*   0.76**  
TGF-  0.52*      0.59*  
TNF-  0. 72*  0.77**  0.58*   0.50* 
IFN-      0.66* 0.51* 0.51*  
IL-2  0. 56*    0.57* 0. 75**   
IL-5  0.63*    0.70* 0.70*   
IL-10  0. 58*  0.74*  0.68* 0. 57*   
IL-13  0.64*  0.54*  0.55* 0.50*  0.57* 
IL-1 0.89***  0.62* 0. 83***      
IL-6 0.80**  0.57* 0.68*      
IL-8 0.64* 0. 60*  0.86***  0.54*    
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Cytokine TNF- IFN- IL-2 IL-10  IL-13  IL-1 IL-6 
IL-5 0.65* 
IL-10 0.52* 0. 78** 
IL-13 0.58* 0.54* 
IL-1 0.70* 0. 56* 
IL-6 0.54* 0.53* 0.83*** 
IL-8 0.76** 0. 51* 0. 80** 0. 54* 0. 80** 0. 73* 
 
Appendix 1.1: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.2: Table of cytokine correlations: Fast TST convertors in response to ESAT6/CFP10 fusion protein at recruitment  
Cytokine EGF G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IP-10 MCP-1 MIP-1 MIP-1 
G-CSF  0.66* 
IL-1ra 0.81*** 0. 72* 0. 57* 
IL-1 0.67* 0.93*** 0.55* 0.75** 
IL-12p40 0.66* 0. 72* 0. 64* 0. 67* 
IP-10  0.63* 
MCP-1 -0.56* 
MIP-1 0.79** 0. 68* 0. 61* 0. 79** 0. 59* 
MIP-1 0.86*** 0.52* 0.56* 0.79*** 0.61* 0.93*** 
TGF- 0.61* 0. 62* 0. 61* 0. 51* 0. 53* 0. 69* 
TNF- 0.56* 0.84*** 0.64* 0.85*** 0.80*** 0.83*** 0.76** 
VEGF 0.62* 0. 77** 0. 73* 0. 59* 0. 74** 0. 58* 0. 63* 
IFN- 0.83*** 0.54* 0.66* 0.50* 
IL-10  0.52* 0. 89*** 0. 57* 0. 64* 0. 89*** 0. 68* 0. 90*** 0. 87*** 
IL-1 0.71* 0.95*** 0.71* 0.90*** 0.76** 0.77** 0.81*** 
IL-6  0.71* 0. 94*** 0. 75** 0. 92*** 0. 75** 0. 78** 0. 84*** 
IL-8  0.84*** 0.56* 0.87*** 0.59* 0.76** 0.75** 
IL-12p70 0.53* 0. 63* 0. 60* 0. 70* 0. 60* 0. 55* 
Appendix 1.2: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Cytokine TGF- TNF- VEGF IFN- IL-10 IL-1 IL-6 IL-8 
VEGF 0.55* 0. 68* 
IL-10  0.54* 0. 88*** 0. 64* 0. 52* 
IL-1 0.54* 0.88*** 0.75**   0.84***       
IL-6  0.65* 0. 83*** 0. 71* 0. 81*** 0. 96*** 
IL-8  0.52* 0.82*** 0.51*   0.79** 0.85*** 0.88***   
IL-12p70 0.65*     0.62* 0. 74** 0. 70* 0. 60* 
Appendix 1.2: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.3: Table of cytokine correlations: Fast TST convertors in response to Rv1733c at recruitment  
Cytokine EGF G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IL-17 IP-10 
IL-1ra 0.67* 
MCP-1 0.60* 
MIP-1 0.53* 0. 63* 
 0.69* 
TGF- 0.52* 0. 62* 0. 75** 
TNF- 0.54* 
IFN- 0.50* 0. 56* 
IL-10 0.56* 
IL-6 0.75** 0.51* 0.66* 
IL-8 0.50* 
IL-12p70 0.52* 0.69* 
 
Appendix 1.3: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Cytokine MCP-1 MIP-1 MIP-1 TGF- TNF- IFN- IL-10 
P 0.82*** 
TGF- 0.52* 
TNF- 0.66* 
IL-10 0.56* 0. 58* 
IL-1 0.51* 0. 64* 
IL-6 0.74* 0.62* 0.67* 0.84*** 
IL-8 
IL-
12p70 0.74* 0.52* 
Appendix 1.3: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.4: Table of cytokine correlations: Fast TST convertors in response to Rv1737c at recruitment  
Cytokine EGF G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IP-10 MCP-1 
GM-CSF 0.52* 0.53* 
IL-1ra 0.64* 
IL-1 0.51* 0.80*** 0.63* 0.65* 
IL-12p40 0.61* 0. 57* 
IP-10 0.68* 0.63* 
MIP-1 0.72* 0. 63* 0. 68* 0. 63* 
MIP-1 0.76** 0.64* 
TGF- 0.59* 0. 57* 0. 74** 0. 57* 0. 63* 
TNF- 0.59* 0.53* 0.68* 0.76** 0.76** 
VEGF 0.60* 0. 72* 0. 52* 0. 52* 
IFN- 0.55* 0.71* 0.79** 
IL-10 0.95*** 0. 54* 0. 58* 0. 72* 0. 55* 
IL-1 0.76** 0. 71* 0. 79** 0. 62* 0. 71* 
IL-6 0.87*** 0.53* 0.59* 0.85*** 0.66* 0.56* 0.52* 
IL-8 
IL-12p70 0.51* 0.57* 0.50* 0.61* 0.80***
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Cytokine MIP-1 MIP-1 TGF- TNF- VEGF IFN- IL-10 IL-1 IL-6 IL-8 
MIP-1 0.80* 
TGF- 0.52* 
TNF- 0.73** 
VEGF 0.53* 
IFN- 0.72* 0.63* 
IL-10 0.72* 0. 74** 0. 51* 0. 67* 0. 62* 0. 60* 
IL-1 0.65* 0. 79** 0. 66* 0. 60* 0. 83*** 
IL-6 0.77** 0.68* 0.60* 0.79** 0.54* 0.84*** 0.77** 
IL-8 0.56* 
IL-12p70 0.80* 0.85*** 0.73** 0.62* 0.69* 0.66* 0.51* 
Appendix 1.4: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
 
 
  
147 
 
Appendix 1.5: Table of cytokine correlations: Fast TST convertors in response to Rv2029c at recruitment 
Cytokine EGF G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IL-17 IP-10 MCP-1 MIP-1
G-CSF 0.59* 
GM-CSF 0.51* 
IL-1ra 0.59* 0.54* 
IL-1 0.70* 0. 64* 
IL-12p40 0.65* 0.61* 
IP-10 0.52* 0.55* 
MIP-1 0.70* 0.63* 0.55* 0.65* 0.60* 
MIP-1 0.69* 0. 64* 0. 69* 0. 59* 0. 88*** 
TNF- 0.67* 0. 65* 0. 51* 0. 50* 0. 72* 0. 82*** 0. 62* 0. 84*** 
VEGF 0.58* 
IFN- 0.65* 0. 63* 0. 73* 
IL-10 0.74** 0.74* 0.63* 0.73* 0.82** 
IL-1 0.55* 0.62* 0.56* 0.57* 0.69* 0.50* 0.76* 
IL-6 0.59* 0. 72* 0. 74* 0. 64* 0. 80** 0. 50* 0. 79* 
IL-8 0.57* 0.56* 0.75** 0.59* 0.58* 0.50* 
IL-12p70 0.70* 0. 68* 0. 73* 
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Cytokine MIP-1 TGF- TNF- VEGF IFN- IL-10 IL-1 IL-6 IL-8 
TGF- 0.69* 
TNF- 0.63* 
IFN- 0.56* 
IL-10 0.71* 0.53* 0.84*** 0.55* 0.53* 
IL-1 0.63* 0.80** 0.50* 0.57* 0.82*** 
IL-6 0.74* 0. 53* 0. 88*** 0. 83*** 0. 71* 
IL-8 0.79** 0.53* 0.66* 0.56* 0.59* 
IL-12p70 0.82*** 0. 59* 0. 66* 0. 57* 0. 61* 0. 79** 
Appendix 1.5:  Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.6: Table of cytokine correlations: Fast TST convertors in response to Rv2450c at recruitment 
Cytokine EGF G-CSF GM-CSF IL-1ra IL-1 IP-10 MIP-1 TNF- IL-10 IL-1 IL-6 
GM-CSF 0.58* 0.70* 0.52* 
IL-1ra 0.64* 0. 78** 0. 63* 
IL-1 0.57* 0.83*** 
IL-12p40 0.52* 
IL-17 0.74* 
MIP-1 0.82*** 
IL-1 0.57* 0.69* 0.54* 0.88 0.92*** 0.58* 0.91*** 0.65* 
IL-6 0.64* 0. 53* 0. 82*** 0. 93*** 0. 57* 0. 91*** 0. 71* 0. 96*** 
IL-8 0.53* 
Appendix 1.6:  Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.7: Table of cytokine correlations: Slow TST convertors at recruitment in response to M.tb PPD  
Cytokine IL-12p40 IP-10 MCP-1 MIP-1 MIP-1 IFN- 
MIP-1 1.00* 
TNF- 0.88* 
IL-10 0.93* 0.87* 
IL-8 0.89* 0. 99* 
Appendix 1.7: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.8: Table of cytokine correlations: Slow TST convertors at recruitment in response to ESAT6/CFP10 fusion protein 
Cytokine GM-CSF IL-1 IL-12p40 IP-10 MIP-1 TNF- IL-1 IL-6 
IP-10 0.94* 0.89* 
MIP-1 0.99* 
VEGF 0.88* 
IFN- 0.89* 
IL-6 0.94* 0.89* 0.94* 
IL-8 0.89* 0. 89* 0. 89* 0. 94* 
Appendix 1.8: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.9: Table of cytokine correlations: Slow TST convertors at recruitment in response to Rv1733c 
Cytokine G-CSF GM-CSF IL-1ra IL-1 IL-17 VEGF IL-1 
IL-1 -0.99* 0.60* 
IL-
12p40 0.54* 
TGF- 0.90* 
VEGF 0.89* 0. 94* 
IL-10 0.89* 0.94* 
IL-1 -0.93* 0. 89* -0.90 * 
IL-6 -0.93* 0.89* -0.90* 1.00* 
Appendix 1.9: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.10. Table of cytokine correlations: Slow TST convertors at recruitment in response to Rv1737c 
Cytokine G-CSF GM-CSF IL-1ra IL-1 IP-10 MCP-1 MIP-1 MIP-1 TGF- TNF- VEGF IL-1 
IL-1 0.94* 
IP-10 0.89* 
MIP-1 1.00* 
MIP-1 1.00* 1. 00* 
TNF- 0.94* 
VEGF 1.00* 1. 00* 1. 00* 
IFN- 0.94* 
IL-10 1.00* 1. 00* 1. 00* 1. 00* 
IL-1 0.94* 0.89* 
IL-6 1.00* 0. 94* 0. 94* 
IL-12p70 0.94 0.94* 0.89* 
Appendix 1.10. Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.11. Table of cytokine correlations: Slow TST convertors at recruitment in response to Rv2029c  
Cytokine G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IP-10 MIP-1 TGF- TNF- VEGF IFN- IL-10 IL-1 
IL-1ra 0.89* 0.89* 
IL-1 0.94* 
IL-12p40 0.94* 0.94* 0.94* 0.89* 
IP-10 0.94* 0. 94* 0. 94* 0. 89* 1. 00* 
MIP-1 0.94* 0.94* 0.94* 0.89* 1.00* 1.00* 
MIP-1 1.00* 0. 89* 0. 94* 0. 94* 0. 94* 0. 94* 
TNF- 0.89* 0.89* 0.94* 0.94* 0.94* 0.09* 
VEGF 0.99* 0. 93* 0. 90* 0. 93* 0. 93* 0. 93* 0. 64* 0. 81* 
IFN- 0.94* 0.94* 0.89* 0.89* 0.89* 0.66* 0.77* 0.99* 
IL-10 0.94* 0. 83* 0. 83* 0. 77* 0. 66* 0. 93* 0. 89* 
IL-1 1.00* 0.89* 0.94* 0.94* 0.94* 0.94* 0.60* 0.83* 0.99* 0.94* 0.94* 
IL-6 0.94* 
IL-12p70 0.93* 0.93* 0.99* 0.99* 0.99* 0.99* 0.93* 0.94* 0.93* 0.81* 0.93* 
Appendix 1.11. Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.12: Table of cytokine correlations: Fast TST convertors at month 6 in response to M.tb PPD  
Cytokine G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IL-17 IP-10 MCP-1 MIP-1 MIP-1 
IL-1 0.67* 0.58* 
IL-12p40 0 .58* 0. 84*** 
IL-17 0.61* 
MCP-1 0 .64* 0. 53* 
MIP-1 0.52* 0.71* 
MIP-1 0.58* 0. 60* 0. 65* 0. 89*** 
TNF- 0.74** 0.61* 0.53* 0.56* 0.51* 
IFN- 0.54* 0. 79** 0. 61* 0. 62* 0. 51* 0. 58* 
IL-2 0.53 0.52* 
IL-5 0.82 *** 0. 72* 
IL-10 0.76** 0.70* 
IL-13 0 .84*** 0. 53* 0. 52* 0. 68* 0. 52* 
IL-1 0.86*** 0.69* 
IL-6 0 .73* 0. 76** 0. 65* 
IL-8 0.81*** 0.55* 0.61* 0.54* 
IL-12p70 0 .55* 
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Cytokine TNF- IFN- IL-5 IL-10 IL-13 IL-1 
IL-2 0.68* 
IL-4 0.52* 
IL-10 0.73* 0.72* 
IL-13 0.57* 0. 51* 0. 71* 
IL-1 0.82*** 0.72* 0.94*** 0.72* 
IL-6 0.57* 
IL-8 0.63* 0.59* 0.60* 0.82*** 
Appendix 1.12: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.13: Table of cytokine correlations: Fast TST convertors at month 6 in response to ESAT6/CFP10 fusion protein  
Cytokine EGF G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IL-17 IP-10 MIP-1 MIP-1 TGF- 
IL-1ra 0.74** 
IL-1 0.78** 
IL-17 0.58* 
IP-10 0.63* 0. 65* 
MCP-1 0.59* 
MIP-1 0.62* 0. 71* 
MIP-1 0.85*** 0.81*** 0.80*** 
TGF- 0.64* 0. 56* 0. 69* 0. 62* 
TNF- 0.77** 0.82*** 0.54* 0.67* 0.86*** 
VEGF 0.67* 
IFN- 0.60* 0.50* 0.52* 0.55* 0.64* 
IL-2 0.83*** 0. 55* 0. 56* 
IL-5 -0.63* -0.62* 0.65* 
IL-10 0.70* 0. 89*** 0. 65* 0. 77** 0. 65* 
IL-13 -0.50* -0.64* 0.53* 
IL-1 0.89*** 0. 91*** 0. 55* 0. 77** 
IL-6 0.88*** 0.52* 0.87*** 0.55* 0.81*** 
IL-8 0.50 0 .51* 
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Cytokine TNF- IFN- IL-2 IL-5 IL-10 IL-13 IL-1 IL-6 
IL-2 0.50* 
IL-10 0.87*** 0. 64* 
IL-13 0.60* 0.55* 
IL-1 0.79** 0. 82*** -0.71 * 
IL-6 0.87*** 0.83** -0.69* 0.95*** 
IL-8 0.53 0. 61* 0. 53* 
Appendix 1.13: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.14: Table of cytokine correlations: Fast TST convertors at month 6 in response to Rv1733c 
Cytokine G-CSF IL-1ra IL-1 IL-12p40 IL-17 IP-10 MIP-1 MIP-1 TNF- IL-1 IL-6 
IL-1 0.79** 
IP-10 0.52* 
MIP-1 0.59* 
TGF- 0.73* 0. 54* 
TNF- 0.53* 
VEGF 0.55* 0. 58* 
IFN- 0.55* 
IL-10 0.63* 0. 67* -0 .56* 0. 61* 0. 69* 
IL-1 0.85*** 0.87*** 
IL-6 0.64* 0. 67* 0. 70* 0. 75** 
IL-12p70 0.57* 0.62* 0.56* 
Appendix 1.14: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001 
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Appendix 1.15: Table of cytokine correlations: Fast TST convertors at month 6 in response to Rv1737c 
Cytokine EGF G-CSF GM-CSF IL-1ra IL-1 IL-17 IP-10 MCP-1 MIP-1 MIP-1 
IL-1 0.53* 
IL-17 0.57* -0.51 * 
MCP-1 0.51* 0.51* 
MIP-1 0.62* 0. 60* 0. 50* 
MIP-1 0.72* 0.51* 
TGF- 0.67* 
TNF- 0.90*** 0.56* 
VEGF 0.55* 0. 73** 
IFN- 0.70* 0.56* 0.60* 
IL-10 0.85*** 0. 61* 0. 54* 0. 62* 
IL-1 0.82*** 0.50* 0.63* 0.52* 0.52* 
IL-6 0.50* 0. 75** 
IL-12p70 0.67* 0.64* 
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Cytokine TGF- TNF- VEGF IFN- IL-10 
IL-10 0.57* 
IL-1 0.59* 0. 83*** 
IL-6 0.83*** 0.50* 
IL-12p70 0.66* 0. 67* 
Appendix 1.15: Spearman correlation Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.16: Table of cytokine correlations: Fast TST convertors at month 6 in response to Rv2029c 
Cytokine EGF G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IL-17 IP-10 MIP-1 MIP-1 
IL-1 0.77* 
IL-17 0.76** 
IP-10 0.59* 
MCP-1 -0.57* 
MIP-1 0.61* 0.69* 
MIP-1 0.74* 0. 67* 0. 80*** 
TGF- 0.62* 
TNF- 0.76*** 0. 57* 0. 52* 
VEGF -0.56* 0.54* 
IFN- 0.53* 0. 68* 0. 58* 
IL-2 -0.61* -0.66* 0.59* -0.58* -0.61* 
IL-10 0.52* 0. 53* 0. 59* 0. 69* 
IL-1 0.75** 0.87*** 0.59* 
IL-6 0.77** 0. 71* 0. 61* 0. 78** 
IL-8 -0.51* 
IL-
12p70 0.64 0. 52* 
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Cytokine TGF- TNF- VEGF IL-2 IL-10 IL-1 IL-6 IL-8 
IL-10 0.70* 
IL-1 0.61* -0.65 * 0. 69* 0. 77** 0. 59* 
IL-6 0.54* -0.71* 0.53* 
IL-12p70 0.87*** 0.59* 
Appendix 1.16: Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.17: Table of cytokine correlations: Slow TST convertors at month 6 in response to M.tb PPD 
Cytokine  GM-CSF IL-1ra IL-17 IP-10 MIP-1 TNF- IFN- IL-2 
IL-17 0.88 
IP-10 0.79 
MIP-1 0.96 
MIP-1 0.69 
TNF- 0.96 0.93 
IFN- 0.88 0.56 0 .89 0 .77 0.85 
IL-2 0.93 0.85 0.86 0.93 
IL-10 0.52 
IL-8 0.54 0.59 0.79 
Appendix 1.17:  Spearman correlation values, all p<0.05. 
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Appendix 1.18: Table of cytokine correlations: Slow TST convertors at month 6 in response to ESAT6/CFP10 fusion protein 
Cytokine G-CSF GM-CSF IL-1 IL-17 IP-10 MCP-1 MIP-1 MIP-1 TNF- IFN- IL-2 IL-5 IL-10 IL-1 IL-6 
IL-1 0.78* 
IP-10 0.90* 0. 90* 
MCP-1 0.76* 
MIP-1 0.76* 0. 72* 
MIP-1 0.71* 0.83* 
TNF- 0.71* 0. 78* 0. 71* 0. 90* 0. 88* 
IFN- 0.88* 0.86* 0.97*** 
IL-2 0.78* 0. 88* 0. 91* 0. 94* 
IL-5 0.81* 0.79* 0.73* 0.87* 0.84* 0.80* 
IL-10 0.86* 0. 71* 0. 52* 0. 83* 0. 81* 0. 79* 
IL-1 0.73* 0.81* 0.93** 0.81* 0.90* 0.74* 0.76* 
IL-6 0.81* 0. 88* 0. 74* 0. 76* 0. 79* 0. 83* 0. 77* 0. 74* 0. 90* 0. 79* 
IL-8 0.85* 0.76* 0.90* 0.90* 0.83* 0.72* 0.74* 0.74* 0.81* 
IL-12p70 0.74* 0. 82* 0. 88* 
Appendix 1.18: Table of cytokine correlations: Slow TST convertors at month 6 in response to ESAT6/CFP10 fusion protein. 
Spearman correlation values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.19: Table of cytokine correlations: Slow TST convertors at month 6 in response to Rv1733c 
Cytokine EGF G-CSF GM-CSF IL-1 IL-12p40 IP-10 MCP-1 TGF- 
Eotaxin -0.84 
GM-CSF 0.83
MIP-1 0.79 0.93
TNF- 0.76 0.79
VEGF 0.88
IFN- 0.74
IL-10 0.81
IL-1 0.90
IL-6 0.81
IL-8 0.74 
Appendix 1.19: Table of cytokine correlations: Slow TST convertors at month 6 in response to Rv1733c. Spearman correlation 
values, all p<0.05. 
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Appendix 1.20: Table of cytokine correlations: Slow TST convertors at month 6 in response to Rv1737c 
Cytokine G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IL-17 IP-10 MCP-1 MIP-1 MIP-1 TGF- TNF- IFN- IL-1 
GM-CSF 0.88* 
IL-12p40 0 .76* 
IL-17 -0.73* 
MCP-1 -0.81 * -0 .81* 
MIP-1 0.74* 0.88* 0.88* -0.78* -0.79* 
MIP-1 0.81* 
TGF- 0.75* 
TNF- 0.83* 0. 81* 0. 83* -0.88 * 0. 90* 
VEGF 0.77* 
IFN- 0.74* 0. 79* 0. 86* 0. 83* 0. 76* 
IL-10 0.74* 0.79* 0.79* 0.90* 
IL-1 0.81* 0. 93* 0. 98** 0. 88* 
IL-6 0.98** 0.90* 0.86* 0.95* 
IL-12p70 -0 .79* 0. 81* 0. 83* 
Appendix 1.20: Table of cytokine correlations: Slow TST convertors at month 6 in response to Rv1737c. Spearman correlation 
values with * denoting p<0.05, ** p <0.001 and ***p< or = 0.0001. 
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Appendix 1.21: Table of cytokine correlations: Slow TST convertors at month 6 in response to Rv2029c 
Cytokine EGF G-CSF GM-CSF IL-1ra IL-1 IL-12p40 IP-10 MIP-1 MIP-1 TNF- IFN- IL-10 IL-1 IL-6 
GM-CSF 0.90 
IL-1 0.88 0. 88 
IL-12p40 0.79 
MCP-1 -0.81 
MIP-1 0.76 0 .67 
MIP-1 0.74 
TNF- 0.79 0 .81 0.76 0.90 
VEGF 
IFN- 0.76 0 .71 0.74 0.95 0.98 
IL-10 0.79 0.74 0.79 0.95 0.90 
IL-1 0.74 0 .74 0.79 0.86 0.86 0.81 0.76 
IL-6 0.79 0.81 0.76 0.79 0.88 0.81 0.88 0.93 
IL-8 0.81 0. 83 0.79 0.83 
IL-12p70 0.74 0.76 0.90 0.83 0.98 0.79 0.93 
Appendix 1.21: Table of cytokine correlations: Slow TST convertors at month 6 in response to Rv2029c. Spearman correlation 
values, all p<0.05. 
 
 
 
 
 
